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Abstract 
AMP-activated protein kinase (AMPK) plays important roles in the regulation of energy 
homeostasis and has been implicated in a number of diseases including diabetes and 
cancer. Obtaining a full picture of AMPK signalling is important for the understanding of 
these disease states and the development of novel therapies.  
AMPK is activated by phosphorylation of T-172 within the α catalytic subunit. While a 
number of AMPK upstream kinases have been identified, identification of the AMPK 
phosphatase has proved elusive. In the first part of this thesis, the identity of the AMPK 
phosphatase(s) was investigated. The data presented shows that treatment of mammalian 
cells with the protein phosphatase (PPP) family inhibitor Calyculin-A caused marked 
increases in AMPK activity. These results indicate that one or more of the AMPK 
phosphatases belong to the PPP family, with the concentration profile pointing towards 
PP1 involvement. However, using siRNA based techniques; it was not possible to 
pinpoint the specific phosphatase(s) that dephosphorylates AMPK. Our results, combined 
with recently published studies, suggest that regulation of AMPK dephosphorylation is a 
complex process with involvement of different protein phosphatases depending on cell-
type and/or conditions of cell stress.  
Next, quantitative mass spectrometry techniques were utilised in order to identify AMPK 
interacting proteins. From the list of candidate interactors, the interaction between AMPK 
and the PAK1 signalling complex was characterised. AMPK directly phosphorylated 
PAK1 on Ser-21 leading to its activation. Activation of AMPK in mammalian cells led to 
increased activity and phosphorylation of endogenous PAK1. PAK1 
activity/phosphorylation was reduced in cortical neurons derived from AMPK α1 
knockout mice compared to wild-type neurons. Furthermore, activation of AMPK with 
A769662 in melanoma cell-lines significantly increased cell invasion and this effect was 
abolished by the PAK1 inhibitor, IPA3. These results show that PAK1 is an AMPK 
substrate and suggest that at least part of the effects of AMPK on axonogenesis and 
tumour formation is mediated through PAK1 signalling.  
In addition to the effects of AMPK on PAK1, PAK1 was shown to directly phosphorylate 
the AMPK α1 subunit at Thr-377 and Ser-403/405. This phosphorylation was able to 
further increase the activity of CaMKKβ phosphorylated AMPK. This finding adds a 
novel layer of control to the regulation of AMPK.  
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 Abbreviations 
ACC Acetyl-Coenzyme A carboxylase 
AICAR 5-aminoimidazole-4-carboximide ribonucleoside 
AMPK 
AMARA 
5’adenosine monophosphate-activated protein kinase 
Synthetic peptide, AMARAASAAALARRR 
CaMKKβ Ca2+/Calmodulin-dependent protein kinase kinase beta 
CAPS 
CBS 
3-[cyclohexylamino]-1-propanesulfonic acid 
Cystathionine beta synthase (domains) 
CREB cAMP-response element binding protein 
DEAE Diethylaminoethyl 
DMEM Dulbecco’s modified eagle’s medium 
DMSO Mimethyl Sulphoxide 
DTT Dithiohtreitol 
EDTA Ethylene diamine tetra-acetic (ethanoic) acid 
et al. et alia 
FAS 
FKHR 
GBD 
Fatty acid synthase 
The forkhead transcription factor (also known as Foxo1) 
Glycogen binding domain 
GFP Green fluorescent protein 
GPAT Glycerol-3-phosphate acyl-transferase 
GS Glycogen synthase 
GST Glutathione S-transferase 
Hepes 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMG-CoA reductase 3-hydroxy-3-methylglutaryl-CoA reductase 
HRP 
HSL 
Horseradish peroxidase 
Hormone-sensitive lipase 
HST High Salt Tween 
IPTG 
KD 
Isopropyl β-D-thiogalactopyranoside 
Kinase dead 
LB medium 
LKB1 
MBP 
PAK1 
PAKtide 
Luria Bertani medium 
Liver kinase B1 
Myelin basic protein 
P21-activated protein kinase 1 
Synthetic peptide, RRRLSFAEPG 
PBS Phosphate-buffered saline 
PEPCK Phosphoenolpyruvate carboxykinase 
PKA Protein kinase A 
Akt/PKB Protein kinase B 
PMSF Phenylmethylsulphonyl fluoride 
PP 
PPM 
qRT-PCR 
Protein phosphatase (e.g. PP1, PP2A, PP5 and PP6) 
Metal dependent phosphatases 
Reverse transcription polymerase chain reaction (real-time) 
PVDF 
SDS- PAGE 
Polyvinylidene difluoride 
Sodium dodecyl sulphate - Polyacrylamide gel electrophoresis 
S.E.M Standard error of mean 
SAMS Synthetic peptide, HMRSAMSGLHLVKRR 
TAE Tris-acetate buffer 
TCEP tris(2-carboxyethyl)phosphine 
TORC2 Transducer of regulated CREB activity 2 
TRIS Trishydroxymethylaminomethane 
WPW Wolff-Parkinson-White syndrome 
WT Wild-type 
ZMP 5-amino-4-imidazolecarboxyamide ribonucleoside monophosphate 
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1 Introduction  
Cells require energy to carry out almost every cellular process, including establishing 
and maintaining ionic concentrations of sub-cellular compartments, transporting 
molecules across cell membranes and the synthesis of macromolecules (e.g. proteins, 
glycogen, DNA etc.) necessary for cellular and whole body function. The main unit of 
energy in the cell is ATP, and the energy generation process involves the hydrolysis 
of ATP to ADP and if needed to AMP.  
 
In order to maintain cellular nucleotide concentrations at optimum levels, processes 
which produce ATP, termed catabolic processes (such as glycolysis and fatty acid 
oxidation) need to be finely balanced with anabolic processes which utilise ATP, 
termed anabolic processes (such as glycogen and protein synthesis). Cellular 
mechanisms are required to detect any changes in the ratio of ATP:AMP+ADP and 
effect changes which will restore balance. For example when the AMP and ADP 
levels rise in the cell relative to ATP, indicating the cell is entering an energy 
deprived state, the cell would act to switch on catabolic processes while switching off 
anabolic processes until the optimum ratio has been restored. Almost all diseases 
involve some measure of dysregulation of cellular energy status. For example, 
diseases ranging from diabetes to cancerous solid tumours all involve alterations in 
the normal regulation of glucose and fatty acid metabolisms. In order to find new 
methods of treatment of these conditions, it is very important to gain a good 
understanding of cellular systems which regulate energy balance. 
 
1.1 AMP-activated protein kinase 
AMP-activated protein kinase (AMPK) is a multi-subunit protein kinase. It functions 
as a cellular energy gauge. AMPK detects changes in the energy state of a cell and 
acts to alter a variety of parameters in order to maintain energy homeostasis (Carling 
et al., 2008; Hardie, 2008; Steinberg and Kemp, 2009). AMPK is highly conserved in 
eukaryotes and is activated by direct phosphorylation by the upstream kinases liver 
kinase B1 (LKB1), Ca
2+
/calmodulin-dependent protein kinase kinase  (CaMKKβ) 
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and transforming growth factor-beta-activating kinase 1 (TAK1) (Carling et al., 2008; 
Momcilovic et al., 2006). However, the physiological role for TAK1 in activating 
AMPK has not been clearly identified. Although acting directly at a cellular level, 
AMPK is indirectly activated in response physiological and pathological stimuli at the 
whole body level, such as hormone stimulation, hypoxia, energy deprivation (e.g. 
starvation), ischemia and exercise, all of which causes increases in cellular AMP:ATP 
ratios (Kahn et al., 2005; Steinberg and Kemp, 2009). Once activated, AMPK acts to 
phosphorylate a number of downstream targets, resulting in a shift away from ATP-
consuming processes, (e.g. fatty acid synthesis, glycogen synthesis and protein 
synthesis) and acts to ‘switch on’ ATP-producing processes, e.g. fatty acid oxidation 
and glycolysis, glucose uptake, and increased food intake (Fujii et al., 2004; Hutber et 
al., 1997; Winder, 2000).  
 
AMPK has been reported to play important roles in many disease states such as 
metabolic syndrome, type II diabetes, various cardiomyopathies etc. (Steinberg and 
Kemp, 2009). More recently, AMPK has also been implicated to have a role in the 
proliferation, migration and invasion of cancer cells. AMPK has ben recognised as an 
important therapeutic target in the treatment of these conditions (Fogarty and Hardie; 
Luo et al., 2010). A number of hormones and cytokines which have effects on whole 
body metabolism also exert an influence on AMPK activities, in addition many 
currently used pharmacological agents such as metformin, phenformin and resveratrol  
have been reported to derive at least part of their therapeutic value from modulation of 
AMPK activity (Ewart and Kennedy, 2012; Hardie et al., 2012; Zhang et al., 2009).   
 
1.1.1 Structure of AMPK 
AMPK is a heterotrimeric enzyme consisting of three subunits, namely the α, β and γ 
(Carling, 2004). The α subunit of AMPK is the catalytic subunit and β and γ play 
regulatory/scaffolding roles. These subunits are always found in complex, and AMPK 
requires all three subunits in order to function as an active kinase both in vivo and in 
vitro. Several isoforms of each subunit have been discovered in nature (namely α1, α2, 
β1, β2, γ1, γ2, and γ3) and different combinations of these subunits can form AMPK 
complexes, allowing 12 combinations in total (Cheung et al., 2000; Kahn et al., 2005).  
The different AMPK isoforms may play different roles in the cell or be localised in 
16 
 
different sub-cellular compartments, for example the α2 subunit has been detected in 
nucleus as well as in the cytoplasm (Salt et al., 1998).  
 
The α subunit contains the kinase domain of AMPK. It has two isoforms (α1 and α2) 
both with a molecular mass of around 63 kDa. Differential expression patterns have 
been reported for the two isoforms with α1 being the predominant form expressed in 
the brain, lungs, kidneys and pancreas, and the α2 subunit being highly expressed in 
the heart and skeletal muscle(Steinberg and Kemp, 2009) .  
 
The β subunit also has two isoforms (β1 and β2) both of which are around 30 kDa in 
mass (although it migrates at 38 kDa on SDS-PAGE gels). The C-terminal domain of 
the β subunits binds both the α and γ subunits whereas the N-terminal region binding 
glycogen and is named the glycogen binding domain (GBD) which suggests that 
AMPK may be directly involved in glycogen metabolism (Hudson et al., 2003; 
Polekhina et al., 2003).  
 
There are three isoforms of the γ subunit (γ1, γ2 and γ3), γ1 and γ2 are the predominant 
isoforms in vivo, with ubiquitous expression in all bodily tissues, γ3 on the other hand 
only shows significant expression in glycolytic skeletal muscle (Birk and 
Wojtaszewski, 2006; Cheung et al., 2000). The mass of γ1 is around 36 kDa, whereas 
γ2 and γ3 possesses large N terminal domains which results in their masses being 63 
kDa and 58 kDa respectively. All γ subunit isoforms contains four tandem repeats 
which are named CBS repeats/motifs due to their similarity to the cystathionine β-
synthase enzyme. The CBS motifs are able to bind the nucleotides ATP, ADP and 
AMP. The binding of ATP under basal conditions helps to keep the activity of AMPK 
low, whereas the exchange of AMP for ATP would signal cellular stress and cause 
allosteric activation of the enzyme and protection from dephosphorylation (Carling et 
al., 1987; Xiao et al., 2011). Several cardiovascular conditions are caused by 
mutations in the γ2 subunit gene, such as Wolff-Parkinson-White (WPW) syndrome, 
as well as some types of hypertrophic cardiomyopathies and glycogen storages 
diseases of the heart (Arad et al., 2002; Gollob et al., 2001).   
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1.1.2 Function and targets of AMPK 
As stated previously, the main function of AMPK is as a cellular energy regulator.  As 
a kinase, the main effect of AMPK is to phosphorylate other proteins. Analysis of the 
peptide sequences around known AMPK targets have revealed several common 
features. Indeed the SAMS peptide (sequence: HMRSAMSGLHLVKRR) (see 
Chapter 2) now used for AMPK kinase assays by most labs are derived from analysis 
of these features (from the AMPK target Acetyl-Coenzyme A carboxylase: ACC). 
The consensus motif for AMPK indicates a preference for hydrophobic residues at +4 
and -5 residues from the serine or threonine residue to be phosphorylated (Woods et 
al., 1996). The functions of AMPK are diverse and have been an area of intense 
research and new effectors continue to be discovered regularly, the following section 
will provide a brief overview of this topic as it is has been extensively reviewed 
elsewhere (Carling, 2004; Hardie et al., 2012; Steinberg and Kemp, 2009). The 
downstream effects of AMPK on various cellular pathways are summarised in Figure 1.1 
with specific targets and phosphorylation sites shown in Table 1.1.  
 
Carbohydrate metabolism 
At a basic level, carbohydrate metabolism involves either the breakdown of glucose 
via glycolysis, its synthesis through gluconeogenesis or its longer term storage as 
glycogen (through glycogenesis and the reverse process of glycogenolysis). As a 
cellular energy regulator, AMPK is involved in all of these processes, acting to inhibit 
anabolic processes and to activate catabolic processes (Figure 1.1/Table 1.1).  
 
In order for the cell to utilise carbohydrates, they first need to be transported across 
the plasma membrane, this is often the rate limiting step in metabolism, especially in 
working skeletal muscle or in tissues responding to insulin signalling (Kubo and 
Foley, 1986). One of the main ways glucose is transported into cells is through 
facilitated diffusion via GLUT transporters, with the insulin sensitive GLUT4 being 
the predominant form expressed in skeletal muscle. It was found that treatment with 
the AMPK activator AICAR (5-aminoimidazole-4-carboximide ribonucleoside) 
stimulated glucose uptake into rat skeletal muscle and heart cells via a 
Phosphoinositide 3-kinase (PI3K) independent pathway (Bergeron et al., 1999; 
Hayashi et al., 1998). This effect is mediated through increased GLUT4 translocation 
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to the cell membrane (Merrill et al., 1997; Russell et al., 1999; Winder and Hardie, 
1999). More recently, there have been reports showing that AMPK phosphorylates the 
protein AS160, which in turn acts to promote the secretion of GLUT4 containing 
vesicles, thereby facilitating their translocation to the membrane (Geraghty et al., 
2007; Kramer et al., 2006). Additionally, chronic AMPK activation (e.g. with AICAR) 
has been shown to increase GLUT4 expression, thereby further elevating the rate of 
glucose uptake (Holmes et al., 1999; Zheng et al., 2001). The above described 
mechanisms appears to be the main ways by which AMPK serves to  restore energy 
balance in exercising muscle. AMPK has been shown to increase insulin sensitivity, 
and studies have shown that adiponectin mediated AMPK activation leads to 
improvements in insulin sensitivity in cultured muscle cells. One explanation for this 
effect comes from the observation of the phosphorylation of insulin receptor substrate 
1 by AMPK in these cells (Jakobsen et al., 2001; Wang et al., 2007).  
 
Once glucose is in the cell, it is converted into glucose-6-phosphate before entering 
glycolysis pathway. This pathway is catalysed by hexokinases and the reverse 
reaction is catalysed by glucose-6-phosphatase. AMPK has been shown to both 
increase the activity and transcription of hexokinase-II, and decrease the expression of 
glucose-6-phosphatase, thereby leading to an increased substrate supply into 
glycolysis (Holmes et al., 1999; Ojuka et al., 2000; Stoppani et al., 2002; Woods et al., 
2000). The enzyme phosphofructokinase-2 (PFK2) is a bi-functional regulator of 
glycolysis and gluconeogenesis. Phosphorylation of cardiac PFK2 at Ser-466 by 
AMPK elevates its kinase activity which in turn catalyses the formation of fructose 
2,6-bisphosphate, leading to the activation of PFK1 and thereby increasing the rate of 
glycolysis (Marsin et al., 2000). AMPK has also been shown to activate the bi 
functional enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) 
which is central to the glycolytic flux (Mendoza et al., 2012).  
 
In addition to stimulating the catabolic process of glycolysis, AMPK also acts to 
inhibit gluconeogenesis. One possible mechanism though which this is achieved is via 
AMPK’s phosphorylation of the CREB-regulated transcription coactivator-2 protein 
CRTC2 (formerly known as TORC2), which causes its sequestration in the cytoplasm 
and thereby inhibiting transcription of gluconeogenesis genes such as glucose-6-
phosphatase (G-6-Pase), and phosphoenol-pyruvate carboxykinase, (da Silva Xavier 
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et al., 2000a; da Silva Xavier et al., 2000b; Koo et al., 2005; Leclerc et al., 1998; 
Lochhead et al., 2000). Furthermore AMPK has been shown to negatively regulate a 
number of other gluconeogenic genes such as HNF-4α, PCG1α and the carbohydrate 
response element binding protein (ChREBP) (da Silva Xavier et al., 2000a; da Silva 
Xavier et al., 2000b; Hong et al., 2003; Jager et al., 2007; Kawaguchi et al., 2002; 
Leclerc et al., 2001). However, more recently this theory has been called into question 
with one group demonstrating that inhibition of gluconeogenesis as a result of 
metformin treatment is independent of the activation of the AMPK pathway (Foretz et 
al., 2010).  
 
AMPK also negatively regulates the storage of glucose as glycogen. In 1989, AMPK 
was shown to phosphorylate and inhibit glycogen synthase (GS) (Carling and Hardie, 
1989). Additionally AICAR treatment in vivo also led to a decrease in GS activity 
(Wojtaszewski et al., 2002). However, the above effect could be are overridden by 
high concentrations of glucose-6-phosphate (Aschenbach et al., 2002).   
 
Fatty acid metabolism 
Like glucose, fatty acids need to be able to cross the plasma membrane into the 
cytoplasm in order to be used in cellular metabolism. Here, AMPK has also been 
shown to be an important regulator, AMPK activation leads to increased fatty acid 
uptake into both heart and skeletal muscle cells (Figure 1.1/Table 1.1) (Luiken et al., 
2003; Shearer et al., 2004a; Shearer et al., 2004b; Steinberg et al., 2006b). 
 
One of the first important cellular targets identified for AMPK is Acetyl-Coenzyme A 
carboxylase (ACC) (Carling et al., 1987). In mammals, there are two isoforms of 
ACC, ACC1 and ACC2, both phosphorylated by AMPK on the residues Ser79 and 
Ser218 respectively (Tong, 2005). ACC1 is a 265 kDa protein which catalyses the 
irreversible carboxylation of acetyl-CoA to produce malonyl-CoA as a substrate for 
fatty acid synthesis. Phosphorylation of ACC results in its inactivation and therefore 
reduced production of malonyl-CoA. This results in a decrease in the rate of fatty acid 
synthesis. Additionally, the presence of malonyl Co-A also inhibits 
carnitine:palmitoyl-CoA transferase (CPT1), which transports activated fatty acids 
into the mitochondria, thereby decreasing the rate of fatty acid oxidation. It can be 
seen that the actions of AMPK would serve to increase fatty acid oxidation via 
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reduction in malonyl Co-A levels. Phosphorylation of ACC at Ser79 and Ser218 are 
now routinely used as indicators for AMPK signalling in vivo (Park et al., 2002b). In 
addition, AMPK has been shown to positively regulate the activity of malonyl-CoA 
decarboxylase, which catalyses the conversion of malonyl-CoA into acetyl-CoA (Park 
et al., 2002a). Furthermore, AMPK may also inhibit the expression of the fatty acid 
synthase (FAS) enzyme, thereby further inhibiting fatty acid production (An et al., 
2007). AMPK also plays a role in inhibiting cholesterol synthesis by negatively 
regulating the HMG-Co-A reductase (Corton et al., 1994). In addition, both the 
mitochondrial glycerol-3-phosphate acyl-transferase (which is a rate limiting enzyme in 
TG synthesis) and  hormone-sensitive lipase (which is responsible for hydrolysis of 
triglycerides into free fatty acids) are inactivated by AMPK (Steinberg et al., 2006a).  
 
Cell growth, survival and migration 
In line with its role in inhibiting anabolic processes, AMPK is a negative regulator of 
new cellular growth, appearing to induce cell cycle arrest at G1/S phase (Figure 
1.1/Table 1.1). This effect is dependent on the tumour suppressor p53, with AMPK 
activation inducing phosphorylation of p53 on serine 15 (Jones et al., 2005). AMPK 
also directly phosphorylate p27 at Thr198 which may act to decrease cell growth 
while promoting survival of existing cells (Liang et al., 2007).  
 
Evidence has emerged that AMPK activation may help cancer cells survive the 
nutrient and oxygen deprivation encountered when a solid tumour grows. Pancreatic 
cancer cells pre-treated with siRNA against AMPK α1 and α2 were found to have 
much lower tolerances to glucose deprivation compared to non-siRNA treated cancer 
cells (Kato et al., 2002). Furthermore, in prostate cancer cells, it has been shown that 
AMPK activity is necessary for the transcription of hypoxia inducible factor 1 (HIF1), 
which allows cancer cells to metabolically better adapt to anaerobic conditions (Lee et 
al., 2003). Recently, the expression of the AMPK β1 subunit has been demonstrated to 
be essential to the survival of numerous prostate cancer cell lines (Ros et al., 2012). 
 
In recent years AMPK has been implicated in the regulation of both normal cell 
migration and cancer cell invasion. Studies have shown AMPK to be involved in the 
process of cytoskeletal reorganisation (Brenman, 2007; Miranda et al., 2010).  A 
study in 2003 found that AMPK was a regulator in hypoxia induced angiogenesis, and 
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suppression of AMPK reduced the migration of human umbilical vein endothelial 
cells (HUVECs) towards VEGF chemo-attractant (Nagata et al., 2003). Adiponectin 
was found to increase the motility of human prostate cells, and this action was 
inhibited by both siRNA directed against AMPK and treatment with the AMPK 
inhibitor compound C (Chiu et al., 2009; Tang and Lu, 2009). Further evidence 
published recently has implicated CaMKKβ acting via AMPK, in promoting 
migration of prostate cancer cells (Frigo et al., 2011). Recently, the pro-migratory 
effect AMPK has been shown in a number of other cell types, both malignant and 
non-malignant. In ovarian cancer cells, lysophosphatidic acid (LPA) induced 
migration was dependent on AMPK expression, with AMPK siRNA knockdown 
impairing LPA induced migration (Kim et al., 2011a). AMPK inhibitors and siRNA 
mediated knockdown of AMPK was found to negate ghrelin induced motility in 
glioma cells (Chen et al., 2011). Additionally, the microRNA-451 has been shown to 
negatively regulate the activities of LKB1/AMPK, thereby suppressing cell migration 
(Godlewski et al., 2010a; Godlewski et al., 2010b).  Also, it was found that 
endothelial nitric oxide synthase activation promoted lymphocyte migration in a 
manner dependent on CaMKKβ/AMPK regulation (Martinelli et al., 2009). A 2010 
study found that AMPK directly phosphorylated the cytoplasmic linker protein CLIP-
170, which is involved in modulating microtubule dynamics. Inhibition of AMPK in 
this system disrupted microtubule stabilisation and directional cell migration (Nakano 
et al., 2010). This could present a possible mechanism for AMPK to exert its pro-
migratory effects.  
 
However, there is contention in the field with relation to the role AMPK plays in cell 
migration and invasion. In the monocyte-like cell line U97, AICAR and phenformin 
have been shown to decrease random motion of cells as well as migration towards 
stromal cell-derived factor (SDF) 1α (Kanellis et al., 2006). Similar effects were 
observed in both vascular smooth muscle and umbilical vein endothelial cells where 
AICAR treatment reduced injury induced cell migration (Esfahanian et al., 2012; 
Peyton et al., 2012; Stone et al., 2013). Additionally, both expression of dominant 
negative AMPK or siRNA knockdown in the prostate cancer cell-line C4-2 led to 
increased malignant behaviour such as cell migration (Zhou et al., 2009). Similarly, 
metformin treatment was seen to reduce migration in glioblastoma cells (Ferla et al., 
2012). In a 2010 study, adiponectin was found to inhibit Lipopolysaccharide (LPS) 
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induced migration of myofibroblasts in a mechanism dependent on AMPK expression 
and activation (Cai et al., 2010). 
 
From the information presented above, it can be appreciated that the current picture of 
AMPK regulation of cell migration is a contradictory one, with AMPK being shown 
to both stimulate and inhibit cell migration. One possibility for this discrepancy is that 
AMPK exerts different effects on different tissue/cell types. The effects of AMPK 
may also depend on whether the cell is cancerous or not. The reliability of studies 
using some AMPK activators or inhibitors needs to be taken into account as 
molecules such as metformin and compound C have been shown to have off target 
effects independent of AMPK. A potential explanation for the pro-migratory effects 
of AMPK is that in some cells, such as those in cancer, following nutrient restriction 
or hypoxia (and the resulting AMPK activation), there will be a need for the cells to 
migrate to a more nutrient/oxygen rich area. Clearly more research is needed before 
any clear conclusion can be drawn.  
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Figure 1.1 Cellular effects of AMPK 
As a regulator of cellular energy homeostasis, AMPK responds to conditions of cellular energy depletion by phosphorylation of downstream targets 
which leads to inhibition of anabolic processes (Red arrows) and stimulation of catabolic processes (Green arrows). Recently, AMPK has also been 
shown to regulate both the migration of cell under physiological conditions and the invasion of cancer cells through adjacent tissues. However, 
evidence for these processes are conflicting, with some sources suggesting a positive role for AMPK and other a negative role. See section 1.1.2 for 
details. 
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1.1.3 Regulation of AMPK activity 
As AMPK is involved in many physiological and pathological processes, it is very 
important for the cell to exert strict regulation of its activity. Currently, there are two 
known methods for direct regulation of AMPK activity: the first and most potent 
being the regulation of phosphorylation of AMPK by upstream kinases and 
phosphatases (Steinberg and Kemp, 2009). Secondly, AMP binding to the γ subunit is 
able to elicit allosteric activation of AMPK (Adams et al., 2004). This also represents 
an important method for the regulation of AMPK activity. Additionally, recently, our 
group have identified that ADP binding the γ subunit helps to protect AMPK from 
dephosphorylation (Xiao et al., 2011). The regulation of AMPK by these processes 
will be discussed in more detail in the following section (an overview of these 
processes is provided by Figure 1.3).  
 
 
 
Table 1.1 Direct targets of AMPK 
Table showing direct protein targets of AMPK, categorised into various different 
cellular functions. From (Towler and Hardie, 2007).  
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Phosphorylation and dephosphorylation of AMPK  
The phosphorylation and dephosphorylation of AMPK represent the major 
mechanisms by which AMPK activity is regulated. The phosphorylation of the key 
residue theronine-172 (Thr-172), in the activation loop of the kinase domain in the α 
subunit is essential for AMPK to become active (Davies et al., 1995; Hawley et al., 
1996; Stein et al., 2000). Indeed when this residue is altered to an alanine using site 
directed mutagenesis, AMPK activity is almost completely abolished. Although other 
residues within AMPK can become phosphorylated, for example serine-485, they do 
not appear to have any direct effect on AMPK activity (Woods et al., 2003b). A 
schematic representation of the AMPK activation by upstream kinases and 
deactivation by upstream phosphatases is shown in Figure 1.2.  
 
Upstream kinases  
Phosphorylation of Thr-172 in vivo is mainly achieved by up-stream kinases LKB1 
and CaMKK (Figures 1.2 and 1.3). LKB1 is a tumour suppressor involved in the 
development of  Peutz-Jeghers Syndrome (PJS) (Hawley et al., 2003; Woods et al., 
2003a)   and CaMKK plays important roles in the CaM-kinase signalling cascade 
(Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005).  
 
The functional LKB1 complex is made of 3 proteins, the LKB1 kinase, STE20-related 
adaptor (STRAD) protein and mouse protein 25 (MO25) (Boudeau et al., 2003; 
Boudeau et al., 2004; Zeqiraj et al., 2009). The binding of STRAD increases LKB1 
activity by 4 to 5 fold and MO25 binding increases the stability of the complex and 
results in its localisation in the cytoplasm (Boudeau et al., 2004). Expression of this 
enzyme is ubiquitous and LKB1 seems to be the main AMPK upstream kinase in 
most metabolic tissues (Carling et al., 2008). Indeed, in LKB1 knockout mouse 
tissues, a drastic reduction in AMPK activity is seen (Sakamoto et al., 2005; Shaw et 
al., 2005; Woods et al., 2011).  
 
Although a number of phosphorylation sites have been identified within LKB1, many 
reports have shown the enzyme as constitutively active (Collins et al., 2000; Sapkota 
et al., 2002). Mutations of these phosphorylation sites to alanine residues has no effect 
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on LKB1 activity, and treatment of purified LKB1 in-vitro with phosphatases does not 
decrease its activity either (Denison et al., 2009).   
 
CaMKKβ, as suggested by its name is activated by increases in intracellular calcium 
levels. It was first identified as an upstream kinase of AMPK by two groups at almost 
the same time (Hawley et al., 2005; Woods et al., 2005). The discovery of this 
upstream kinase showed that AMPK was involved in calcium mediated signalling. 
Subsequently many hormones and cytokines which lead to activation of the G protein 
coupled receptor pathway (the Gq-phospholipase C axis), has been shown to mediate 
their effects at least partially through AMPK.  CaMKKβ is expressed in more limited 
set of tissues compared to LKB1. It is highly expressed in many areas of the brain, 
(such as the hippocampus, dentate gyrus, hypothalamus, and cerebellum) where it 
regulates important functions such as memory and cerebellar development. It is also 
expressed at low levels many other organs including skeletal and smooth muscle, 
kidneys, and the thymus (Racioppi and Means, 2012).  
 
A third, more controversial up-stream kinase candidate is TAK1 (transforming growth 
factor- (TGF) -activated kinase-1. However the physiological role of this regulation 
is not clearly defined (Momcilovic et al., 2006; Xie et al., 2006).  
 
Protein Phosphatases acting on AMPK  
As described above, in the last ten years there have been great advances made in the 
identification of upstream kinases of AMPK. However, this is only half the story, the 
reverse reaction in which AMPK is inactivated involves the dephosphorylation of 
Thr-172 and is mediated by protein phosphatases. Due to the characterisation of 
LKB1 as constitutively active, this dephosphorylation step could be more important in 
the regulation of AMPK activity, compared to that of phosphorylation (Lizcano et al., 
2004; Woods et al., 2005; Woods et al., 2003a).  More recent data showing AMP + 
ADP binding to AMPK protects the enzyme from dephosphorylation also add further 
importance to this step (Figure 1.2) (Davies et al., 1995; Sanders et al., 2007b; Suter 
et al., 2006; Xiao et al., 2011).   
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Compared to our understanding of the AMPK upstream kinases, much less is known 
of the phosphatases which act to dephosphorylate it. In recent years, a number of 
potential AMPK phosphatases have been reported, these studies will be discussed 
later in this section. First, brief descriptions of the main phosphatase classes are 
provided below.  
 
Overview of protein phosphatases 
Protein phosphorylation is a reversible post translational modification catalysed by 
protein kinases and reversed by protein phosphatases. Protein phosphatases are 
divided into two major classes according to their substrate specificity: tyrosine 
specific and serine/threonine phosphatases (Shi, 2009; Zhang, 2002). As the major 
activation site of AMPK is the Thr-172 residue, this section will focus on the 
Serine/Threonine phosphatases. Of note, there are also a class of dual specificity 
phosphatases which are able to dephosphorylate all three afore mentioned residues 
(although generally classed under protein tyrosine phosphatases). 
 
The serine/threonine phosphatase family consists of three distinct classes, divided 
according to their structure: The phospho-protein phosphatase (PPP) class, the metal-
dependent (Mg
2+
) phosphatase (PPM) class and aspartate-based phosphatases 
(represented by FCP class phosphatases) (Shi, 2009). As the only known substrate for 
FCP phosphatases is the C-terminal domain (CTD) of RNA polymerase II, it is of no 
relevance to this study and will not be discussed further.  
 
Surprisingly, the number of phosphatases appears to be 2-3 times fewer than those of 
kinases. This may suggest comparison to kinases, phosphatases have a greater 
dependence on interaction with regulatory other cellular proteins in order to confer 
specificity.  
 
The Phospho-Protein Phosphatase (PPP) class 
The PPP class of phosphatases consists of multi-subunit enzymes, and are split into a 
number of sub-classes. The limited number of catalytic subunits in each sub-class are 
able to associate with a much larger number of regulatory subunits. Main members of 
the PPP class include PP1, PP2A, PP2B and other members include PP4, PP5, PP6, 
and PP7 for which less is known about (Shi, 2009; Virshup and Shenolikar, 2009). 
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This class of phosphatases account for the majority of phosphatase activity in an in-
vivo environment.  
 
PP1 is the major subclass of the PPP family and is expressed in all eukaryotic cells. In 
cells, an active PP1 complex consists of a catalytic subunit and a single regulatory 
subunit. There are three different PP1 catalytic subunit isoforms, which are highly 
conserved among eukaryotes, namely PP1Cα , PP1Cβ, and PP1Cγ, all three of which 
are around 30 kDa in mass and show high levels of similarity apart from the domains 
which allow it to bind with different PP1 regulatory subunits. The free catalytic 
subunits of PP1 have high activity and low specificity, and require the binding of 
regulatory subunits to confer specificity (Cohen, 2002; Terrak et al., 2004).  
 
There are over 50 known regulatory subunits of PP1, these act to confer substrate 
specificity, as well as assisting the sub-cellular targeting of the various complexes 
(Ceulemans and Bollen, 2004; Cohen, 2002).  These regulatory subunits share little 
homology apart from a common PP1 catalytic unit binding motif. An example of the 
regulatory subunits influencing the specificity of PP1c is highlighted here, when the 
regulatory subunit: myosin phosphatase targeting subunit (MYPT1) binds to PP1C, it 
causes a change in conformation of in the catalytic cleft which results in a substantial 
increase in activity for the myosin light chain and a concurrent decrease in activity to 
other potential substrates (Gallego and Virshup, 2005; Terrak et al., 2004). This 
dependency on regulatory subunits for specificity creates difficulties for the study of 
PP1 targets in vitro, as in many studies, the catalytic subunits used to dephosphorylate 
potential targets without regulatory subunits, and potentially producing misleading 
results (Davies et al., 1995; Sanders et al., 2007b).   
 
Apart from the regulatory subunits, another layer of regulation for PP1 is achieved via 
endogenous inhibitory proteins such as Inhibitor-1 (I-1) (Cohen and Nimmo, 1978), 
inhibitor-2 (I-2) (Foulkes and Cohen, 1980), DARPP32 and CPI-17  (Eto et al., 1997; 
Walaas and Greengard, 1991). The inhibition of PP1 by these proteins is thought to be 
achieved through binding to the phosphatase catalytic site.  
 
The PP2A class of phosphatases have much in common with that of PP1 in that they 
also exist predominantly in multi-subunit forms. PP2A is an extremely abundant 
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protein, accounting for 0.1% - 1% of total cellular protein content (Gallego and 
Virshup, 2005). In cells they mostly have two conformations: as a hetero-dimeric core 
enzyme or a hetero-trimeric holoenzyme. The two subunits which make up the 
dimeric core enzymes is a catalytic subunit (of around 36 kDa) and a scaffolding 
subunit (around 65 kDa, also known as PR65), both of which has two different 
isoforms (named as α and β isoforms (Shi, 2009). This association with the 
scaffolding subunit is unique for among PPP enzymes, although other PPP members 
share significant sequence homology with PP2A. Like PP1, the PP2A catalytic 
subunits have relatively little substrate specificity and will dephosphorylate many 
potentially non-physiological substrates in vitro.  Like PP1, there are a plethora of 
regulatory proteins that interact with PP2A. They are split into four main families, 
B55, B56, PR48 and PR93, with the numbers corresponding with their molecular 
masses, each of which includes multiple isoforms. In most cases, in order to confer 
specificity the enzyme would need to be in the trimeric conformation attached to a 
regulatory subunit. Indeed, although purification of the core dimer have been made 
from various tissues, some studies have suggested that these are in fact artefacts 
produced by the purification process and only the trimeric complex exists in vivo 
(Cohen, 1989; Depaoli-Roach et al., 1994). This conclusion would be logical, as 
based on the activity of the PP2A catalytic subunit in vitro, it would be very difficult 
to see how the enzyme’s activity can be contained in vivo without a regulatory subunit, 
and unrestricted/unspecific phosphatase activity could be toxic to cells (Gallego and 
Virshup, 2005). According to current knowledge, the PP2A scaffolding subunit binds 
tightly to the catalytic subunit, thereby forming a structure to which the regulatory 
subunits can bind.  
 
The metal dependent (PPM) class 
Compared to PPP family members, PPM (previously named PP2C) isoforms have 
little sequence homology and are thought to be essentially self-directed in terms of 
targeting and substrate specificity, conferred via various structural domains. These 
enzymes are thought to have evolved independently from the PPP family (Barford et 
al., 1998). As implied by the name, the activities of these phosphatases are dependent 
on the binding of Mg
2+ or Mn
2+ ions. Up to now, there has been at least 17 members 
of the PPM class identified (Lu and Wang, 2008).  
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In contrast to the PPP family, PPM phosphatases are single subunit enzymes, with no 
regulatory or scaffolding subunits, but they do possess domains within the catalytic 
subunit which may confer substrate specificity, which is rather similar to the situation 
seen with tyrosine phosphatases. In addition, these enzymes are also resistant to 
okadaic acid and calyculin A and other classical inhibitors of the PPP family (Swingle 
et al., 2007).  
 
Members of the PPM family are involved in a wide range of cellular processes. A 
important process regulated by the PPM phosphatases are the stress signalling 
pathways, such as the Mitogen-activated protein kinase (MAPK) pathway. Several 
reports have shown the critical function that PPM isoforms play in correct MAPK 
signalling (Hanada et al., 2001; Takekawa et al., 1998). In addition, PPM has also 
been implicated in PI3Ks and Protein Kinase B (PKB/Akt) signalling, protein 
ubiquitination and cell metabolism, as well as signalling in death/survival. This topic 
has been the subject of excellent recent reviews, which provides more details on the 
regulation and function of PPM isoform (Lu and Wang, 2008; Stern et al., 2007).   
 
Candidates for the AMPK phosphatase 
The first indications for the identity of the AMPK phosphatase came from studies 
performed in the late 1980s and early 1990s. Studies performed in vitro, where 
PP2C/PPM1A or the catalytic subunits of PP2A or PP1 was incubated with pre-
activated AMPK (or AMPK isolated from mammalian cell extracts), showed that all 
these phosphatases are able to dephosphorylate AMPK at Thr-172 and decrease its 
activity (Davies et al., 1995; Sanders et al., 2007b; Suter et al., 2006). From the 
research by Davies et al, it can been seen that treatment with PPM1A results in a more 
pronounced reduction of AMPK activity when compared to that of PP2A (Davies et 
al., 1995).  It was possible to infer from these results that PPM1A could be the in vivo 
AMPK phosphatase. Indeed PPM1A has become the defacto phosphatase to use when 
conducting the in vitro dephosphorylation of AMPK. As explained in the previous 
section, the studies quoted above have inherent problems. As although PPM 
phosphatases are single subunit enzymes, members of the PPP family almost always 
require the binding of regulatory subunits to confer target specificity, thus it would 
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appear that these results for PP2A and PP1 have limited in vivo relevance due to the 
lack of the multitude of regulatory subunits.  
 
The first study in a more physiological ex vivo system was published by Moore et al 
in 1991. It was noted by researchers that when hepatocytes were isolated from rats 
they had very high initial AMPK activities, which decreased over time as they were 
cultured. This was most likely due to the hypoxia induced increase in AMP:ATP or 
ADP:ATP ratios in the cells as they were isolated. Next, okadaic acid, a selective 
phosphatase inhibitor of the PPP family phosphatases, but not the PPM family was 
used to treat newly isolated hepatocytes. It was found that while okadaic acid 
inhibited the decrease in phosphorylation in acetyl-CoA carboxylase (ACC), the 
decrease in AMPK activity/phosphorylation was not blocked (Moore et al., 1991). 
This result suggests that while the ACC-phosphatase maybe a member of the PPP 
family (most likely PP2A), the AMPK phosphatase is likely to be one or more 
members of the PPM family. Additional evidence supporting this hypothesis was 
published more recently. In L6 myotubes, it was observed siRNA knockdown of 
PPM1A abolished the ability of TNF-α to decrease AMPK activity, although no effect 
on basal activity was reported (Steinberg et al., 2006b). PPM1A siRNA also reversed 
the downstream effects of TNF-α on AMPK, such as the suppression of ACC 
phosphorylation, fatty acid oxidation and insulin mediated glucose uptake. More 
recently, quercetin, a naturally occurring flavonoid was reported to activate AMPK in 
mice, while at the same time depressing PPM1A and PPM1B expression (Lu et al., 
2010). In 2012, it was reported that N-myristoylation of PPM1A and PPM1B is 
essential to their ability to dephosphorylate AMPK Thr-172, siRNA mediated 
knockdown of PPM1A and PPM1B both increased AMPK phosphorylation in cells 
over-expressing AMPK LKB1, whereas knockdown of the other PPM members had 
no effect (Chida et al., 2013). Furthermore, the authors identified that PPM1A and 
PPM1B must be N-myristoylated in order to dephosphorylate AMPK.  While this 
thesis was in progress, another study was published where shRNA was used to create 
stable knockdowns of PPM isoforms in HEK293 cells. PPM1E silencing caused a 
significant elevation of AMPK Thr-172 phosphorylation levels. PPM1E depletion 
also augmented phenformin induced increase in AMPK phosphorylation. Additional 
data from this study also suggest PPM1F contributed to the regulation of AMPK 
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phosphorylation. This study and its relevance to my results will be discussed in more 
detail in Chapter 3 (Voss et al., 2011).  
 
Aside from the PPM family, in recent years, members of the PPP family have also 
been implicated as AMPK phosphatases, making the field more contentious. When 
various purified phosphatases were used to dephosphorylate protein homogenate 
fractions from cortical neurons, it was found that PP1, PP2A and PPM1A all reduced 
AMPK phosphorylation at Thr-172, whereas PP2B had no effect (Kuramoto et al., 
2013).  In a yeast two-hybrid screen, deletion of PP2A was found to affect the 
glucose-regulated interaction between the α2 and γ1 subunits of AMPK. It was also 
found that PR65 (the scaffolding subunit of PP2A) interacted with AMPK α2 
(Gimeno-Alcaniz and Sanz, 2003). A 2005 study where rat hepatocytes were treated 
with increasing concentrations of various PPP inhibitors (including okadaic acid, 
calyculin A, microcystin and tautomycin) all resulted in significant increases in both 
AMPK Thr-172 and ACC phosphorylation with dose response characteristics 
indicating PP2A/PP1 contribution. The inhibitors does not seem to affect motility of 
the upstream kinase LKB1 on SDS-gels, indicating its phosphorylation was not 
altered. The authors however think that the effect of the inhibitors on AMPK 
phosphorylation is indirect and suggest the phosphorylation at multiple sites (in 
addition to Thr-172) maybe increased by these phosphatase inhibitors, due to the 
presence of multiple low mobility bands of phosphorylated AMPK (Samari et al., 
2005). Exposure of bovine aortic epithelial cells to palmitoleic acid, which activates 
PP2A, reduced AMPK-Thr-172 phosphorylation. Furthermore, use of okadaic acid 
and siRNA knockdown of PP2Ac are able to abolish the effect of palmitate on AMPK 
(Wu et al., 2007).  
 
In another study published during my project, PP1 and its R6 regulatory subunit were 
shown to regulate the glucose induced dephosphorylation of AMPK in mouse 
pancreatic beta cells (MIN6) (Garcia-Haro et al., 2010). The implications of this paper 
will be discussed in more detail in Chapter 3.  
 
As can be seen, much of the evidence discussed above was published after this thesis 
commenced in 2009, and the consensus at that point was that the AMPK phosphatase 
most likely belonged to the PPM family, with little siRNA based studies having been 
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published. It was against this backdrop that my work to identify the AMPK 
phosphatase was started. However, it can be appreciated that the picture today is a 
rather more complex one. There is no consensus as to the identity of the AMPK 
phosphatase(s), with all major classes of serine/threonine phosphatases having been 
put forward as potential candidates. 
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Figure 1.2 Regulation of AMPK by phosphorylation 
The activity of AMPK is predominantly determined by phosphorylation of the Thr-172 residue of 
the α subunit. This Phosphorylation is catalysed by upstream kinases, LKB1 and CaMKKβ, more 
recently TAK1 was shown to phosphorylate and activate AMPK (there are some dispute within the 
field). At the time of starting this thesis, PP2A and PPM/PP2C have been shown to 
dephosphorylate AMPK in vitro, however, the protein phosphatase regulating AMPK activity in 
vivo is unknown.  
 
AMP/ADP: allosterically activates AMPK (step labelled as 1) as well as protecting the enzyme 
from dephosphorylation (step labelled as: 2)  
 
Additionally, recent studies have implicated AMP and ADP in promoting the phosphorylation of 
AMPK dependent upon β-subunit myristoylation (Oakhill et al., 2010; Oakhill et al., 2011).  
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1.1.4 Regulation of AMPK by whole body signals 
As well as being regulated by immediate imbalances in the AMP or ADP to ATP 
ratios, calcium fluxes and other intracellular signals, AMPK activity has been found 
to be influenced by a number of hormonal signals. These signals induce AMPK to 
responds to changes in the energy state of tissues or at the whole organism level. A 
schematic representation of the intracellular and whole body signals which serve to 
regulate AMPK is shown in Figure 1.3.  
 
AMPK plays an important role in appetite regulation by acting as a relay for various 
whole body signals. Injection of a virus encoding a constitutively active form of 
AMPK into rat hypothalamus caused increases in appetite and body weight of these 
animals, whereas injection of dominant negative AMPK caused the opposite effect 
(Minokoshi et al., 2004).  
 
AMPK also plays important roles downstream of the appetite regulating hormones 
ghrelin and leptin. Ghrelin is an important hunger signal, being secreted before meals 
to increase appetite, leptin on the other hand is secreted by adipocytes to signal satiety, 
acting to decrease feeding. In the hypothalamus, leptin injection caused a decrease in 
hypothalamic AMPK activity, whereas ghrelin administration caused an opposite 
effect, this was then associated with an increase in feeding (Andersson et al., 2004; 
Minokoshi et al., 2004). Unexpectedly, in contrast to the CNS, leptin exerts an 
opposite effect on AMPK in peripheral tissues, with leptin acting to increase AMPK 
activity and thereby stimulating fatty acid oxidation in skeletal muscle (Minokoshi et 
al., 2002). This rather paradoxical result perhaps reflects the differing roles that 
AMPK plays in these tissues, with AMPK acting to elevate intracellular ATP levels in 
the short term, via increased fatty acid oxidation in peripheral tissues while 
concurrently increasing feeding (which will not yield an immediate energy benefit). 
Recently a study has shown Intra-peritoneal (IP) administration short-chain fatty acid 
acetate into mice caused reductions in pAMPK (at Thr-172) and pACC levels (S79) in 
hypothalamic tissues, these effects were associated with a reduction in appetite in 
these mice (Frost et al., 2013, accepted for publication in Nature Communications, 
Apr 2014).   
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Like leptin, the hormone adiponectin is secreted by adipose tissue and regulates a 
number of metabolic processes such as carbohydrate metabolism and fatty acid 
oxidation. Adiponectin has been shown to play important roles in counteracting the 
detrimental effects of a number of metabolic conditions such as type II diabetes, diet 
induced obesity, and fatty liver. Combined treatment of leptin and adiponectin has 
been shown to completely reverse insulin resistance in mouse models (Yamauchi et 
al., 2001).  In skeletal muscle, adiponectin activated AMPK via signalling through 
adiponectin receptor 1 (AdipoR1), leading to increased anabolic production of ATP 
via increased fatty acid oxidation and glycolysis (Yamauchi et al., 2002; Yamauchi et 
al., 2007).  
 
Aside from the hormones described above, AMPK activity/expression has been found 
to be regulated by a number of other whole body signalling proteins. The cytokine 
interlukin-6 (IL-6) has been found to activate AMPK, with AMPK signalling being 
suppressed in many tissues of IL-6 KO mice (Kelly et al., 2004). TNF-α has been 
found to decrease AMPK signalling, with a concurrent increase in the expression of 
PPM1A phosphatase (Steinberg et al., 2006b). The sex hormone oestrogen has been 
shown to directly activate AMPK in cultured muscle cells, whereas 
dihydrotestosterone infusion led to a decrease in AMPK activity in adipocytes (D'Eon 
et al., 2005; McInnes et al., 2006).  
 
In can be seen  from information provided in the above section that AMPK plays vital 
roles in the regulation of energy balance at a cellular and whole body level, and 
gaining a full understanding of the regulation AMPK is of vital importance in 
devising new treatments for a many diseases ranging of diabetes to cancer.  
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Figure 1.3 Regulation of AMPK activity 
Diagram showing various cellular and extra-cellular pathways regulating AMPK activity. Green arrows indicate stimulatory effects on activity whereas 
red as red arrows indicate inhibitory effects on activity.  Adapted from ScienceSlides online (http://www.scienceslides.com/). 
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1.2 PAK1 
The p21-activated kinase 1 (PAK1) belongs to the PAK family of serine/threonine 
kinases and has a molecular mass of 68 kDa. PAK proteins are important controllers 
of cell polarity, actin cytoskeletal organisation, cellular morphology, migration and 
invasion. The PAK family consists of 6 members which are divided into two groups, 
with PAK1-3 belonging to group 1 and PAK 4-6 belonging to group 2 (Bokoch, 
2003).  
 
PAK1 was identified as an AMPK interacting protein in chapter 5 and its association 
with AMPK was characterised in chapters 5 and 6. A review of the structure, 
regulation and function of PAK1 is provided below.  
 
1.2.1 Structure and regulation of PAK1 
PAK1 is the best understood member of all the PAK kinases and was initially 
identified as a downstream effector of the Rho GTPases Rac and Cdc42. It contains a 
C terminal kinase domain and a N terminal regulatory domain. The regulatory domain 
consists of a GTPase binding domain (PBD) as well as an auto-inhibitory domain 
(AID). A diagram showing the primary structure of PAK1 is shown in Figure 1.4. 
The main distinguishing feature between group 1 and group 2 PAKs are that the group 
2 PAKs lacks the auto-inhibitory domain, as a result the group 2 PAK possesses a 
higher basal activity compared to those of group 1. The main mode of activation of 
group 1 PAKs is via through direct binding to the activated forms of the GTPases 
Rac1, Rac2, Rac3 and Cdc42 (Knaus et al., 1998; Manser et al., 1994; Mira et al., 
2000). It is also activated by less well known GTPases TC10, CHP, and Wrch-1 
(Aronheim et al., 1998; Neudauer et al., 1998; Tao et al., 2001). The PAK1 protein 
exists as a protein dimer in cells with the auto-inhibitory domain of one PAK1 
molecule pressed against the kinase domain of the other thereby inhibiting it (Parrini 
et al., 2002; Zhao et al., 1998).  Data from structural studies reveal that upon the 
binding of GTPases a major structural change occurs in the inhibitory domain, thereby 
disrupting its interaction with the kinase domain of the dimer protein. After release of 
the kinase domain, PAK1 undergoes auto-phosphorylation on various sites, with 
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phosphorylation of Thr-423 in the kinase domain being the most important in gaining 
full kinase function towards its substrates, and also relief from continued auto-
phosphorylation (Lei et al., 2000; Zenke et al., 1999). Other important 
phosphorylation sites which affect PAK1 activity include Ser-144, Ser-198/Ser199 
and Ser-203 (Chong et al., 2001). All group 1 PAK kinases complex with the focal 
adhesion-associated proteins, known as PIX proteins. PIX proteins in turn are tightly 
associated with the ARF GTPase-activating protein 1 (GIT-1), and both proteins form 
an activation complex with PAK1 (Turner et al., 1999). GIT-1 is a ubiquitous protein 
localized to focal adhesions, cytoplasmic complexes and membrane protrusions. It 
interacts with various GTPases to help regulate focal contact assembly and 
cytoskeletal dynamics (Hoefen and Berk, 2006; Manser et al., 1998). PIX proteins are 
guanine nucleotide exchange factors (GEFs) which act to recruit and activate GTPases, 
which then bind to and activate PAK1. PIX together with GIT-1 direct PAK1 to focal 
adhesions at leading edges of motile cells, where the complex performs its actions 
(Manabe et al., 2002; Zegers et al., 2003).  
 
Aside from the auto-phosphorylation caused by GTPase binding, additional 
mechanisms of direct regulation of PAK1 activity have also been discovered. Protease 
mediated digestion have been shown to activate PAK1 (Benner et al., 1995). GIT1, 
which associates with PAK1 and βPIX have also been observed to activate PAK1 
independent of GTPases (Loo et al., 2004). Direct phosphorylation by 3-
phosphoinositide-dependent kinase 1 (PDK1) at Thr-423 on PAK1 has been proven to 
activate the kinase (King et al., 2000). Furthermore, Akt has also been shown to 
activate PAK1 by direct phosphorylation on the Ser-21 residue without requiring the 
involvement of either Cdc42 or Rac1. Phosphorylation at the Ser-21 site decreases 
PAK1 binding to the adaptor protein Nck in order to modulate migration of Rat1 cells 
(Zhou et al., 2003). Additionally, phosphorylation of PAK1 at Ser-212 by cyclin 
dependent kinase 5 (CDK-5), is involved in the regulation of neurite growth (Banerjee 
et al., 2002). These results demonstrate the ability of PAK1 activity and interactions 
to be regulated by upstream kinases in addition to binding by GTPases. A diagram 
(Figure 1.5) illustrating the process of activation of PAK1 and its downstream effects 
is shown .  
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Interestingly, two members of the PPM phosphatase family, PPM1E and PPM1F have 
been shown to be effective negative regulators of PAK1, mediating the de-
phosphorylation the enzyme at Thr-423 (Koh et al., 2002). These phosphatases have 
been found in complex with the PIX proteins. The presence of these potent 
deactivators of PAK1 in the same complex may help explain the ability of PAK1 to be 
rapidly deactivated (Zhan et al., 2003). In addition to dephosphorylation, there are 
other mechanisms by which the enzyme is negatively regulated. The PAK interacting 
protein hPIP1, which shares sequence homology with the yeast PAK regulator Skb15, 
have been shown to interact with PAK to inhibit Ccd42/Rac mediated activation. 
Over-expression of hPIP in the COS-7 cell-line or mouse embryonic fibroblasts led to 
down regulation of PAK-mediated c-Jun N-terminal kinase and nuclear factor kappa 
B signalling pathways, resulting in abnormal cell morphologies (Xia et al., 2001). In 
2004, a study showed that the protein nischarin, originally identified as an integrin 
binding protein, directly interacted with the C-terminal domain of Rac bound PAK1. 
This binding inhibits the ability of PAK1 to phosphorylate downstream targets 
resulting in decreased cell migration. Indeed RNAi based knockdown of nischarin in 
the phaeochromocytoma derived cell-line PC12 led to increased cell migration 
(Alahari et al., 2004). Similarly, the protein merlin, coded for by the Nf2 tumour 
suppressor gene interacted with the GTPase binding domain of PAK thereby 
inhibiting its activity (Kissil et al., 2003) 
 
 
 
 
 
 
 
 
1.2.2 Upstream signals for PAK1 activation 
Having discussed the direct mechanisms of PAK1 activation, below is a brief 
summary of the indirect upstream signals that lead to the activation of PAK1. 
Extracellular signals acting upon receptor tyrosine kinases and G protein coupled 
receptors leads to PAK1 activation (Figure 1.5). In general these pathways activate 
Figure 1.4 Primary structure of PAK1 
The p21 (Rac/Cd42)-binding domain (PBD), auto-inhibitory domain (AID) and kinase 
domain are shown. Additionally, the binding sites on PAK1 to the adaptor Nck and the 
guanine exchange factor PIX are indicated.  
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PAK1 through sequential activation of PI3K and a guanine nucleotide exchange factor 
(GEF) which then activates Cdc42 or Rac (Menard and Mattingly, 2003). Several 
examples of upstream PAK1 activators are introduced below.  
 
In vascular smooth muscle cells, LPA, which has been suggested to mediate it pro-
migratory effects through AMPK was shown to also increase PAK1 activity by over 3 
fold (Kim et al., 2011a; Schmitz et al., 2002). In 2003 it was shown that basic 
fibroblast growth factor signalling activated PAK1 and protected cells against 
apoptosis (Alavi et al., 2003).. In the intestine, insulin or insulin like growth factor 
(IGF-1) treatment led to increased PAK1 Thr-423 phosphorylation, which was 
abolished by the PAK1 inhibitor IPA3. This activation was found to be PI3K 
dependent (Sun et al., 2009; Tsakiridis et al., 1996). Furthermore, PAK1-/- mice have 
been found to exhibit impaired global glucose tolerance after IP or oral glucose 
challenges, furthermore, these mice also exhibited peripheral insulin resistance 
(Chiang et al., 2013; Wang et al., 2011).  
 
1.2.3 Function and targets of PAK1 
As a kinase, the main function of PAK1 is to phosphorylate other proteins. To date, 
Over 40 PAK1 substrates have been identified. There is a limited degree of flexibility 
in the peptide sequences that PAK1 is able to phosphorylate. In 2007, a study was 
performed using a peptide library to comprehensively characterise the consensus 
phosphorylation motifs of Group 1 and 2 PAKs. It was found that PAK1 and PAK2 
shared virtually identical substrate recognition motifs which are distinct from the 
group 2 PAKs. Both PAK1/2 showed a preference for arginine at all positions from -5 
to -1 from the phosphorylation site and large hydrophobic residues in positions +1 to 
+3 (Rennefahrt et al., 2007). In another study, the group 1 PAK proteins are also 
found to prefer basic amino acids at positions +2 and +3 (Tuazon et al., 1997). The 
reason for the discrepancy between the two studies is not clear, however the findings 
from the 2007 studies have been used to design specific peptide substrates for PAK1, 
which has been used subsequent studies (Strochlic et al., 2010). Additionally, group 1 
and 2 PAKs exhibited a marked preference for serine over threonine as the phosphor-
acceptor site. However when existing PAK substrates were mapped against the 
predicted recognition sequences generated, it was found that none of the known 
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substrates scored within the top 2% of the of the predicted sites. This may suggest that 
other factors such as the tertiary structure of substrates, protein interactions, 
subcellular localisation are perhaps more important in determining PAK substrates 
(Rennefahrt et al., 2007).  
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Figure 1.5 Activation of PAK1 and downstream targets 
Signalling from receptor tyrosine kinases (e.g. insulin, EGF receptors) and G-protein-coupled 
receptors activates Rac1/Cdc42. Which then binds to and activates PAK1.  In addition, kinases 
such as Akt and CDK-5 are able to directly phosphorylate and activate PAK1. PAK1 activation 
is enhanced and stabilised by auto-phosphorylation. Activated PAK1 then phosphorylates a 
range of downstream targets mediating the motility/migration properties of cells and cellular 
survival and proliferation.  
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1.2.4 PAK1 function in physiology and pathology 
As stated above, PAK1 is an important regulator of cytoskeletal dynamics, cell 
polarity, morphology, motility and invasion (Figure 1.5). PAK1 is expressed in most 
tissue types, with especially high levels seen in the neuronal tissues, cardiac muscle 
and neutrophils (Burbelo et al., 1999; Clerk and Sugden, 1997; Dharmawardhane et 
al., 1999). Often, the activation of PAK1 results in its translocation from one area of 
the cell to another. Upon PAK1 activation in NIH3T3 cells, PAK1 redistributed from 
the cytosol to the cell periphery (Dharmawardhane et al., 1997; Kichina et al., 2010).  
Several studies have also shown PAK1 localisation to focal adhesions upon activation 
(Manser et al., 1997; Sells et al., 2000). 
 
Many recent reports show that PAK1 is heavily involved in various physiological and 
pathological processes. Dysregulation of PAK1 activity promotes carcinogenesis, and 
up-regulation of PAK1 are been seen in many types of cancer as well as after stroke 
and other ischemic conditions. This enzyme, primarily acting downstream of the 
GTPases Cdc42 and Rac phosphorylates or interacts with many cytoskeletal adaptor 
proteins, cytoskeletal filament proteins, guanine nucleotide exchange factors, 
integrins, as well as other kinases and phosphatases (Bokoch, 2003; Dummler et al., 
2009).  
 
In the last two decades, PAK1 has emerged as a positive regulator of cell motility and 
migration. Cell migration and invasion through the extracellular matrix is a complex 
process, involving extensive reorganisation of the cellular actin structure, the 
degradation of extracellular components using proteases and the disruption of existing 
cell-cell junctions to facilitate movement. Hormones and growth factors such as 
insulin and platelet derived growth factors (PDGF) have been shown to be able to 
recruit PAK1 to into membrane ruffles (Sells et al., 2000). Expression of 
constitutively active PAK1 induced the formation of large membrane ruffles, as well 
as filipodia in Swiss 3T3 fibroblasts and REF52 cells (Sells et al., 1997). It is at these 
leading edges of cells and membrane ruffles that PAK1 acts on downstream targets to 
facilitate cell motility. The microinjection of constitutively active PAK1 into both 
Hela cell and Swiss 3T3 fibroblasts caused the loss of stress fibres along with loss of 
focal adhesions. These results were similar to the effect produced upon the injection 
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of Cdc42 or Rac into cells (Manser et al., 1997).  Further studies where the PAK1 
auto-inhibitory domain was over-expressed in order to induce inhibition of the 
enzyme produced the opposite results to those shown above (Zhao et al., 1998). The 
dynamics of cellular microtubules are involved in many cellular processes such as 
chromosomal segregation, motility and cell morphology. PAK1 directly interacts with 
and phosphorylates tubulin cofactor B (TCoB). This phosphorylation is essential for 
the proper polymerization of new microtubules (Vadlamudi et al., 2005). PAK1 has 
been demonstrated to be important in neuronal development, including the formation 
of dendritic spines (Kreis and Barnier, 2009). Pak1 has been shown to co-localise 
with the postsynaptic density protein 95 (PSD95) in dendritic spines. PSD95 is a 
membrane associated guanylate kinase (MAGUK) scaffolding protein located in 
neural postsynaptic densities, colocalisation of PAK1 with this protein suggests that it 
is involved in synaptic development (Hayashi et al., 2007).  
 
The spatial-temporal activation pattern of PAK1 is consistent with it having a role in 
actin reorganisation during cell movement (Sells et al., 2000). Studies in the fibroblast 
cell line NIH-3T3 and in human micro-vascular endothelial cells (HMVEC) showed 
that the expression of constitutively active PAK1 increased myosin light chain (MLC) 
phosphorylation as well as cell migration (Kiosses et al., 1999; Sells et al., 1999). 
PAK1 and PAK2 are also strongly activated by the chemoattractant fMLP in human 
neutrophils (Ding et al., 1996). The chemokine CXCL1 induces Cdc42 and PAK1 
activation resulting in increased chemotaxis. CXCL1 induced chemotaxis was 
inhibited by the expression of dominant negative PAK1 (Wang et al., 2002a).  
 
Aside from regulation of cell motility, PAK1 has been implicated as having a role as a 
promoting controller of cycle progression, chromosome dynamics, and normal cell 
division. In the study referenced above where active forms of PAK1 were over-
expressed in MCF-7 cells, the investigators also observed disruptions to normal 
organisation of mitotic spindles and an abnormal number of centrosomes (Vadlamudi 
et al., 2000). The Aurora kinases and Polo-like kinase 1 (PLK-1) are both important 
controllers of mitosis. During mitosis, PAK1 is recruited to centrosomes where it 
binds GIT1 and PIX, and is activated by GIT1 independently of Cdc42 or Rac1. 
Activated PAK1 have been shown to phosphorylate and activate Aurora-A and PIK-1 
in two independent studies (Maroto et al., 2008; Zhao et al., 2005). The activation of 
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Aurora-A caused altered centrosomes formation, whereas activation of PLK1 is 
important in the establishment of functioning bipolar spindles. PAK1 has also been 
shown to co-localise with Histone H3 on condensing chromatin and phosphorylate it 
at Ser-10. As this phosphorylation is a required step for the induction of DNA 
compaction at the start of mitosis, it can be seen that PAK1 may play a pivotal role in 
the cell cycle (Li et al., 2002).   
 
Another pathway PAK1 is involved in is that of cell survival, acting to down regulate 
pro-apoptotic signals and promoting cell survival and proliferation. PAK1 have been 
shown to directly phosphorylate and inactivate the pro-apoptotic protein: BCL2-
antagonist of cell death (BAD), thereby preventing it from forming a complex with 
the anti-apoptotic proteins Bcl2 and Bcl-X. This leads to increased cell survival in the 
FL5.12 and NIH 3T3 cell-lines tested. Dynein light chain (DLC1) and its interacting 
protein BimL (a Bcl-2 family protein) have also been reported to inhibit Bcl-2, PAK1 
has also been shown to phosphorylate both these proteins leading to their inactivation 
and preventing BimL binding to Bcl-2 (Vadlamudi et al., 2004). The pro-proliferation 
transcription factor NFkappaB is activated by PAK1, however the exact mechanism 
by which this activation happens is still under investigation (Balasenthil et al., 2004; 
Dadke et al., 2003; Friedland et al., 2007). PAK1 also directly phosphorylates and 
inactivates the transcription factor FKHR (forkhead transcription factor, also known 
as Foxo1) which promotes the transcription of pro-apoptotic genes. After FKHR is 
phosphorylated by PAK1, it is confined to the cytosol and therefore unable to perform 
its actions (Mazumdar and Kumar, 2003). 
 
1.2.5 PAK1 activation and expression in cancer 
From the description in the above section about the physiological roles of PAK1 in 
promoting cell survival, proliferation, migration and angiogenesis, it can be seen that 
stimulation of the activity/expression of this kinase can promote tumour formation. 
PAK1 has been shown either to be overexpressed or abnormally activated in a variety 
of human cancers (Table 1.2). Of all types of tumours, the abnormal PAK1 signalling 
is best understood in breast carcinoma and neurofibromatosis, although it is also 
implicated in the development of other cancers such as melanomas, lung and 
endometrial cancers (Lu et al., 2013; Ong et al., 2011a; Ye and Field, 2012).  
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Of the 6 PAK isoforms, PAK1 is most often over-expressed in cancers. PAK1 
overexpression has been observed in more than 50% of human breast cancers and 
around 70% of colorectal cancers (Table 1.2) (Carter et al., 2004).  There is also a 
correlation between high grade breast cancers with both the protein level and kinase 
activity of PAK1 (Vadlamudi et al., 2000). In a study of the tumorigenic progress of 
MCF10A mammary epithelial cells, the level of PAK1 expression positively 
correlated with the stage of progression into cancer cells. This suggests that abnormal 
PAK1 activity/expression not only has a function in active tumours, but also has role 
to play in tumorigenesis (Li et al., 2008). Recently, a study of primary tissue sample 
from melanoma patients with the wild-type BRAF gene showed that PAK1 protein 
was over-expressed in 27% of samples (Ong et al., 2013). Additionally, PAK1 over-
expression has also been reported in squamous non-small cell lung carcinomas 
(NSCLCs) and lymph node metastasis of breast cancers (Ong et al., 2011a). Two 
possible mechanisms that underlie the overexpression of PAK1 in cancers have been 
explored, the first being gene amplification and the second is micro-RNA down 
regulation. The PAK1 gene is located within the 11q13 genomic region, and 
amplification of this region has been reported in a number of cancers including breast, 
bladder, and ovarian carcinomas (Bekri et al., 1997; Bostner et al., 2007). MicroRNAs 
such as miR-7 have been shown to act as negative regulators of PAK1. Transfection 
of the microRNA miR-7 into breast cancer cells reduced PAK1 expression. 
Additionally, endogenous miR-7 levels inversely correlated with that of PAK1 
(Reddy et al., 2008). Although there is much evidence of PAK1 over-expression in 
cancers, there is significantly less evidence for the existence of PAK1 activating 
mutations in tumour cells. While a mutation of PAK4 has been found in colorectal 
carcinoma, its effect on the activity of the enzyme is not clear (Parsons et al., 2005).  
 
In addition to regulating cell migration in physiological tissues, PAK kinases have 
been implicated as pro-invasion regulators in a number of human cancers. Expression 
of an active form of PAK1 in MCF-7 breast cancer epithelial cells led to increased 
rate of cell migration (Vadlamudi et al., 2000).  In another study, where siRNA was 
used to deplete PAK1 and PAK2 individually in T47D breast cancer cells, it was 
found that both PAK1 and PAK2 promoted cancer invasion (Coniglio et al., 2008). 
Interestingly, the two PAK enzymes seem to mediate their effects thorough different 
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mechanisms. For example, PAK1 knockdown had a significant inhibitory effect on 
the lamellipodia protrusions on the motile edge of cell, as well as the size of focal 
adhesions, in contrast after PAK2 depletion, lamellipodia protrusions were not as 
strongly inhibited and there was actually an increase in the size of focal adhesions. 
PAK1 depletion also caused dephosphorylation of cofilin (a protein involved in actin 
disassembly in cytoskeletal reorganisation) whereas PAK2 knockdown did not. In 
another study, introduction of the microRNA miR-7 (which has been shown to 
negatively regulate PAK1 expression) reduced parameters such as growth, motility, 
invasiveness and the tumorigenic potential of highly invasive breast cancer cells 
(Reddy et al., 2008).  
 
In addition to facilitating cancer cell invasion, PAK1 also plays a role in promoting 
proliferation of malignant cells and the growth of tumours. Over-expression of PAK1  
in endometrial cell-lines increased the proliferation of those cells whereas RNAi 
mediated knockdown of PAK1 reduced cellular proliferation (Lu et al., 2013). 
Treatment of melanoma tumour xenograft models with the PAK1 inhibitor PF-
3758309 resulted in 93% and 63% inhibition in tumour growth for SK-MEL23 and 
537MEL xenografts respectively (Ong et al., 2013). In NSCLCs, inhibition of PAK1 
led to delayed cell-cycle progression, and dual inhibition of PAK1 and X 
chromosome-linked inhibitor of apoptosis increased apoptosis of these cells (Ong et 
al., 2011a). Recently, RNAi knockdown of PAK1 has been reported to inhibit the 
growth, angiogenesis and migration of PC3 prostate cancer cells (Goc et al., 2013).  
 
Neurofibromatosis types 1 and 2 are autosomal dominant inherited disorders where 
neurocrest derived cells (such as Schwann cells) form neurofibromas. They are caused 
by loss of function mutations in the NF1 and NF2 genes, which act to inhibit neural 
cell growth. PAK1 directly phosphorylates the NF2 gene product merlin, which 
inhibits its growth suppressive abilities (Kissil et al., 2002). There is also a reciprocal 
mechanism by which merlin regulates PAK1. Merlin is able to bind inactive PAK1, 
thereby preventing its activation by Rac (Kissil et al., 2003; Kreis and Barnier, 2009). 
It can be seen that after the loss of function of NF2 during tumorigenesis, PAK1 
activity becomes less regulated. This causes increased activity of the Rac signalling 
pathway and leads to increased membrane ruffling and cell proliferation (Kissil et al., 
2003; Pelton et al., 1998; Shaw et al., 2001).  
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From the roles that PAK1 play in cancer highlighted above, it can be seen that this 
kinase is a viable target for the development of anti-tumour agents.  The development 
of small molecule PAK1 inhibitors is currently underway and if fruitful could help 
combat a number of cancers (Goc et al., 2013). 
Location of primary 
neoplasm 
Type of alterations 
 
References 
Brain Increased phosho-PAK1 
levels 
(Aoki et al., 2007) 
Breast 
 
Gene amplification/over-
expression  
(Balasenthil et al., 2004; 
Bekri et al., 1997; Holm et 
al., 2006) 
Lung (NSCLC) Protein overexpression (Ong et al., 2011a) 
Liver Gene amplification/over-
expression 
(Ching et al., 2007) 
Kidney Protein over-expression 
and increased PAK1 
activity 
(O'Sullivan et al., 2007) 
Colorectal  Protein over-expression (Carter et al., 2004; 
Parsons et al., 2005) 
Bladder Gene amplification/over-
expression  
(Ito et al., 2007) 
Ovarian Gene amplification/over-
expression 
(Brown et al., 2008; 
Davidson et al., 2008) 
T-cell lymphonma Gene amplification (Mao et al., 2003) 
Neurofibromatosis Dysregulation of activity (Hirokawa et al., 2004; 
Kissil et al., 2003; Pelton 
et al., 1998; Shaw et al., 
2001) 
Melanoma (wild-type 
BRAF) 
Overexpression (Ong et al., 2013) 
 
 
1.24 PAK and AMPK 
 
1.2.6 PAK1 and AMPK  
As can be seen from the above sections, AMPK and PAK1 are involved in the 
regulation of some very similar processes. Both enzymes regulate the survival of cells 
under both physiological and pathological situations (e.g. in cancer). PAK1 and 
AMPK both play a role in the regulation of normal cell migration and cancer cell 
invasion, with evidence that both enzymes are pro-migratory. With these overlapping 
Table 1.2 Cancers with alterations in PAK1 activity/expression 
This table was adapted from (Dummler et al., 2009), with additional information from 
other sources 
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roles, it is possible that the AMPK and PAK1 signalling pathways may intersect at 
some point. However, it was only relatively recently that these new roles for AMPK 
have been discovered and the ongoing paradigm in the field remains that AMPK’s 
main role is as a regulator of metabolic processes. This perhaps explains why until 
recent years, little research was done to investigate any potential interplay between 
the AMPK and PAK signalling pathways, and only a handful of papers have been 
published which link the two pathways.   
 
The first study to implicate AMPK as having a role in regulating PAK activity was 
conducted in 2008 (Lee et al., 2008). The researchers showed that treatment of C2C12 
mouse myotubes with retinoic acid (a Vitamin A metabolite) or AICAR resulted in 
activation of AMPK, Rac1 and also PAK in a time dependent fashion. Pre-treatment 
with the AMPK inhibitor, Compound C abolished retinoic acid induced Rac1 
activation, therefore suggesting that Rac1 and PAK are downstream targets of AMPK. 
Rather strangely, this paper does not specify which isoform of PAK was activated by 
AMPK, information from the material and methods sections would suggest that it is 
group-1 PAK (Kreis and Barnier, 2009). Furthermore, retinoic acid activation of 
PAK1 resulted in activation of its target cofilin (Delorme et al., 2007). This effect was 
blocked by pre-treating C2C12 cells with either compound C or siRNA against the 
AMPK α1 subunit. As cofilin is an actin binding factor primarily involved in actin 
assembly, the findings of this study would suggest a role for AMPK in regulating 
cytoskeletal arrangement by regulating the Rac1-PAK pathway. Further evidence 
suggesting a role for AMPK in the regulation of the Rac1-PAK1 axis was published 
in 2011, while work on this thesis was on going. In this publication, the researchers 
found AMPK activation by AICAR led to increased phosphorylation of PAK1/2 (on 
Thr-423 and Thr-402 respectively) and WAVE2 which are downstream effectors of 
Rac1. These and other effects of AMPK activation led to increases in the phagocytic 
ability of macrophages and neutrophils. Pre-treatment of cells with AMPK α1 siRNA, 
compound C or Rac inhibitors was able to abolish the increase in phagocytosis 
induced by AICAR (Bae et al., 2011).   
 
It can be seen from the studies described above that AMPK is likely to have a role in 
regulating PAK1 activity. However, results from both these studies would suggest 
that this regulation is indirect acting via Rac1, as in both cases activation of Rac1 
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preceded PAK activation. In addition, treatment with a Rac1 inhibitor was able to 
reverse the effects brought about by AMPK activation.  
 
A recent study using a novel chemical genetics approach to screen for AMPK 
substrates identified PAK2 as being target of AMPK. AMPK α2 directly 
phosphorylated PAK2 on Ser-20 (Banko et al., 2011). Further to this, elevation in the 
levels of myosin regulatory light chain induced (MLC) by the AMPK activator 
A769662 in U2OS cells was reversed by the co-expressing a non-phosphorylatable 
version of PAK2 (S20A). This result would suggest that the ability of AMPK to 
regulate MLC is at least partly mediated by PAK2.  However, to our knowledge, there 
is currently no published evidence to implicate any direct interaction of AMPK and 
PAK1 and any direct mechanism by which these enzymes regulate each other.  
 
Although perhaps not directly relevant to AMPK, both of the upstream kinases of 
AMPK, LKB1 and CAMKK beta have been shown to regulate PAK1 activity in vivo 
(Saneyoshi et al., 2008) . In a 2008 study by Saneyoshi and colleagues, CaMKK beta 
and CaMK1 were shown to interact with the PAK1/Git1/βPIX complex which results 
in the phosphorylation of βPix at Ser-516 which in turn led to activation of the Rac1-
PAK1 axis. This activation then led to increased formation of spines and synapses in 
hippocampal neurons. Inhibition of either CaMKK beta of CaMKI by 
pharmacological inhibitors, siRNA treatment or expression of dominant negative 
isoforms in hippocampal neurons resulted deceased spine formation, as did expression 
of the βPIX S516A mutant form. Expression of constitutively-active PAK1 on the 
other hand was able to reverse the inhibition of spine formation caused by the 
inhibition of CaMKI or the βPIX S516A mutant. While the above study revealed that 
CaMKK beta positively regulated PAK1 activity, LKB1 was shown to have the 
opposite effect. LKB1 was found to directly phosphorylate PAK1 on The-109 in the 
P21 binding domain which resulted in inhibition of its kinase activity. Additionally, 
knockdown of LKB1 in HCT116 colon cancer cells caused an increase in PAK1 
activity while enhancing migration of these cells, and expression of LKB1 in LKB1 
null MEFs led to both decreased PAK1 activity and PAK1 mediated cell migration. 
Furthermore, the non- phosphorylatable PAK1 T109E mutant was resistant to LKB1 
inhibition (Deguchi et al., 2010). Taken together the results of these would suggest 
that while the predominant effect of interplay between the AMPK and PAK1 
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signalling pathways results in activation of the Rac1-PAK1 axis, LKB1 seems to exert 
an inhibitory effect, which is in-line with its effects as a tumour suppressor.  
 
The AMPK related kinase SAD-A (synapses of amphids defective/aka BRSK2) has 
recently been shown to interact with PAK1 and directly phosphorylate it at the key 
activation residue Thr-423 (Nie et al., 2012).  This phosphorylation leads to an 
elevation of glucose-stimulated insulin secretion from pancreatic β islet cells. 
Decreasing either PAK1 activity or expression was able to abolish the above effect.  
 
1.3 Summary and aims 
Gaining a full understanding of the function of AMPK and its regulation is very 
important for devising new treatments for diseases of metabolism and cancer. As 
outlined in this chapter, the primary way by which AMPK is activated is through 
phosphorylation of the Thr-172 residue within the α subunit. At the time of this study, 
LKB1 and CaMKKβ were identified as the upstream kinases of AMPK, whereas the 
protein phosphatase(s) responsible for the dephosphorylation of AMPK remain 
unidentified. The aim in the first part of this thesis was to identify the protein 
phosphatase(s) acting on AMPK using both transformed cell-lines and primary 
mammalian cells and investigate the physiological significance of this regulation.    
 
In the second part of this study, quantitative mass spectrometry techniques were 
utilised in order to identify AMPK interacting proteins, initially with a view of 
identifying AMPK phosphatases. From the results generated, PAK1 was identified as 
a novel interactor of AMPK. Following validation of this interaction the functional 
and physiological significance of the association between AMPK and PAK1 was 
investigated.  
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2 Materials and Methods 
2.1 Materials 
 
2.1.1 General Reagents  
Adenosine monophosphate (AMP), Adenosine diphosphate (ADP), Adenosine 
triphosphate (ATP), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
Tris(hydroxymethyl) aminomethane (Tris), ethylene glycol tetraacetic acid (EGTA), 
ammonium persulphate, magnesium chloride (MgCl2), sodium fluoride (NaF), sodium 
pyrophosphate(Na4P2O7), dithiothreitol (DTT), N,N,N’,N’-tetramethylethylenedamine 
(TEMED), protein A/G-sepharose, sorbitol, β-mercaptoethanol, water soluble 
dexamethasone, 3,3’,5-Triiodo-L-tyronine sodium salt (T3), BSA, agarose, N-
cyclohexyl-3-aminopropanesulfonic acid (CAPS), glycine, D-mannitol, ionomycin, N 
N dimethyldodecyl amine N oxide (DDAO), Taq DNA polymerase, NP-40, 
ampicillin, perchloric acid, potassium phosphate, hydrogen peroxide, Dimethyl 
sulfoxide (DMSO), Triton X-100, 1-1,dimethyl biguanide hydrochloride (metformin) , 
Calyculin A and Kodak biomax MR-1 film were obtained from Sigma (Poole, UK). 
Polyvinylidene difluoride (PVDF) membrane was from Perkin Elmer (Beaconsfield, 
UK).  AICA-Riboside (AICAR) and Okadaic acid, were from Calbiochem 
(Nottingham, UK).  Ribojuice siRNA transfection reagent was from Novagen 
(Nottingham, UK).  Plasmid miniprep, maxiprep, polymerase chain reaction (PCR) 
and gel purification kits, QIAquick gel extraction kit, RNeasy columns, quantitect 
primers and quantitative reverse transcription PCR (qRT-PCR) kit were from Qiagen 
(Crawley, UK). Cal Phos transfection kit was from Clontech (Saint-Germain-en-Laye, 
France).  NaOH, sodium lauryl sulfate (SDS), NaCl, Tween 20, glycerol, 
ethylenediaminetetraacetic acid (EDTA), ethanol, methanol, KCl, KH2PO4, NaHCo3, 
choloroform and glucose were from VWR (West Sussex, UK). Restriction enzymes 
were from Promega (Southampton, UK) and New England Biolabs (Hitchin, UK). 
3MM chromatography paper and P81 phosphocellulose paper were obtained from 
Whatman (Maidstone, UK).  RPMI, Neurobasal media, DMEM,  non essential amino 
acids, Penicillin/Streptomycin, insulin, sodium pyruvate, optiMEM, and B27 
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supplement were from Gibco (Paisley, UK). Complete EDTA free protease inhibitor 
cocktail, collagenase H and Rapid DNA ligation kit were from Roche (Burgess Hill, 
UK). SAMS peptide (HMRSAMSGLHLVKRR) was synthesised by the MRC 
Peptide Synthesis Unit. DC Protein assay kit was from Biorad (Hertfordshire, UK).  
[γ-32P]ATP (6000 Ci/mmol), and Amersham Hyperfilm MP film, was obtained from 
GE healthcare (Amersham, UK).  ECL Supersignal West Femto kit, dialysis cassettes 
and Dharmacon siGLO Red transfection indicator, Control non-targeting siRNA and 
targeting siRNAs (Silencer Select siRNA) were obtained from Ambion (Invitrogen). 
Active PAK1 and PAKtide peptide was obtained from Stratech (UK). Myelin basic 
protein was obtained from Sigma. 
13
C arginine and 
13
C lysine for SILAC media 
supplementation was obtained from CK Gas (Leicestershire, UK).  
 
2.1.2 Buffers 
All chemicals for buffers were of experimental grade and were either bought from 
commercial sources or made in house:  
HST (high salt buffer) – 20mM Tris, pH 7.4, 500mM NaCl, 0.5% (v/v) Tween 20 
Protein Sample Buffer – 50mM Tris-HCl, pH 7.4, 2.5% (w/v) SDS, 1% (v/v) β-
mercaptoethanol, 10% glycerol, 0.05% (w/v) bromophenol blue. 
SDS-PAGE Buffer – 50mM Tris-HCl, pH 8.4, 400mM glycine, 0.1% (w/v) SDS. 
Tris/Glycine Buffer – 25mM Tris, 192mM glycine, 10% Methanol. 
CAPS transfer buffer: 10 mM CAPS (N-cyclohexyl-3-aminopropanesulfonic acid) 
powder (pH 10.5), 10% methanol 
BufferA/Homogenisation Buffer - 50mM Tris, pH 7.4, 50mM sodium fluoride, 
5mM sodium pyrophosphate, 1 mM EDTA, 250mM sucrose, 1mM dithiothreitol, 
4µg/ml trypsin inhibitor,0.1mM phenylmethylsulfonyl fluoride, 1mM benzamidine. 
Cell Lysis Buffer - 50mM Hepes pH7.4, 50mM sodium fluoride, 5mM sodium 
pyrophosphate, 1mM EDTA, 10% (v/v) glycerol, 1% triton TX-100, 1mM 
dithiothreitol, 4µg/ml trypsin inhibitor, 0.1mM phenylmethylsulfonyl fluoride, 1mM 
benzamidine. 
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Buffer C (HGE) - 50mM Hepes pH7.4, 1mM EDTA, 10% (v/v) glycerol and 1% 
triton TX-100, 1mM dithiothreitol, 4µg/ml trypsin inhibitor, 0.1mM 
phenylmethylsulfonyl fluoride, 1mM benzamidine. 
Bacterial lysis buffer: 50 mM Hepes pH 7.4, 300 mM NaCl, 25 mM Imidazole  
Bacterial elution buffer: 50 mM Hepes pH 7.4, 300 mM NaCl, 300 mM Imidazole 
Storage buffer: 50 mM Hepes pH 7.4, 300 mM NaCl, 1mM Tris(2-carboxyethyl) 
phosphine Hydrocholride (TCEP) 
DNA-Loading Buffer – 0.1% (m/v) Orange G, 50% glycerol 
Phosphate-Buffered Saline (PBS) – 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1.4mM KH2PO4, pH7.4. 
TAE – 40mM Tris, 20mM acetic acid, 1mM EDTA, pH 8.0. 
Luria Burtani (LB) Broth – 1% (w/v) tryptone, 0.5% yeast extract, 0.5% (w/v) NaCl. 
LB agar plate:  As LB broth with 1.5% (w/v) agar and the appropriate antibiotic 
added 
 
SOC media: 20 mM glucose, 2% (w/v) tryptone, 0.5% (w/v), yeast extract, 0.05% 
(w/v) NaCl 
 
2.1.3 Antibodies 
Primary antibodies used for immunoblotting are as follows: anti-AMPK-α1 and anti-
AMPK-α2 (sheep) (kind gift from Professor Grahame Hardie, Dundee), anti-AMPK-β 
(in house, Rabbit), anti-phospho-AMPK (P-Thr-172) (Cell Signalling), anti-PPM1A 
(Acris), anti-PPM1B (Abcam), anti-ILKAP(Acris), anti-V5 (Invitrogen), and anti-
FLAG M2 (Sigma UK), anti PP2A (Cell Signalling), anti-HA tag (C29F4) (Cell 
signalling), anti-total PAK1 (Cell signalling), anti-phospho-PAK1 (T423) (cell 
signalling), anti-phospho-PAK1 (S199) (Cell signalling), anti PSD95 (Abcam), anti-
GIT1 (Cell signalling), anti-PIX (Cell Signalling),  All dilutions of primary antibodies 
were at 1:1000, except Anti-AMPK-β which was at 1:5000.  
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2.1.4 Cells 
Bacterial: 
JM109 competent cells were from Promega (Southampton, UK). BL21-Condonplus 
(DE3) RIL cells for protein expression were from Agilent Technologies (Cheshire)  
 
Mammalian:  
HEK-293 cells were purchased from American Cell Type Culture Collection 
(Middlesex). COS-7 cells were available in house. MIN6 β cells were a gift from 
James Leiper (MRC). WM1361, WM1366 and WM1791c, WM266.4 cells were a gift 
from Richard Marais (CRUK). Primary mouse hepatocytes were isolated by Angela 
Woods. Primary mouse cortical neurones from both WT and AMPK α1 KO mice were 
isolated by Shuai Zhang and Nicola Bright in house.  
 
2.1.5 Proteins 
Recombinant AMPK complex (α1β1γ1) was expressed in Eschericha coli and purified 
by David Carmena or Shuai Zhang as in sections 2.2.7 and 2.2.8.  Recombinant wild 
type and mutant PAK1 proteins were expressed in Eschericha coli and purified as 
described in sections 2.2.7 and 2.2.8.  
 
2.1.6 Compounds 
The AMPK activator A-769662 (a kind gift from Astrazeneca, UK) was dissolved in 
DMSO and kept for a maximum of 2 weeks at -20 ºC with only one freeze thawing 
cycle. STO-609 was obtained from Torris (Ellisville, Missouri) was dissolved in 
DMSO prior to treatment. Okadaic acid was obtained from Calbiochem (Subsidiary of 
Merck, Darmstadt, Germany) Calyculin A was obtained from Sigma. IPA-3 was 
obtained from Tocris.  
 
2.1.7 Plasmids 
Mammalian expression constructs were cloned into pcDNA3.1 vector (Paisley, UK).  
Bacterial expression constructs for PAK1 were cloned into the pETduet vector which 
were available in house.  
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2.1.8 Mice 
Both wild type (AMPKα1+/+) and AMPKα1−/− mice were available in house 
(originally generated by Benoit Viollet, Université Paris Descartes) and has been 
derived as reported previously (Jørgensen et al., 2004).  
 
2.2 Methods    
2.2.1 Agarose gel electrophoresis  
DNA material was resuspended in 10x Loading buffer (Invitrogen) and resolved on a 
1% agarose gel at 100V. Band were visualised with UV light.  
 
2.2.2 Polymerase chain reaction (PCR) and DNA Cloning 
DNA was amplified by PCR using the high fidelity Pfu enzyme with 50ng of template 
and a total reaction volume of 50 μl. Qiagen gel extraction kit was used to exercise 
DNA from gels. The PCR products were digested with the appropriate restriction 
enzymes and cloned into pETduet vectors for bacterial expression and pcDNA3.1 
vectors for mammalian expression.  
 
2.2.3 Site Directed Mutagenesis  
Point mutations in plasmids were generated using the QuikChange II Site-Directed 
mutagenesis Kit according to the manufacturer’s instructions. Briefly DNA template 
was mixed with forward and reverse primers containing the relevant mutation/s with 
the appropriate buffers after which the Pfu DNA polymerase was added to the 
reaction mixture. The mixture (50 μl) was subject to PCR reaction with the conditions 
as follows: 95 ºC for 30 seconds, 12  or 18 cycles (12 cycles for point mutations and 
18 cycles for mutable amino acid changes) of 95 ºC for 30 seconds, 55 ºC for 1 
minute and 68 ºC for 1 minute per kilobase of plasmid. After cycling a final extension 
step of 5 minutes at 68 ºC is applied. The mixture incubated with 1ul of DPN1 
endonuclease at 37 ºC for 2hr to digest the methlyated template DNA (which has been 
purified from bacteria). The digested mixture is then transformed into XL10- Gold 
Supercompetent cells according to manufacturer’s protocols. The DNA is then 
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purified using the Qiagen mini-prep kit and the mutations confirmed by DNA 
sequencing (MRC, CSC Sequencing Service).  
 
2.2.4 Bacterial transformation and culture growth 
For JM109 cells transformation 50 μl of cells were mixed with 50 ng or 100 ng of 
vector, the mixture was incubated on ice for 15 minutes and heat shocked at 42 ºC for 
90 seconds. After a further incubation of 2 minutes on ice, 750 μl of SOC media was 
added to the mixture and incubated at 37 ºC for 30 min with shaking.  
 
For BL21 cells a 100ul aliquot of cells were incubated with 0.2 μl β- mercaptoethanol 
on ice for 10 minutes. 50 μg of plasmid DNA was then added to the mixture and 
incubated on ice for a further 30 minutes. The cells were then heat shocked at 42 ºC 
for 20 seconds, and mixed with 750 μl pre-heated SOC media and incubated at 37 ºC 
with shaking. 
 
For XL-10 Gold cells, 50ul of cells were mixed with 1μl of PCR reaction product and 
incubated on ice for 30 minutes. The mixture was then heat shocked at 42 ºC for 45 
seconds, and then incubated on ice for a further 2 minutes. 750 μl of pre-heated SOC 
media was then added and incubated at 37 ºC with shaking. 
 
For all cell type described above, after transformation, cells are spun at 15,000 rpm 
and the pellet resuspended in 100 μl of LB media and plated on LB agar plates with 
the appropriate antibiotic added (e.g. 100 μl/ml ampicillin and 50 μg/ml kanamycin). 
The plated are incubated for 24 hr at 37 ºC. A single colonies were then used to 
inoculate LB broth with the appropriate antibiotics.  
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2.2.5 Determining DNA/RNA concentration and DNA sequencing 
The concentration of DNA/RNA concentration was determined using the NanoDrop 
ND-1000 spectrometer for an absorbance at 260 nm.  
Sequencing for expression plasmids were done by the MRC CSC Sequencing Service 
with the 3730xl DNA analyser and viewed with the DNAstar program.  
 
2.2.6 Expression and purification of recombinant proteins in E.coli 
The vectors for the expression of Wild-Type and mutant forms of His-AMPK, GST-
PAK1 construct (co-expressed with untagged PP1 in the pETduet vector) (kind gift 
from Dr Katrin Rittinger, NIMR, MRC) were transformed into BL-21 CodonPlus 
(DE3)-RIL cells were done as described Chapter 2 and plated onto agar plates 
containing the appropriate antibiotics.  
 
A single colony is picked from the plate and incubated in a starting culture (25 ml) of 
antibiotic inoculated LB media. After incubation overnight with shaking at 37  ºC the 
starting culture was using to seed a larger culture (500 ml to 2000 ml), the size of 
which depends on efficiency of expression of the particular protein and the amount of 
protein required for experimental purposes. The culture was incubated at 37 ºC with 
shaking until an OD600 of 0.6 – 0.8 was obtained (as blanked by fresh LB media). In 
the case of AMPK complexes, protein expression was induced by adding isopropyl β-
D-thiogalactopyranoside (IPTG) to the mixture to a final concentration of 1 mM, and 
the bacterial suspension incubated for 4 hours at 25 ºC. In the case of PAK1 
complexes, IPTG was added to the mixture to a final concentration of 0.4 mM and the 
bacterial suspension incubated for over night (approximately 12 hours) at 25 ºC.  
 
After IPTG induction of expression overnight, the bacteria was pelleted by 
centrifugation at 6000 rpm. The pellet was washed once in PBS buffer and 
resuspended in bacterial lysis buffer containing protease inhibitor cocktail (EDTA 
free) (Roche). The mixture was sonicated for 8 cycles (1 minute on 1 minute off) on 
ice to release proteins. The suspension was then taken through a freeze thawing cycle 
at -80 ºC, after which Triton TX-100 was added to the mixture to a final concentration 
of 1% (v/v) and incubated for 30 min at 4 ºC. The suspension then was the centrifuged 
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at 15,000 rpm to remove the bacterial cell bodies and at 4 ºC for 30 min. With the 
pellet discarded the supernatant was filtered with a 0.4 μm filter, and kept either at -80 
ºC or 4 ºC. 
 
For purification using a manual column, either nickel-Sepharose (for AMPK 
purification) or glutathione (for PAK1 purification)  containing columns was 
equilibrated with bacterial lysis buffer and then incubated with the supernatant for 30 
min at 4 ºC for binding. The column is then washed with 3x volume of lysis buffer 
and the bound protein eluted with bacterial elution buffer, with fraction taken for  
every 1ml of the elution. A aliquot (usually 15 μl) of every eluted fraction is then 
visualised/analysed using SDS-PAGE electrophoresis, and eluted proteins 
concentrated using a VivaSpin column (Vivascience). The protein was washed into 
storage buffer with the spin column also to rid the sample of imidazole.  
 
In the case of automated purification with the ACTA system (for some AMPK 
complexes), the nickel sepharose column was equilibrated with 6x column volumes of 
Bacterial Lysis buffer before protein binding. The bacterial supernatant was then ran 
through the column at a rate of 1ml/min, to allow protein binding. The column was 
then washed with 5x column volumes of lysis buffer and the protein eluted with 
Bacterial elution buffer (20 ml – 30 ml) into fraction of 1ml each. SDS-PAGE 
electrophoresis is then used to identify which fractions contain the desired protein and 
the protein was concentrated and buffer exchanged into storage buffer using Vivaspin 
columns.  
 
In some cases the eluted proteins were then subjected to gel-filtration purification on a 
HiLoad Superdex 200 column (Amersham Biosciences) linked to the ACTA system. 
The column was first equilibrated with Storage buffer, and the eluted protein ran 
through this column at 1 ml/min, and fraction of 1ml were taken. The fractions 
containing the desired proteins were pooled and concentrated using the Vivaspin 
columns. The concentration of bacterially expressed proteins were identified using 
NanoDrop ND-1000 spectrometer for an absorbance at 280 nm (with storage buffer 
acting as a blank for the measurement).  
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2.2.7 Radio-labelling of proteins and auto-radiography  
Proteins were incubated in the presence or absence of activated kinase (either active 
PAK1 or AMPK) in buffer containing 200 μm [γ-32P] ATP, 2.5 mM MgCl2 for 30 min 
at 30 °C (for phosphorylation with active PAK1) or 37 °C (for phosphorylation with 
active AMPK). The reaction was terminated by the addition of protein sample buffer 
and resolved by SDS-PAGE. The gels were coomassie blue stained, dried and 
subjected to auto-radiography.  
 
2.2.8 Activation of AMPK by CaMKKβ 
Purified bacterially expressed AMPK (inactive) was incubated with CaMKKβ at a 
ratio of 1:200 (e.g. 1 μg CaMKKβ with 200 μg AMPK) in the presence of buffer 
containing 1 mM ATP and 2.5 mM MgCl2 for either 1 hour at 37 ºC or overnight at 
room temperature. Titrations from the resulting mixture was taken into the SAMS 
peptide assays to validate activation of AMPK.  
 
2.2.9 PAK1 activation of AMPK 
Active PAK1 (200 ng) was incubated with CaMKKβ phosphorylated  AMPK (2 μg) 
for 30 minutes at 37 °C with shaking, this was done in buffer containing 1 mM ATP 
and 2.5 mM MgCl2, for a total volume of 50 μl. After this, 2 μl of the reaction mixture 
was diluted to 10ul with 50 mM Hepes buffer then taken into the SAMS Peptide assay.   
 
2.2.10 Kinase activity assays 
 
SAMS peptide assay 
The activity of AMPK was measured by the phosphorylation of the synthetic SAMS 
peptide (HMRSAMSGLVLKRR), by the incorporation of [γ-32P]-ATP. The SAMS 
peptide has a sequence derived from the AMPK phosphorylation sites on Acetyl-Co-
A carboxylase. Samples were made up to 25 μl in the presence of 50 mM Hepes pH 
7.4, 200 μM SAMS 10mM Hepes, 0.2 % Triton, 5 mM MgCl2, and 200 μM ATP, [γ-
32
P]ATP (specific radioactivity approximately 250 cpm/pmol). This is then incubated 
at 37 °C for 20 or 30 minutes with shaking. The blank mixture is identical to the 
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reaction sample mixture with the exception that it does not contain SAMS peptide. 
After this 20 µl of the mixtures were then blotted onto a piece of P81 paper 
(approximately 1cm
2
 in area). The P81 paper is then washed with 1% (v/v) 
phosphoric acid to remove unincorporated 
32
P-ATP. The paper is then air-dried and 
placed in scintillation tubes and covered with 2 ml of scintillation fluid and placed in 
a Beckman scintillation counter (Beckman LS60000SC), which determines the counts 
per minute.  
 
PAK1 kinase assays (MBP and PAktide assays) 
The activity of PAK1 was measured by the phosphorylation of the synthetic PAKtide 
(RRRLSFAEPG), by the incorporation of [γ-32P]-ATP. The PAKtide has a sequence 
derived from known PAK1 phosphorylation sites. Samples were made up to 25 μl, 
with either 1 mg/ml Myelin basic protein (for MBP assay) or 0.5 mg/ml PAKtide (for 
PAKtide assay)  in the presence of 50 mM Hepes pH 7.4, 2.5 mM glycerol phosphate, 
5 mM MgCl2, and 200 μM ATP, [γ-
32
P]ATP (specific radioactivity approximately 
250 cpm/pmol). This is then incubated at 30 °C for 10 or 20 minutes with shaking. 
The blank mixture is identical to the reaction sample mixture with the exception that it 
does not contain PAKdtide peptide. After this 20ul of the mixtures were then blotted 
onto a piece of P81 paper (approximately 1cm
2
 in area). The P81 paper is then washed 
with 1% (v/v) phosphoric acid to remove unincorporated 
32
P-ATP. The paper is then 
air-dried and placed in scintillation tubes and covered with 2 ml of scintillation fluid 
and placed in a Beckman scintillation counter (Beckman LS60000SC), which 
determines the counts per minute.  
 
2.2.11 Mammalian Cell culture 
HEK293 (Human Embryonic Kidney) and COS7 were cultured in high glucose 
DMEM (4.5 g/L) (Gibco-41966) supplemented with 10% Fetal Calf Serum (FCS) and 
N-glutamine (4mM) at 37°C and 5% CO2. Cells were changed into fresh media 
without FCS supplementation 4 hours prior to any cell treatments.  
 
Mouse insulinoma pancreatic cells (MIN6) was kindly provided by Dr. James Leiper 
(CSC MRC, UK). MIN6, WM1366 and WM1361 cells were grown and maintained in 
high glucose DMEM (4.5 g/L)(Gibco-41966),  supplemented with 10% FCS and N-
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glutamine (2 mM), 100 μM 2-mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml 
streptomycin at 37°C  and 5% CO
2
. For glucose concentration exchange experiments, 
the cell maintenance media was removed from MIN-6 cells and the cells washed once 
with PBS. The cells were the supplemented with fresh media as shown above (but 
without FCS) with either 3 or 25 mM glucose as indicated.  
 
Isolation of primary hepatocytes 
Isolation of primary hepatocytes was carried out as previously described (Foretz et al., 
1998) with some amendments.  Isolation experiments were kindly performed by Dr. 
Angela Woods and Dr. Alicia Barcia.  Anaesthetised mice were cannulated in the 
inferior vena cava and the liver was perfused with Perfusion buffer at 37 °C (138 mM 
NaCl, 50 mM HEPES, 5.56 mM glucose, 0.5 mM EGTA, 5.4 mM KCl, 0.338 mM 
Na2PO4, 0.44 mM KH2PO4, 4.17 mM NaHCO3, carboxygenated, pH 7.4).  After 
washing with perfusion buffer for 15 minutes the liver was digested with collagenase 
buffer (Perfusion Buffer minus EGTA, 5 mM CaCl2 with 0.025 % (w/v) collagenase 
H).  Digested livers were removed and hepatocytes were released and filtered, and 
washed twice with ice cold Perfusion Buffer followed by washing with ice cold M199 
buffer. Cells were plated onto collagen coated plates in plating medium (M199, 
Penicillin/Streptomycin, 10% (v/v) bovine serum albumin (BSA), Ultroser G, 100 nM 
T3, 100 nM dexamethasone, 100 nM Insulin ).  4 hours later plating medium was 
removed and replaced with overnight medium (M199, Penicillin/Streptomycin, 100 
nM dexamethasone, 1 nM Insulin) and cells were cultured for ≥ 16 hr in this medium.  
The following day medium was changed to M199 supplemented only with penicillin 
and streptomycin at least 2 hours before treatment. 
 
Preparation of primary neurons 
Animal use was in accordance with local rules and with the regulations and guidance 
issued under the Animals (Scientific Procedures) Act (1986). Primary cortical neurons 
were prepared from WT (wild-type) and AMPKα1
−/−
 E14 (embryonic day 14) animals 
as described previously (Lesuisse and Martin, 2002). Briefly, cortices from embryos 
in a single litter were dissected, meninges were removed and tissue was pooled. 
Cortices were roughly chopped before incubation in 0.25% trypsin/EDTA followed 
by trituration. Cells were pelleted by centrifugation, resuspended and plated in 
Neurobasal medium supplemented with B27, 100 units/ml penicillin, 100 μg/ml 
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streptomycin, 0.25 μg/ml amphotericin B, 300 μM glutamine and 25 μM 2-
mercaptoethanol. Treatments were carried out on neurons grown for a minimum of 
7 days in vitro, and all media were obtained from Invitrogen. 
 
2.2.12 Mammalian cell treatment 
HEK293, primary mouse hepatocytes (isolated by Angela Woods), primary mouse 
embryonic cortical neurons, WM1361 and WM1366 cells were treated with a 
selection of agents which activate endogenous AMPK including: AICAR (Sigma), 
Metformin (Sigma), hydrogen peroxide (in House), Ionomycin (Invitrogen) 
IPA3phenformin (Sigma), A-769662 compound (a kind gift from Astrazeneca), and 
M991 compound (A kind gift Astrazeneca, originally developed by Merck Sharp & 
Dohme Corp. and Metabasis Therapeutics, Inc.). Phosphatase inhibitors okadaic acid 
(Calbiochem) and calyculin A (Sigma) are also used to treat HEK293 and mouse 
hepatocyes. Primary mouse embryonic cortical neurons were also treated with the 
AMPK inhibitor compound C and the CaMKKβ inhibitor STO609.  Specifically, 
WM1361 cells were treated with the PAK1 inhibitor IPA3 (Tocris, Bristol, UK). 
Specific conditions and concentrations are shown in the results section and figure 
legends. All reagents were dissolved in water with the exception of calyculin A, A-
769662 and the M991 compounds which were dissolved in DMSO. 
 
2.2.13 Mammalian cell transfection 
For transfection of plasmid DNA into both HEK293 cells and COS7 cells, cells were 
seeded into 6 well plates at 5 x 10
4
 cells/cm
2
 and transfected the following day using 
0.5ug/cm
2
 of plasmid DNA following the standard product protocols (PEI and 
calcium phosphate). Cells were treated and lysed 48h after transfection for analysis. 
For transfection of plasmid DNA into MIN6 cells, cells were seeded into 6 well plates 
at 1 x 105 cells/cm
2
 and transfected the following day with Lipofectamine 2000 
(Invitrogen), according to the manufacturer’s instructions. Cells were lysed 48 hours 
following transfection for analysis.  
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2.2.14 Small interfering RNA (siRNA) silencing 
HEK293 Cells were treated with either mock negative control scrambled siRNA or 
with 2 different siRNA oligonucleotides (Ambion) designed for the silencing of a 
particular target gene. Cells were transfected at 50-70% confluency with the indicated 
siRNA concentrations using the Ribojuice reagent according to the product protocols. 
Cells were treated lysed after 48hr of incubation.  
 
2.2.15 Generation of Mammalian PPM expression constructs 
Constructs for the PPM isoforms PPM1A, PPM1D, PPM1F and PPM1G were 
obtained from Source Bioscience. The fragment of interest was cut with the 
appropriate restriction enzymes and Phusion High-Fidelity DNA Polymerase 
(Finnzymes) was used for the PCR amplification with the conditions as follows; 
initial denaturing step of 98ºC for 30 seconds, followed by 35 cycles of 98ºC for 10 
seconds, 55ºC for 30 seconds and 72ºC for 1--minute, and then a final extension step 
of 72ºC for 5--minutes. The PCR product was cut and ligated and cloned into the 
pcDNA3.1/v5-His-TOPO vector using the manufacturer’s protocols. The plasmids 
was amplified in E.coli JM109 competent cells (Stratagene). A Maxi Prep was carried 
out using a Qiagen kit. The cDNA was sequenced using the sequencing service at the 
MRC Clinical Sciences Centre.  
 
2.2.16 Cell lysis 
Cells were washed with PBS and lysed into lysis buffer (50mM Hepes pH7.4, 50mM 
NaF, 5mM NaPP, 1mM EDTA, 10% (v/v) glycerol and 1% triton TX-100, 1mM DTT, 
4µg/ml trypsin inhibitor, 0.1mM PMSF, 1mM benzamidine). The process if known as 
fast lysis and was done as quickly as possible to prevent activation of AMPK. Cell 
lysates were centrifuged at 18000g for 15min, with the supernatant containing 
cytosolic proteins being retained.  
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2.2.17 Protein concentration determination for mammalian cell 
lysates 
Protein concentration for both cell lysates and tissue homogenates was determined 
using the BioRad (Hertfordshire) Bradford protein assay system according to the 
manufacturers’ protocol with the absorbance at 595 nm measured using a standard 
computerised spectrometer device. 
 
2.2.18 Determination of ratio of nucleotides within cells 
Cells were first washed with PBS and lysed with 5% (v/v) perchloric acid.  Cell 
lysates were centrifuged at 18000g for 15min, with the supernatant containing the 
nucleotides being retained. The supernatant was then washed with 10% (of the 
supernatant volume) of a mixture of 1:1 ratio of 1,1,2 –trichlorotrifluoroethane and 
tri-n-octylamine. Ion-exchange chromatography was then use to separate the different 
nucleotides using a SMART chromatography system (Amersham Biosciences). The 
nucleotides were detected by their absorbance at 254nm and compared with known 
standards containing nucleotides. The amount of each nucleotide is calculated by the 
integrated program as the area under each curve peak. The AMP/ADP:ATP ratio is 
calculated from the above information.    
 
2.2.19 Western blotting  
Samples were boiled in electrophoresis sample buffer and resolved on polyacryamide 
(10/12%) by SDS-PAGE. Proteins were transferred PVDF membrane (Immobilon-FL, 
Millipore) at 30 V overnight; subsequently membrane were blocked with PBS 
containing 5% skimmed milk powder for 1hr.  
 
Antibodies were diluted in 5ml High Salt Tween (HST) buffer (20mM Tris, pH 7.4, 
500mM NaCl, 0.5 % Tween (v/v)), and incubated with the membrane for two hours at 
room temperature or overnight at 4ºC. Primary antibodies were detected using 
fluorescently linked secondary antibodies (Alexa Fluor, Invitrogen/LICOR IRye 
antibodies). These were visualised using an Odyssey Infrared Imager (Licor 
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Biosciences). Quantification was performed using Odyssey infrared imaging 
software).  
 
2.2.20 AMPK Immunoprecipitation from cell lysates 
AMPK was immunoprecipitated from cell lysates before assaying for activity after 
cell treatments, transfections and siRNA knockdown experiments.  Lysate of 100 μg 
total protein was made up to a total volume of 100 μl with lysis buffer then incubated 
at 4 °C for 1-2 hours with 20μl of 50% protein A slurry and 0.5 µl the pan-AMPK-β 
subunit antibody.  The supernatant was removed and the resin was washed 2 times 
with Hepes buffer A (50mM Hepes, 1mM EDTA, 10% glycerol, 1mM DTT, 1% 
Triton, protease inhibitor cocktail) before use in the AMPK-activity assay.    
 
2.2.21 RNA extraction 
Cells were plated in 6 well plates and cells were either transfected with siRNA or 
allowed to grow for 72 hours after plating.  Cells were then washed in PBS and 
scraped into 1ml TRIzol and incubated for 5 minutes at room temperature. 
Chloroform was added and the cells were inverted for 15 seconds before a further 3 
minute incubation.  Mixture was then spun at 12000 g for 15 minutes to separate the 
RNA fraction in the upper aqueous phase. Ethanol was added (0.53 % v/v) before 
adding this to the RNA easy column.  The column was washed with Buffers RW1 and 
PPE before elution of the RNA in RNAse free water.  Samples were stored at -80°C 
before use. 
 
2.2.22 qRT-PCR 
Specific Primers for each target was purchased by Sigma and diluted to the 
manufacturers required concentrations. RT-PCR reaction was carried out on the 
Opticon DNA engine 2 using the Qiagen SYBR Green kit as per manufactures 
instructions.  Briefly, 10 ng of total RNA was incubated with SYBR green RT-PCR 
mastermix, RT mix and appropriate primer assay mix and subjected to reverse 
transcription, followed by 40 cycles of extension. A no-RT control where RNA was 
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subjected to a mock reverse transcription reaction was carried out as a control to 
ensure no genomic DNA contamination.  
 
2.2.23 Immunoprecipitation of phosphatases and in-vitro 
dephosphorylation assay 
Over-expressed PPM proteins were immunoprecipitated fromcrude cell lysate using 
5ul of anti-V5 antibody (Invitrogen) and 50ul of protein G slurry made to a total 
volume of 1ml.  Binding was allowed to take place for 6hr at 4 C; the supernatant was 
removed washed 2 times with Hepes buffer A (50mM Hepes, 1mM EDTA, 10% 
glycerol, 1mM DTT, 1% Triton, protease inhibitor cocktail). The resin was the 
incubated with 100ng bacterially expressed AMPK (activated using CAMKK β) 
(From Faith Mayer) in the presence of 2.5 mM MgCl2 at 37 ºC for 30 min, made up to 
a total volume of 80 µl. Positive control was provided by the incubation of active 
AMPK with of bacterially expressed PPM1A (from Faith Mayer) with 2.5mM MgCl2 
under the same conditions. The samples were then taken into a SAMS-peptide assay.  
 
2.2.24 In-vivo Crosslinking and analysis 
HEK293 and COS7 Cells were cultured as described above in Chapter 2 and co-
transfected with AMPK expression constructs encoding α1, β1, γ1 respectively with 
expression proceeding for 48h. Cells are washed with PBS and covered with 2mls of 
1% paraformaldehyde (per well of 6 well plate) for 5/15 minutes, the crosslinking 
cycle is quenched using ice cold 1.25 M glycine for 5 minutes and washed again with 
glycine before cell lysis as described. 
 
AMPK was co-immunoprecipitated from 200 μg of crude cell lysate with AMPK-β 
subunit antibody and 50ul of protein A slurry, with the reaction allowed to proceed 
overnight (10hr). The resin was washed 3 times with PBS and crosslinking was 
reversed by heating the resin in 2x sample buffer (Sigma) to 60 ºC overnight. The 
coimmunoprecipitated proteins were eluted from the resin (5 min at 100 ºC) and the 
eluted proteins resolved using SDS page electrophoresis. The gel was sent for mass 
spectrometric analysis.  
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2.2.25 Stable isotope labelling by amino acids in cell culture and 
quantitative mass spectrometry 
HEK293 cells were grown in parallel in DMEM (4.5 g/L) media containing either 
‘heavy’ (13C) or ‘light’ (12C/normal) isotopes of the amino acids arginine and lysine 
(
13
C isotopes obtained from CK gas, UK) for 10 passages. After this, cells were 
treated as indicated in individual experiments and lysed as shown in 2.2.16 and 2.2.20. 
Lysates from cells grown in ‘heavy’ isotope media were subjected to 
immunoprecipitation with the following antibodies: AMPK pan-β-subunit antibody 
(in house), AMPK α subunit antibody (in house), AMPK pThr-172 antibody (Dundee 
University), while lysates from cells grown in ‘light’ isotope media was subjected to 
immunoprecipitation reactions with the corresponding pre-immune serum or non-
targeting IgG from the same species. Following immunoprecipitation and washing 
once with Cell lysis buffer (see 2.1.2) and once with PBS, the immuno-prellets were 
mixed and resolved with SDS-PAGE. Protein bands were visualised by staining with 
Simply Blue Stain ® (Invitrogen) using the manufacturers protocol. Samples were 
analysed using mass spectrometry analysis (MRC proteomics unit). Briefly, samples 
were excised using a scalpel and processed. Proteins were digested using trypsin 
overnight and applied to a Thermo Scientific LTQ Orbitrap XL hybrid FTMS (Fourier 
Transform Mass Spectrometer) operating in positive polarity Raw data files were 
analysed using MaxQuant software (http://www.maxquant.org/), data were searched 
against the Uniprot mouse database that was current at the time. 
 
2.2.26 Collagen based invasion assay  
Cells were pre-incubated with the indicated concentration of A769662 compound for 
16 hours and then resuspended in serum-free collagen I at 2.3 mg/ml to a final 
concentration of 1 × 10
3
 cells/100 μl. Aliquots of 100 μl were dispensed into 96-well 
ViewPlates (Perkin-Elmer) coated with bovine serum albumin. Plates were 
centrifuged at 300 × g and incubated at 37°C/10% CO2 for 30 min before fetal calf 
serum1 of 10% (in DMEM) was added. After 16 hr incubation, cells were fixed in 
formaldehyde (final concentration 4%) and stained with 5 μg/ml Hoechst 33258 
(Molecular Probes-Invitrogen). Confocal Z slices were collected from each well at 50 
μm and 3 μm (bottom of well) with an INCELL3000 high-content microscope. 
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Nuclear staining was quantified with INCELL3000 software with the Object Intensity 
module. Samples were run in quadruplicate and averaged. The invasion index was 
calculated as number of cells at 50 μm divided by the total number of cells. Data are 
presented as fold of invasion index of non-A769662 treated cells.  
 
2.2.27 Transwell invasion assay 
Transwell invasion assay kits (24 well format) were obtained from Millipore (Merck 
group) (catalogue code: ECM550). Prior to conducting the invasion assay, each 
invasion chamber  was transferred into a 24 well plate well and equilibrated by adding 
300 μl of pre-warmed serum free DMEM free media and allowing equilibration to 
take place for 2 hours after which this media is removed. 500 μl of media containing 
20% FBS was added into the lower chamber. A suspension of WM1361 melanoma 
cells was prepared at a concentration of 1x10
6
 cells/ml. At this point pharmacological 
compounds were added into this suspension. 300 μl of this cell suspension was placed 
into each insert (resulting in 3.3 x 10
5
 cells per insert) and the assay incubated at 
37ºC/5% CO2 for 48 hours to allow invasion of cells to take place.  
 
After this, the media was removed from the top and bottom chambers and a cotton 
tipped swab used to remove both the ECM matrix and non-invading cells from inserts 
leaving only the cells which have invaded through the ECM matrix and cell-
permeable membrane. Invaded cells were stained using staining solution supplied for 
20 minutes, and unspecific staining removed by three washes with sterile water. A 
standard light microscope was used to image stained cells with 5 fields taken at 10x 
magnification for each insert. Cells in each field were then counted manually and 
averaged. Data was plotted in graph form with the average number of cell per field 
plotted for each different treatment.  
 
2.2.28 Statistical analyses 
Statistical calculations were performed in Microsoft Excel. Error bars are given as 
standard error of the mean. Differences between data sets were analysed by Student’s 
t tests and one way ANOVA where appropriate (when comparing more than one 
group of data). Differences were considered significant if P < 0.05. 
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3 Identification of AMPK phosphatase(s)  
3.1 Introduction:  
It is well known that the main mechanism by which AMPK activity is regulated is via 
the phosphorylation and dephosphorylation of the Thr-172 residue on the α subunit 
(Hawley et al., 1996). It can thus be appreciated that the identification of the upstream 
kinases and phosphatases are of utmost importance for us to gain a full picture of 
AMPK signalling pathway. While both LKB1 and CaMKKβ have been identified as 
AMPK upstream kinases, there is still a lack of consensus in the field as to the 
identity of the upstream phosphatase(s).  The existing literature (at the time of starting 
this thesis) is sometimes contradictory, with almost all major classes of protein 
phosphatases suggested to regulate AMPK activity, (Davies et al., 1995; Gimeno-
Alcaniz and Sanz, 2003; Moore et al., 1991; Samari et al., 2005; Steinberg et al., 
2006b; Wu et al., 2007). The existing literature on possible AMPK phosphatases has 
been extensively reviewed in chapter 1.  
 
Most of the publications referenced above are not dedicated studies specifically 
designed for the identification of the AMPK phosphatase. In this chapter, an approach 
starting from first principles and using a variety of experimental techniques, including 
phosphatase inhibitors and siRNA silencing, was undertaken to identify the AMPK 
phosphatase(s) in mammalian cell-lines  
 
3.2 Results: 
3.2.1 Pharmacological activation of AMPK in HEK293 cells  
To initially characterise the AMPK activity profile in HEK293 cells, AMPK was 
immunoprecipitated from HEK293 cell lysates under basal conditions using 
antibodies specific for either α1 or α2 subunits of AMPK. After immunoprecipitation, 
the resulting immune-complexes were subjected to assays using the SAMS peptide. 
This was done to investigate if both α1 and α2 are expressed and active in HEK293 
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cells. The specific activities of AMPK immune-complexes containing α1 or α2 
subunits are shown in Figure 3.1.    
 
Having verified that both AMPK α1 and α2 are expressed and active in HEK293 cells, 
experiments were performed to determine the activity of LKB1 and CaMKKβ are in 
these cells. In this experiment, a two-step kinase assay was performed where vitro 
activation of recombinant AMPK by immunoprecipitated LKB1 or CaMKKβ from 
cell lysates of un-stimulated HEK293 cells was measured, as shown in Figure 3.2. It 
can be seen that both AMPK upstream kinases are active in HEK293 cells with the 
specific activity for LKB1 (average of 2027 U/mg) being roughly 3 times that of 
CaMKKβ (average of 705 U/mg) activity. Although, as different antibodies are used 
for the immunoprecipitation reactions, this makes direct comparison of specific 
activities somewhat difficult.  
 
To establish whether AMPK activity can be modulated in HEK293 cells, they were 
treated with a variety of pharmacological agents previously reported to activate 
AMPK in various cell types. AMPK activities were then measured with the SAMS 
peptide assay. As shown in Figure 3.3, AMPK activity increased 6.6 fold after 
treatment by H2O2, by 6.4 fold after treatment by DNP (2,4-Dinitrophenol), by around 
6.1 fold with phenformin, and by 2.9 fold with ionomycin. Treatment with 100 µM or 
200 µM of the direct activator A-769662 resulted in a 3.2 and 5 fold elevation in 
AMPK respectively. On the other hand, treatment with the AMPK activators AICAR 
or metformin had no significant effects on AMPK activity in HEK293 cells.  
 
As seen from the above results, AMPK α1 and α2 catalytic subunits are expressed in 
HEK293 cells and AMPK can be dynamically modulated by various treatments, it 
was decided that HEK293 cells would be an appropriate model to investigate the 
regulation of AMPK by protein phosphates(s).  
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Figure 3.1Activity of AMPK α1 and α2 isoforms in HEK293 cells 
Antibodies targeting either AMPK α1 and α2 subunits were used to immunopreciptate AMPK 
complexes from soluble HEK293 lysate (50μg total protein). The SAMS peptide assay was 
used to determine AMPK activity. Data shown represent averages and standard errors (SEM) 
from 3 independent experiments and are shown as specific activity of the kinase 
(pmol/min/mg) 
 
 
Figure 3.2 Activity of upstream kinases of AMPK in HEK293 cells 
Antibodies targeting either the upstream kinases LKB1 and CaMKKβ were used to 
immunopreciptate from the HEK293 protein lysates (100ug). The immune-complexes were 
used to phosphorylate 0.2ug - 1ug of recombinant AMPK (α1β1γ1) (in the presence of calcium 
and calmodulin). AMPK activation by the upstream kinases was then assayed using the SAMS 
peptide. Activities are plotted as U/mg of lysate protein, where 1 unit is the activity of 
LKB1/CaMKKβ required to activate recombinant AMPK by 1 nmol/min/mg of protein. Data 
shown represent averages and standard errors (SEM) from 3 independent experiments.  
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Figure 3.3 Activation of AMPK in HEK293 cells 
HEK293 cells in serum free media were treated with the following compounds: AICAR at 0.5 
mM or 1.0 mM for 30 minutes, 2 mM metformin for 2 hours, 0.5 mM H2O2 for 15 minutes, 5 
mM Phenformin for 30 minutes, 0.5 mM DNP for 30 minutes, 2.5 μm ionomycin for 5 
minutes and A769662 at 100 μm or 200 μm for 1 hour. After treatment AMPK was 
immunoprecipitated using the pan-β-subunit antibody and AMPK activity determined. Results 
are shown as fold AMPK activity relative to the mock control treatment experiment. Data 
shown represent averages and standard errors (SEM) from 3 independent experiments.  
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3.2.2 Okadaic acid treatment of HEK293 cells 
Okadaic acid is a potent inhibitor of most phospho-protein phosphatases (PPP), with 
IC50 values for PP1 of around 30 nM and around 0.1 – 0.3 nM for PP2A (Swingle et 
al., 2007). On the other hand, this compound has no effect on the activity of PPM 
phosphatases and thus can be used as a tool to discriminate between different 
phosphatase classes of potential AMPK phosphatases. The concept behind this 
experiment is that inhibition of the AMPK-phosphatase should allow the 
constitutively active LKB1 to facilitate an increase in AMPK phosphorylation/activity. 
 
HEK293 cells were treated for 60 minutes with increasing concentrations of okadaic 
acid and the cells lysed. The phosphatase responsible for dephosphorylating acetyl-
CoA carboxylase (ACC) is okadaic acid sensitive (Moore et al., 1991). As such, the 
cell lysate was subjected to immune-blot analysis and probed for phospho-ACC 
(pSer-79) to reveal whether okadaic acid is having its desired effect.  While treatment 
with 10 nM okadaic acid did not lead to significant changes in ACC phosphorylation 
(Figure 3.4), 50 nM and 500 nM treatments led to a 2 fold and 2.5 fold increase 
respectively.  
 
Aside from phosphorylation at the Thr-172 residue, AMPK can also be allosterically 
activated by AMP. As okadaic acid causes inhibition of a significant proportion of the 
cellular phosphatase activity, it is possible that there could be an associated increase 
in the levels of AMP or ADP relative to ATP. Thus, nucleotide extraction was 
performed on control and okadaic acid treated cells with the positive control cells 
being treated with DNP (which has been previously seen to elicit a reduction in the 
ratio of ATP to AMP/ADP). The relative levels of AMP, ADP and ATP determined 
by ion-exchange chromatography as described in chapter 2. The amount of 
nucleotides are taken as the area under each nucleotide peak. In most cell types, under 
basal conditions, the peak for ATP would be much larger than that of ADP, which 
would in turn have a much larger peak than AMP.  While easily detectable peaks for 
ATP and ADP were observed, a peak for AMP could not be detected under these 
conditions (although an AMP peak was visible for DNP treated cells), this is most 
likely due to the much lower cellular AMP concentrations compared to ADP and ATP. 
Thus the ATP:ADP ratio was used instead (Figure 3.5). Treatment with DNP was 
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used as a positive control as an agent known to cause a change in nucleotide ratios 
(previous work in our lab). DNP treatment caused a 78% drop in ATP:ADP ratio from 
~12 to ~7. Treatment at 50 nM and 500 nM okadaic acid also caused a slight drop in 
ATP:ADP ratio of 9.5% and 12% respectively, although these small changes were not 
statistically significant.  
 
Based on above findings, HEK293 cells were subjected to okadaic acid treatments at 
concentrations of up to 500 nM. From the SAMS peptide assay results, there was a 
small increase in both AMPK α1 and α2 activities when cells were treated with the 
higher concentrations okadaic acid, i.e. 18% and 23% for AMPK α1 and 6% and 14% 
for AMPK α2 under 50 nM and 500 nM treatments respectively. However the, levels 
of these changes were not statistically significant (Figure 3.6).  
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Figure 3.4 Inhibition of the ACC phosphatase using okadaic acid 
HEK293 cells were either left untreated or treated with water soluble okadaic acid 
at the following concentrations: 10 nM, 50 nM and 500 nM, for 60 minutes after 
which cells were lysed. Cellular lysates were resolved using SDS-PAGE and 
subjected to western blot analysis for pACC (pS-79) and actin. Representative 
western blot shown above. The relative level of signal were quantitated using the 
Licor Odyssey software against Actin and is plotted in graphical form above. Data 
shown represent averages and standard errors (SEM) from 3 independent 
experiments.  
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Figure 3.5 Treatment with okadaic acid does not alter the 
ATP:ADP ratios in HEK293 cells 
Nucleotides were extracted from HEK293 cells which were left untreated, treated 
with water soluble okadaic acid at the following concentrations: 10 nM, 50 nM 
and 500 nM, for 60 minutes or treated with DNP at 0.5 mM for 15 minutes. The 
cell were lysed and adenine nucleotides levels determined and ATP:ADP ratios 
calculated.  
* Indicates a significant decrease in ADP:ATP ratios with DNP compared to 
control treatment (0nM Okadaic acid) as judged by one way ANOVA (P<0.05). 
Data shown represent averages and standard errors (SEM) from 3 independent 
experiments. 
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Figure 3.6 Okadaic acid has no significant effect on the activity of 
AMPK α1 and α2 isoforms in HEK293 cells 
HEK293 cells in serum free media was treated with okadaic acid at the indicated 
concentrations and cells lysed.  Antibodies targeting either AMPK α1 and α2 subunits 
were used to perform immunoprecipitation reaction and activity of AMPK α1 and α2 
determined using the SAMS peptide assays. Results are shown as fold AMPK 
activity relative to the mock treatment control. Data shown represent averages and 
standard errors (SEM) from 3 independent experiments.  
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3.2.3 Endogenous expression of PPM family phosphatases in 
HEK293 cells  
In order to elucidate the phosphatase acting on AMPK, a logical approach would be to 
alter the endogenous expression of individual PPM phosphatases in HEK293 cells by 
either RNAi knockdown or transient over-expression and determine if there is a 
change in AMPK activity. There are a total of 17 known PPM phosphatases so far 
identified, the results obtained with okadaic acid treatement would suggest that the 
AMPK phosphatase(s) is likely to belong to this family (Lu and Wang, 2008). With a 
view of employing RNAi for the knockdown of individual PPM phosphatases, the 
expression levels of these phosphatases in HEK293 cells was first profiled. 
Quantitative-RT-PCR was used to measure the relative mRNA level of these 
phosphatases. The levels of mRNA for these phosphatases were compared to the 
mRNA levels of ALAS1 (δ-aminolevulinate synthase) a reference gene which has 
previously been found to be expressed in a similar range to the PPM phosphatases (Li 
et al., 2009). As can be seen from Figure 3.7, mRNA expression for 16 out of the 17 
PPM isoforms was detected. Expression for the T-cell activated PP2C isoform was 
not detected in these cells and thus was not included in the subsequent knockdown 
studies. From the data, the relative the mRNA levels of PPM1G was found to have the 
highest expression of the PPMs tested at approximately 110% of the mRNA levels of 
ALAS1; the next highest expressed PPM is PPM1B at approximately 80% the level. 
The remaining PPMs were expressed at lower levels. ALAS1 was used as the house 
keeping gene for all qRT-PCR experiments in this thesis.  
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3.2.4 Optimisation of siRNA mediated protein knockdown in 
HEK293 cells: 
Due to lack of potent and specific PPMs inhibitors, it was decided to use siRNA to 
perform transient knockdowns of PPM phosphatases in HEK293 cells individually. 
The rational for this experiment is that the decrease in the protein level of the AMPK-
phosphatase should cause a decrease in the phosphatase activity acting upon AMPK, 
therefore resulting in an increase in the phosphorylation and activity of AMPK.  
 
SiGLO, a fluorescent tagged non-specific siRNA oligo-nucleotide (tagged with DY-
547) was use to optimise transfection conditions. Three different transfection reagents 
were tested to find the most efficient agent for siRNA transfection into HEK293 cells. 
SiGLO was transfected using each of the agents and the transfection efficiency was 
determined by the percentage of cells containing the fluorescent SiGLO 24h post 
transfection (data not shown). Transfection with the RiboJuice reagent gave the 
highest percentage (over 96%) of cells containing siGLO and thus was chosen for use 
in future experiments (Figure 3.8).     
 
It is important to verify that the siRNA knockdown method does not have an effect on 
AMPK activity at basal levels or its ability to be activated by exogenous stimuli. Non-
targeting control siRNA (Ambion) (abbreviated to siControl) was transfected in 
HEK293 cells to a final concentration of 10 nM, 15 nM and 25 nM, these cells were 
either lysed while at basal conditions or after treatment with phenformin. As shown in 
Figure 3.9, basal AMPK activities (non-treated), or following phenformin treatment, 
were not significantly affected by the siControl at any of the concentrations tested.  
 
As mRNA levels are not a direct measurement of protein levels in the cells, we 
obtained antibodies targeting PPM1A to optimise the concentration of siRNA for 
knockdown experiments and to use these conditions for all PPM knockdowns. Two 
different specific siRNA oligo-nucleotides targeting PPM1A were obtained, and 
transfected into HEK293 cells separately or together at final concentrations of 5 nM, 
10 nM and 25 nM (combined concentration of both siRNA nucleotides). Cells were 
lysed after 72 hours and subjected to immuno-blot analysis probing for PPM1A. It 
was found that when both siRNA oligos were transfected together a greater level of 
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knockdown was achieved compared to when siRNA was transfected individually 
(data not shown). In light of this, it was decided to transfect two individual siRNA 
constructs together in future experiments. With double siRNA transfection at a total 
concentration of 10 nM (i.e. each siRNA oligo at 5 nM), a decrease of around 52% of 
PPM1A protein was achieved, compared to control siRNA transfection, while at 15 
nM (i.e. each siRNA oligo at 7.5 nM) around 60% knockdown was achieved, the most 
efficient knockdown of around 75%, was seen with a final total siRNA concentration 
of 25 nM (Figure 3.10). SiRNA concentrations beyond 25 nM was not used for 
knockdown of individual phosphatases due to the likelihood of cell toxicity.  
 
Next, the time-course of knockdown of PPM1A was determined. HEK293 cells were 
lysed either 48 h or 72 h post transfection and cell lysates subjected to immuno-blot 
analysis to determine the amount of PPM1A remaining after these periods. Due to the 
rapid growth of HEK293 cells, knockdown was not allowed to proceed longer than 72 
h, due to the cells becoming over-confluent (This usually occurred around 96 h post 
transfection). As shown in Figure 3.11, 48 h after transfection the percentage of 
PPM1A protein remaining was around 25%, the most efficient knockdown of PPM1A 
was seen 72 h after transfection with 18% remaining. Thus, it was decided that 
knockdowns should proceed for 72 h in all future experiments.  
 
3.2.5 Knockdown of PPM isoforms in HEK293 cells 
siControl or siRNA targeting individual PPM isoforms were transfected into HEK293 
cells, and cells were lysed into Trizol after 72 h and total cellular RNA extracted. As 
it was impractical to obtain specific antibodies targeting every PPM isoform, analysis 
using qRT-PCR was used to determine the level of mRNA remaining, allowing an 
indirect indication of the efficiency of knockdown to be calculated. As shown in 
Figure 3.12, siRNA silencing resulted in a >50% reduction in mRNA levels for all 
PPMs tested, with the most efficient knockdown of >75% being achieved for PPM1A, 
PPM1B, PPM1F, PPM1J and ILKAP, PHLPP1 PDP1 and PDP2. Knockdown 
efficiencies for the other PPM isoforms varied between around 58% for PPM1E and 
72% for PPM1L.  
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To further confirm that the reductions in mRNA levels resulted in a reduction in 
protein levels, antibodies were obtained for three further PPM isoforms (in addition to 
PPM1A): PPM1B, PPM1H and ILKAP. After siRNA knockdown for 72 h, cell 
lysates were subjected to western-blot analysis with these antibodies (Figure 3.13). 
With PPM1B, there was an average of approximately 71% of depletion in protein 
levels, with PPM1H there was approximately 62% depletion and for ILKAP there was 
around 59% knockdown after siRNA transfection.  
 
3.2.6 Effect of PPM knockdown on AMPK activity  
To test if a reduction in the levels of PPM phosphatases affected AMPK activity, 
AMPK was immunoprecipitated from cell lysates transfected with either control 
siRNA or PPM siRNA using the pan-β subunit antibody, and AMPK activity in the 
immune complexes determined. As seen from Figure 3.14, AMPK activity after 
siRNA knockdown of the PPM isoforms varied from 80% (PPM1M) to 115% 
(PPM1F) when compared to control siRNA transfection. There was no significant 
alteration in AMPK activity when any of the PPMs were knocked down. However for 
the knockdown of isoforms PPM1F, PPM1H and PPM1L, while the average AMPK 
activities were not significantly higher than control samples (the average activity 
values were 15% - 20% higher than control but did not reach significance), there was 
some variation in activity data recorded for individual experiments, with the highest 
activity recorded in individual experiments being 151% (PPM1F), 158% (PPM1H) 
and, 145% (PPM1L) (data not shown).  
 
In view of these data, and the possibility that PPM1F, PPM1H and PPM1L all 
contributed to the dephosphorylation of AMPK, all three phosphatases were knocked 
down concurrently in HEK293 cells (with a final siRNA concentration of 37.5 nM, i.e. 
12.5 nM for each phosphatase). Q-RT-PCR was used to measure the remaining 
mRNA levels for each of these phosphatases Figure 3.15A. Due to the lower 
concentration of siRNA used for each PPM isoform, the knockdown achieved in this 
experiment was marginally lower than when individual phosphatases were silenced. 
Reduction in mRNA levels of between ~65% (PPM1F) and ~75% (PPM1L) were 
seen in these samples. AMPK activity from these knockdown samples are shown in 
Figure 3.15B. Although an elevation in activity of around 16% was observed in the 
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knockdown samples compared to control samples, this does not represent a further 
increase compared to individual knockdown of the phosphatases. Furthermore these 
results did not reach statistical significance (P value ~0.2) 
 
Next, to determine if the AMPK α1 and α2 were dephosphorylated by different 
phosphatases, antibodies specific for the α1 and α2 subunits were used to 
immunoprecipitate AMPK from control and knockdown samples and AMPK activity 
assayed (Figure 3.16). No significant changes in α1 or α2 AMPK activities were 
observed when PPM phosphatases were knocked down.  
 
Next I investigated if the depletion of phosphatases can augment the levels of AMPK 
activation seen when cells are treated with an AMPK activator. Experiments were 
performed where HEK293 cells subjected to siRNA mediated PPM knockdown for 72 
h were treated with the AMPK activator phenformin. The AMPK activities in these 
samples were assayed and compared to phenformin activated cells subjected to 
control siRNA transfection.  As seen from Figure 3.17, no significant difference in 
the levels of AMPK activation was observed between control samples and samples 
where PPMs have been knocked down.  
 
85 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Expression of PPM phosphatase isoforms in HEK293 
cells  
RNA was extracted from HEK293 cells and analysed using qRT-PCR for the PPM 
isoforms listed using specific primers, mRNA expression of PPM isoforms were 
quantified against the housing keeping gene ALAS1. Data shown represent 
averages and standard errors (SEM) from 3 different experiments.  
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Figure 3.8 Validation of  siRNA (SiGLO) transfection in HEK293 
cells 
HEK293 cells were plated onto ploy-L-Lysine coverslips and transfected with 
SiGLO (DY-547 labelled) siRNA. Cells were fixed with formaldehyde 48 h post 
transfection. The Leica DMIRE2 microscope was used to obtain bright field and red 
channel images with 10x objective lens. The efficiency siRNA transfection was 
determined by dividing the total number of cells by the number of cells containing 
SiGLO across 10 different fields.  
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Figure 3.9 siControl  has no effect on AMPK activity or AMPK activation 
HEK293 cells were treated with 0 – 25 nM of control siRNA (siControl), 72 h post 
transfection, cells were treated with phenformin (30 min) or left untreated. After cell lysis, 
AMPK was immunoprecipitated with the pan-β-subunit antibody and activity determined 
using SAMS peptide assay. Data shown represent averages and standard errors (SEM) from 3 
different experiments. Results are shown as fold AMPK activity relative to experiments where 
no siRNA was introduced.  
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Figure 3.10 Optimisation of siRNA concentration for PPM 
knockdown 
HEK293 cells were transfected with increasing concentrations of siControl or siRNA 
targeting PPM1A, and cells lysed 72 h after transfection. Lysates were resolved using 
SDS-PAGE and subjected to western blot analysis for PPM1A and tubulin 
(representative blot shown). The relative level of protein expression are quantitated 
using the Licor Odyssey software and normalised with tubulin. Expression shown 
represent averages and standard errors (SEM) from 3 different experiments.  
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Figure 3.11 Optimisation of time course for PPM knockdown 
HEK293 cells were transfected with 25 nM of siControl or siRNA targeting 
PPM1A, and cells lysed 48 hours or 72 h after transfection. Lysates were resolved 
using SDS-PAGE and subjected to western blot analysis for PPM1A and tubulin 
(representative blot shown). The relative level of protein expression after 48 h and 
72 h of siRNA mediated knockdown are quantitated using the Licor Odyssey 
software and normalised with tubulin. Data shown represent averages and standard 
errors (SEM) from 3 different experiments.  
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Figure 3.12 Knockdown of PPM isoforms in HEK293 cells  
HEK293 cells were transfected with either siControl or siRNA against each of the 16 
PPM isoforms at a final concentration of 25 nM. Knockdown was allowed to proceed 
for 72 h after which the cells were lysed and RNA extracted. Levels of mRNA for the 
PPM isoforms were determined using qRT-PCR. Levels of knockdown was calculated 
by comparing mRNA expression in HEK293 cells treated with PPM siRNA with 
those transfected with siControl. Data shown represent averages and standard errors 
(SEM) from 3 independent experiments.  
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Figure 3.13 Validation of protein knockdown of PPM1B, PPM1H and 
ILKAP 
HEK293 cells were transfected with either siControl or siRNA against PPM1B, PPM1H 
or ILKAP isoforms into at a final concentration of 25 nM. Cells were lysed after 72 h 
and lysates were resolved using SDS-PAGE and subjected to western blot analysis with 
PPM1B, PPM1H and ILKAP antibodies (representative blot shown). Tubulin was used 
as the loading control. The relative level of protein expression were quantitated using the 
Licor Odyssey software normalised with Tubulin. Data shown represent averages and 
standard errors (SEM) from 3 different experiments.  
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Figure 3.14 Knockdown of individual PPM phosphatases does not 
affect basal AMPK activity 
HEK293 cells were transfected with either non-targeting siRNA or siRNA against 
each of 16 PPM isoforms at a final concentration of 25 nm, after 72 h the cells were 
lysed. AMPK was immunoprecipitated using the pan-β-subunit antibody (from 50 
μg total protein) and the activity of AMPK determined. Results are shown as fold 
AMPK activity relative to siControl transfection. Data shown represent averages and 
standard errors (SEM) from 3 independent experiments.  
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Figure 3.15 Multiplexed knockdown of PPM1F, PPM1H and 
PPM1L in HEK293 cells  
HEK293 cells were transfected with either siControl or siRNA against PPM1F, 
PPM1H and PPM1L at a final concentration of 37.5 nM (12.5 nM for each siRNA 
oligo). A. After 72 h the cells were lysed and RNA extracted. The mRNA levels of 
PPM isoforms in both control and knockdown samples were determined using 
qRT-PCR. Data shown represent averages and standard errors (SEM) from 3 
independent experiments.  
B. After this cells were either lysed or treated with 5 mM phenformin for 30 
minutes and then subjected to lysis. AMPK immunoprecipitated (from 50 ug total 
protein) and activity assayed. Results are shown as fold AMPK activity relative to 
the siControl transfection. Data shown represent averages and standard errors 
(SEM) from 3 independent experiments.  
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Figure 3.16 Knockdown of individual PPM phosphatases does not 
affect activity of AMPK α1 or α2 isoforms 
HEK293 cells were transfected with either non-targeting siRNA or siRNA against  
each of the 16 PPM isoforms at a final concentration of 25 nm, after 72 h the cells 
were lysed. AMPK was immunoprecipitated with antibodies targeting either 
AMPK α1 or α2 subunits (from 50 μg total protein) and the activity of AMPK 
assayed. Results are shown as fold AMPK activity relative to siControl 
transfections. Data shown represent averages and standard errors (SEM) from 3 
independent experiments.  
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Figure 3.17 Knockdown of individual PPM phosphatases does not 
affect the level of AMPK activation by phenformin 
HEK293 cells were transfected with either siControl or siRNA against each of the 
16 PPM isoforms at a final concentration of 25 nM. After 72 hrs, the cells were 
treated with 5 mM Phenformin for 30 minutes. After treatment cells were lysed 
and AMPK immunoprecipitated using the pan-β-subunit antibody (from 50 µg 
total protein) and AMPK activity determined. Results are shown as fold AMPK 
activity relative to siControl transfection  
 
 
 
96 
 
3.2.7 Over-expression of PPM isoforms in HEK293 cells 
Concurrently with the phosphatase knockdown experiments, plasmid constructs 
encoding for the PPM isoforms PPM1A, PPM1D, PPM1F and PPM1G were obtained 
(Source BioScience Limited (UK)). These phosphatases were over-expressed in 
HEK293 cells to see if an elevation in phosphatase activity can result in a decrease in 
AMPK activity. As shown by previous studies, both members of the PPP and PPM 
classes have been reported to dephosphorylate AMPK in vitro (Davies et al., 1995; 
Sanders et al., 2007b). To look at whether this dephosphorylation occurs in cells, the 
effect of phosphatase overexpression on AMPK activity was investigated.  
 
PPM constructs were cloned in house (by this candidate) into the mammalian 
expression vector pCDNA3.1-V5 (available in house) and transfected into HEK293 
cells. 48 hours post transfection the cells were lysed and immuno-blotted for 
phosphatases expression using an anti-V5 tag antibody. Figure 3.18 shows western 
blots probing for the expressed phosphatases and the control over-expression of β-
galactosidase. The levels of expression of these phosphatases were variable with 
PPM1A giving the highest levels of expression, followed by PPM1G, PPM1F then 
PPM1D. The level of expression of PPM1A is around 6.6 fold higher than that of 
PPM1D, as analysed by western blot quantitation (data not shown).  
 
To determine if these phosphatases are active as expressed, they were 
immunoprecipitated from cell lysate using the anti-V5 tag antibody and used to 
dephosphorylate active AMPK in vitro. As seen in Figure 3.19, all recombinant PPM 
phosphatases significantly decreased AMPK activity. PPM1F produced the most 
pronounced decrease in AMPK activity followed by PPM1A and PPM1G. The 
PPM1D immune-complex had the least effect on AMPK activity, lowering it to 
around 46% of the control immunoprecipitation. Bacterially expressed PPM1A was 
used as a positive control.  
 
Next, AMPK was immunoprecipitated from cells over-expressing these phosphatases 
or β-galactosidase, and AMPK activity determined. As shown in Figure 3.20, no 
significant changes in AMPK activity were observed in immune-complexes from 
lysates over-expressing PPMs as compared with the controls lysates. Similarly, no 
97 
 
significant changes in AMPK activity were observed in cells over-expressing 
phosphatases that were treated with phenformin, as compared to phenformin treated 
control samples over-expressing β-galactosidase. These results are interesting in that 
they seem to suggest a level of specificity of phosphatase action in a cellular 
environment that does not exist in vitro assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Overexpression of PPM isoform constructs in HEK293 
cells  
HEK293 cells were transfected with pcDNA-3.1-V5 expression constructs 
encoding PPM1A, PPM1D, PPM1F or PPM1G in turn. After 48 hours cells were 
lysed and resolved using SDS-PAGE and subjected to western blot analysis with 
the following antibodies: anti-V5-Tag (to detect over-expressed phosphatases), 
anti- β-galactosidase, and anti-actin antibodies.  
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Figure 3.19 Validation of the activity of overexpressed PPM 
phosphatase s 
HEK293 cells were transfected with pcDNA-3.1-V5 expression constructs 
encoding the indicated phosphatases, 48 h later cells were lysed and lysates (500  
µg) were immunoprecipitated using the anti-V5 antibody. The immuno-complexes 
were used to dephosphorylate activated recombinant AMPK (45 min at 37 ºC). A 
positive control is provided where bacterially expressed purified PPM1A (Labelled 
Bacterial PPM1A) was used to dephosphorylate active AMPK. The graph show 
the relative AMPK activity of samples overexpressing PPM phosphatase compared 
to negative controls (overexpressing β-galactosidase).  
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Figure 3.20 PPM overexpression does not alter basal AMPK 
activity or activation by phenformin 
HEK293 cells were transfected with expression constructs encoding the indicated 
phosphatases. 48 h later cells were incubated in the presence or absence of 5 mM 
phenformin for 30 minutes and then lysed. AMPK was immunoprecipitated using 
the pan-β-subunit antibody (from 50 µg total protein) and activity determined. 
Results are shown as fold AMPK activity relative to that of cells expressing β-gal.  
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3.2.8 Okadaic acid titration in cytosolic suspensions of HEK293 cells 
As described in Chapter 2, in this study, the buffer used to lyse mammalian cells 
normally contain phosphatases inhibitors such as sodium fluoride, sodium 
pyrophosphate and EDTA. However if these inhibitors are not included, action by 
endogenous phosphatases present in the cytosolic preparations would result in near 
complete dephosphorylation of AMPK (Carling et al., 1987).  
 
Considering the inconclusive results from the experiments shown above, an 
experiment was devised to shed more light on the class of phosphatase that 
dephosphorylates AMPK in cells. HEK293 cells were lysed in ice-cold buffer with or 
without the usual phosphatase inhibitors and the insoluble fraction removed by 
centrifugation (14,000 rpm for 15 minutes). In the samples where no phosphatase 
inhibitors were included, okadaic acid was supplemented at various concentrations 
(0nM, 5nM, 40nM, 100nM, 200nM and 500nM) to inhibit the action of endogenous 
phosphatases. The concentrations used were determined using  IC50 values for okadaic 
acid found in literature (Swingle et al., 2007). The aliquots of HEK293 lysates were 
incubated at 37 ºC with shaking for 45 minutes to allow the dephosphorylation 
reaction to proceed. AMPK was then immunoprecipitated and its activities 
determined.  
 
The results for this experiment are shown in Figure 3.21. At a concentration of 5 nM, 
there was no significant protection of phosphatase mediated decrease in AMPK 
activity, as compared with samples where phosphatase inhibitors were included at 
time of lysis. At this concentration, most PP2A activity in the cell lysate should be 
inhibited, whereas most of PP1 activity should remain (Swingle et al., 2007). When 
okadaic acid is increased to 40 nM, around the IC50 value for PP1, 63% of AMPK 
activity is protected. When okadaic acid concentration is increased to 100 nM and 
above, AMPK activity was then fully protected as compared to samples initially lysed 
in the presence of phosphatase inhibitors.  
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Figure 3.21 Okadaic acid supplementation protects AMPK from 
dephosphorylation in cytosolic suspensions 
HEK293 cells were lysed in the presence or absence of phosphatase inhibitors 
normally used in cell lysis buffer (see section 2.1.2). The bar labelled: “All PIs” 
are were lysed in the presence of 50mM sodium fluoride, 5mM sodium 
pyrophosphate and 1mM EDTA. Samples lacking phosphatase inhibitors were pre-
supplemented with increasing concentrations of okadaic acid. Cytosolic 
suspensions were then incubated at 37 ºC for 45 minutes with shaking to allow 
dephosphorylation to take place. AMPK was then immunoprecipitated using the 
pan-β-subunit antibody, and activity assayed. Results are shown as percentage 
AMPK activity relative to the cells lysis in the presence of sodium fluoride, 
sodium pyrophosphate and EDTA.  
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3.2.9 Calyculin-A treatment of HEK293 cells and mouse hepatocytes 
As no promising candidates for the AMPK phosphatase emerged from the PPM 
knockdown studies, and in view of the results for cell suspension studies shown above, 
it was decided to carry out another phosphatase inhibitor screen with Calyculin A.  
Calyculin A is an inhibitor of PPP phosphatases with greater potency of inhibition 
than okadaic acid. (IC50 values of 0.5 – 1 nM for PP2A and of ~2nM for PP1) 
(Swingle et al., 2007).  
 
Firstly, HEK293 cells were subjected to Calyculin A treatment of 10 nM, 20 nM and 
50 nM for 30 minutes, the resulting cell lysate was subjected to western-blot analyses 
for a phospho-ACC, a known PP2A target (Moore et al., 1991). As shown in Figure 
3.22, there was a very considerable increase in p-ACC levels of 3.26 fold and 3.78 
fold respectively for 10 nM and 20 nM treatments. These increases are larger than that 
see for okadaic acid treatments (Figure 3.4).  
 
After confirming that calyculin A inhibited phosphatases in HEK293 cells, AMPK 
was immunoprecipitated from these samples and assayed for activity. As can be seen 
from Figure 3.23, treatment at both 10 nM and 20 nM were able to cause elevations 
in AMPK α1 and α2 activities by around 50%. Both of these changes were statistically 
significant.  
 
As with the okadaic acid treatment, ATP:ADP ratios were also determined following 
calyculin A treatment. As shown in Figure 3.24, while DNP did cause a clear 
decrease in ATP:ADP ratio, calyculin A treatment up to 20 nM did not result in any 
significant change in ATP/ADP ratios. These results suggest that calyculin A does not 
cause any significant perturbations in cellular nucleotide levels, and therefore the 
elevation in AMPK activity observed is unlikely due to protection against 
dephosphorylation by AMP/ADP or allosteric activation.   
 
As shown in Figure 3.3, 15 minute hydrogen peroxide treatment causes significant 
activation of AMPK in HEK293 cells. However, if after treatment, the cell media 
containing H2O2 is removed and replaced with fresh media without AMPK activators, 
AMPK activity decreases from around 3.5 – 5 fold of basal levels to around 1.2 –1.5 
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fold within one hour. In view of this, an experiment was performed where calyculin A 
was applied to the replacement media at concentrations of 10nM and 20nM after 
activation with H2O2, to see if this could prevent the decrease in AMPK activity to a 
significant extent. The cells were lysed after 60 minutes and AMPK activity 
determined. From Figure 3.25, it can be seen that when calyculin A was not 
supplemented, AMPK activity decreased to around 50% of the H2O2 activated state 60 
minutes after media replacement. However at both 10 and 20nM, calyculin A caused 
a significant, albeit non-complete protection of AMPK activation of around 80% of 
the H2O2 activated state. These results therefore would suggest that the major AMPK 
phosphatase(s) is one or more members the PPP phosphatase family.  
 
In an effort to reproduce above results in HEK293 cells in a more physiological cell 
type, calyculin A was used to treat primary mouse hepatocytes for one hour at 
concentrations of 10nM, and 20nM to see if phosphatase inhibition has any effect on 
AMPK activity in a primary mouse cells. In order to demonstrate that calyculin A is 
having the intended action, treated hepatocytes lysates were subjected to western blot 
analysis probing for p-ACC, as Figure 3.26 shows Calyculin A treatment at 10nM 
and 20 nM causes significant increased p-ACC levels. 
 
As shown in Figure 3.27, Calyculin A treatment at 10 nM caused a ~50% elevation in 
AMPK activity and at 20 nM a ~55% elevation was seen. These results are similar to 
those obtained for HEK293 cells, and provides further evidence for the AMPK 
phosphatase(s) being one or more members of the PPP family. With the concentration 
used indicating PP1 involvement. Nucleotide extraction was also done for these cells. 
As with HEK293 cells, treatment with Calyculin A did not lead to any significant 
decrease in ATP:ADP ratios (Figure 3.28).  
104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 Inhibition of the ACC phosphatase using calyculin A 
in HEK293 cells 
HEK 293 cells were either mock treated or treated with calyculin A at 10 nM or 20 
nM for 30 minutes, after which cells were lysed. Cellular lysates were subjected to 
western blot analysis for p-ACC (pS-79) and actin. The relative level of signal 
were quantitated using the Licor Odyssey software against Actin. Data shown 
represent averages and standard errors (SEM) from 3 independent experiments.  
 
* Indicates a significant increase in activity with calyculin A relative to control (0 
nM) as judged by one way ANOVA (P<0.05). 
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Figure 3.23 Calyculin A treatment activates AMPK α1 and α2 isoforms in 
HEK293 cells 
HEK293 cells in serum free media were treated with calyculin A for 30 minutes at the 
indicated concentrations and cells lysed.  Antibodies targeting AMPK α1 or α2 subunits 
were used to perform immunoprecipitation reaction and activity determined.  
* Indicates a significant increase in activity with calyculin A relative to control (0 nM) as 
judged by using an one way ANOVA (P<0.05). Data shown represent averages and 
standard errors (SEM) from 3 independent experiments. 
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Figure 3.24 Treatment with calyculin A does not alter the 
ATP:ADP ratios in HEK293 cells 
Nucleotides were extracted from HEK293 cells which were mock treated, treated 
with water soluble calyculin A at: 10 nM, 20 nM, for 30 minutes or treated with 
DNP at 0.5 mM for 15 minutes. The cell were lysed and adenine nucleotides levels 
determined and ATP:ADP ratios calculated. Data shown represent averages and 
standard errors (SEM) from 3 independent experiments. 
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Figure 3.25 Protection of dephosphorylation of AMPK in HEK293 
cells after H2O2 treatment 
HEK293 cells in serum free media was treated with H2O2 (0.5 mM) for 15 minutes. 
After treatment, cells were either lysed or H2O2 containing media was replaced with 
serum free media supplemented with calyculin A and incubated for 60 minutes at 37 
ºC and then lysed. AMPK activity determined. Results are shown as percentage 
AMPK activity relative to H2O2 treated cells which has not undergone further 
incubation (Control).  
* Indicates a significant difference in activity with camples treated with calyculin A 
compared to 0 nm calyculin treatment as judged by an one way ANOVA (P<0.05). 
Data shown represent averages and standard errors (SEM) from 3 independent 
experiments.  
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Figure 3.26 Inhibition of the ACC phosphatases using calyculin A in 
mouse primary hepatocytes 
Mouse primary hepatocytes were either left untreated or treated with water soluble 
calyculin A at 10 nM and 20 nM for 30 minutes, after which cells were lysed. Proteins 
were resolved using SDS-PAGE and subjected to western blot analysis for pACC (pS-
79) and actin. The relative level of signal was quantitated using the Licor Odyssey 
software against tubulin.  
* Indicates a significant increase in activity with calyculin A relative to control (0 nM) 
as judged by one way ANOVA (P<0.05). Data shown represent averages and standard 
errors (SEM) from 3 independent experiments.  
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Figure 3.27 Calyculin A treatment activates both AMPK α1 and α2 
isoforms in mouse primary hepatocytes 
Primary mouse hepatocytes in serum free media were treated with calyculin A for 30 
min at the indicated concentrations and cells lysed.  Antibodies targeting either AMPK 
α1 and α2 subunits were used to perform immunoprecipitation reaction and activity 
determined.  
* Indicates a significant increase in activity with calyculin A relative to control (0 nM) 
as judged by one way ANOVA (P<0.05). Data shown represent averages and standard 
errors (SEM) from 3 independent experiments. 
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Figure 3.28 Treatment with calyculin A does not alter the ATP:ADP 
ratios in mouse primary hepatocytes 
Nucleotides were extracted from mouse primary hepatocytes which were mock treated 
or treated with calyculin A at: 10 nM, 20 nM, for 30 minutes or treated with DNP at 
0.5 mM for 15 minutes. The cell were lysed and adenine nucleotides levels determined 
and ATP:ADP ratios calculated. Data shown represent averages and standard errors 
(SEM) from 3 independent experiments. 
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3.2.10 Knockdown of PPP isoforms in HEK293 cells and mouse 
hepatocytes 
In view of the results from calyculin A treatments, the knockdown of PPP isoforms 
were conducted. As most of these phosphatases exist as multimeric complexes, it was 
decided to knockdown the catalytic subunits of PPP isoforms which should provide a 
rate limiting factor of phosphatase activity.  
 
There are two different catalytic subunit isoforms for PP2A, PP2Aα and PP2Aβ, for 
PP1 there are 3 catalytic subunits PP1α, β, and γ. In addition siRNA for PP5 and PP6 
were also obtained. The mRNA expression profiles for these subunits were 
determined in HEK293 cells using qRT-PCR which showed that all the above 
enzymes were expressed in this cell-line (data not shown). SiRNA against all three 
PP1 isoforms were transfected together into HEK293 cells to achieve knockdown of 
global PP1 protein (Figure 3.29A), both PP2A isoforms were also silenced together 
(Figure 3.29B). PP4 and PP5 were silenced individually as they only consisted of one 
isoform each (Figure 3.29C). 72 hours post-transfection, a decrease in the mRNA of 
PPP isoforms of between 64% (PP6) - 79% (PP1γ) was seen (Figure 3.29). 
Antibodies against PP2A and PP1α were also obtained to validate knockdown 
(Figure 3.30) which showed that the protein levels of both enzymes were 
significantly reduced (to 32%- 43% mRNA of remaining after knockdown).  
 
As shown in Figure 3.31, there were no significant changes in basal AMPK activity 
knockdown of any PPP isoforms with or without activation by phenformin. In view of 
this, an additional experiment was conducted, where the highest expressing isoform of 
PP1 and PP2A: PP1α and PP2Aβ were knocked down together and AMPK activity 
determined (Figures 3.29D and 3.31). This experiment did not produce any 
significant alterations in the level of AMPK activity or activation by phenformin. 
 
As calyculin A treatment caused a significant elevation in AMPK activity in mouse 
hepatocytes, it was decided to use siRNA to knockdown PPP family members in these 
cells to see if any changes in AMPK activity can be elicited. Primary mouse 
hepatocytes are a more physiological cell type compared to HEK293 cells, however it 
is much more difficult to achieve good transfection efficiencies in these primary cells.  
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Initially, the efficiency of siRNA transfection in hepatocytes was determined by using 
fluorescent tagged siRNA siGLO. Various transfection reagents (such as Ribojiuce 
and Lipofectamine) and other conditions were tried, but no SiGLO were observed 
inside the cells as imaged by fluorescent microscopy (data not shown).   
 
Having had no success with the SiGLO reagent, further attempts at siRNA 
transfection targeting the PP1 and PP2A catalytic subunit isoforms into hepatocytes at 
concentrations of up to 50nM were carried out. Cells were lysed after 24 h, 48 h and 
72 h, but analysis with qRT-PCR showed no significant changes in mRNA levels of 
PP1 and PP2A isoforms after siRNA treatment at any time point tested (data not 
shown). Based on these results, it seemed unlikely to be able to introduce siRNA into 
these cells and achieve any significant knockdown. It was thus decided not to pursue 
knockdown of phosphatases in primary hepatocytes any further.  
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Figure 3.29 Knockdown of PPP isoforms in HEK293 cells  
In independent experiments, HEK293 cells were transfected with either siControl or 
siRNA against various PPP isoforms. 72 h later cells were lysed and RNA extracted. 
Levels of mRNA for the PPP isoforms were determined using qRT-PCR.  Levels of 
knockdown were calculated by comparing mRNA expression in cells treated with PPP 
siRNA with those transfected with siControl. All graphs shown represent averages and 
standard errors (SEM) from 3 independent experiments.  A. Graph showing percentage 
mRNA remaining after PP1 knockdown. B. Graph showing percentage mRNA 
remaining after PP2A knockdown. C. Graph showing percentage mRNA remaining 
after PP4 or PP5 knockdown. D. Graph showing percentage mRNA remaining after 
multiplexed knockdown of PP1α and PP2Aβ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
C. D. 
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Figure 3.30 Validation of protein knockdown of PP1 and PP2A 
HEK293 cells were transfected with either siControl or siRNA against PP1 and PP2A 
isoforms (25 nM final concentration). Cells were lysed after 72 hours and lysates were 
subjected to western blot analysis with PP1 and PP2A antibodies (representative blots 
shown above). Tubulin was used as the loading control. The relative level of protein 
expression were quantitated using the Licor Odyssey software against tubulin. Data 
shown represent averages and standard errors (SEM) from 3 different experiments. 
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Figure 3.31 Knockdown of PPP isoforms does not affect the level of AMPK 
activation by phenformin 
HEK293 cells were transfected with either siControl or siRNA targeting the PPP isoforms 
indicated. Knockdown was allowed to proceed for 72 h. Cells were then  lysed or growth 
media were replaced with serum free media and treated with 5 mM phenformin for 30 
minutes and before cell lysis. AMPK was then activity determined. Results are shown as fold 
AMPK activity relative to siControl transfection. Data shown represent averages and 
standard errors (SEM) from 3 independent experiments.  
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3.3 Discussion 
The dephosphorylation of AMPK α at Thr-172 is of vital importance for the 
regulation of the enzyme, as phosphorylation of this residue is absolutely required for 
AMPK activity. Furthermore, as LKB1 has been determined to be constitutively 
active (Hawley et al., 2003; Woods et al., 2003a), this places further importance in the 
dephosphorylation step to regulate AMPK activity. All these factors make the 
identification of the AMPK phosphatase(s) of great importance to both the 
understanding of this signalling pathway and potentially modulating for AMPK 
activity for therapeutic purposes.   
 
While two upstream kinases of AMPK have been identified as LKB1 and CaMKKβ 
in 2003 and 2005 respectively, and much work has been done subsequently to 
elucidate the finer details of their regulation of AMPK activity (Hawley et al., 2003; 
Woods et al., 2005; Woods et al., 2003a), the phosphatase(s) which regulates the 
dephosphorylation step remains relatively under investigated.  At the beginning of this 
project, very little direct evidence was available as to the identity of the AMPK 
phosphatase. Several earlier studies has implicated AMPK phosphatase as belonging 
to the PPM/PP2C family, while further evidence gained through pharmacological 
inhibition of phosphatases also indicated a role for the PP2A family (Gimeno-Alcaniz 
and Sanz, 2003; Moore et al., 1991; Samari et al., 2005). Through the course of this 
study however the field has become much more contentious, with every class of 
protein phosphatases being suggested to regulate AMPK activity. The implications of 
these new results are discussed later in this section.  
 
Characterisation of AMPK activity and activation in a model cell-line 
It was important at the beginning of this study to identify a cell-line which fulfilled 
several criteria. First, it needs to be relatively well characterised with relatively rapid 
rate of division. It also needs to be easily transfectable with plasmid DNA and siRNA, 
enabling the expression and knockdown of specific candidate phosphatases. In 
addition this cell-line needs to expresses AMPK at relative high levels and the activity 
of endogenous AMPK should be able to be dynamically manipulated.   
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HEK293 was chosen cells as the model cell-line as it fulfils all the criteria laid out 
above. Previous studies have shown that both AMPK upstream kinases, LKB1 and 
CaMKKβ are expressed in HEK293 cells and AMPK activity was readily detectable 
(Sanders et al., 2007a). Furthermore, HEK293 cells are easily transfectable and 
generally expresses exogenous plasmids at high levels. Having said this however, 
there are many clones of HEK293 cells in circulation and therefore it was still 
important to characterise the particular batch of cells used in this study.  
 
Initial characterisation of HEK293 cells involved determining the level of overall 
AMPK activity and the contribution by either AMPK α1 or α2 containing complexes 
respectively. In these cells, AMPK α1 containing complexes have higher specific 
activities than α2 containing complexes (Figure 3.1). However, as different antibodies 
are used in the immunoprecipitation of these complexes, drawing a direct comparison 
would be difficult. This experiment does however indicate that both AMPK α1 and α2 
are expressed and active in these cells.  
 
Using antibodies specific for the upstream kinases, both CaMKKβ and LKB1 was 
shown as being expressed and active in HEK293 cells, and that LKB1 activity was 
over 2 fold higher than that of CaMKKβ. However, again, as different antibodies 
were used for immunoprecipitation of the two upstream kinases, direct comparison 
would be difficult. Additionally, as CaMKKβ has not been activated in these samples 
while LKB1 is constitutively active, there is a possibility that when CaMKKβ is 
activated it may well stimulate AMPK to a greater extent than LKB1 (Collins et al., 
2000; Sapkota et al., 2002).   
 
As in changes in AMPK activity was the main readout in the experiments to identify 
the AMPK phosphatase, it was important to show that AMPK activity can be 
dynamically modulated in these cells. As HEK293 is a widely used cell-line, previous 
publications have shown that many AMPK activators are effective in these cells 
(Sanders et al., 2007a; Voss et al., 2011). In this study, indirect activators such as 
metformin, Phenformin were used, as well as the AICAR (which is taken up into cells 
and phosphorylated to form ZMP, an AMP analogue). In addition, compounds which 
cause a reduction in intracellular ATP levels were used (i.e. H2O2 and DNP), and 
finally the direct allosteric activator of AMPK, A769662 was also included. All 
118 
 
compounds used, with the exception of metformin and AICAR caused significant 
activation of AMPK (Figure 3.3). The lack of activation by metformin corroborates 
previous results by other members of our lab (data not published) and the inability of 
AICAR to activate AMPK in HEK293 has been reported previously (Marsin et al., 
2000). While phenformin is cell permeable, HEK293 cells lack the OCT transporters 
necessary for the transport of metformin across the cell membrane, and ZMP has been 
reported not to accumulate in HEK293 cells (Kimura et al., 2005; Wang et al., 2002b).  
 
Phosphatase inhibition in HEK293 cells by okadaic acid  
To elucidate the identity of the AMPK phosphatase, it was decided to use protein 
phosphatase inhibitors which specifically target particular classes of phosphatases, 
narrowing down on the specific family that this enzyme belongs to, i.e. the PPP or 
PPM families. Although there are a number of PPP family inhibitors which are widely 
used in research, there are no PPM inhibitors currently available, thus the PPP 
inhibitor okadaic acid was used in this experiment. Okadaic acid is a marine toxin 
isolated from Halichondria okadai, and is a potent inhibitor or almost all PPP family 
phosphatases (Swingle et al., 2007). An useful feature of okadaic acid is that it has 
different affinities for different PPP phosphatases. The IC50 values for PP2A and PP4 
are around 0.1 nM, the value for PP5 is higher at approximately 3.5 nM, for PP1 on 
the other hand the IC50 is around 15 – 50 nM. Thus, by treating cells with varying 
concentrations of Okadaic acid, it maybe possible to gain insights into the subclass of 
PPP phosphatases the AMPK phosphatase(s) belongs to.  
 
Although there was some consensus in the field at the beginning of this study that one 
or more PPM members was the mostly like candidate for the AMPK phosphatase, 
data derived from phosphatase inhibitors have shown contradictory results. As an 
example, in isolated rat hepatocytes, while some sources report okadaic acid as having 
no effect on AMPK activity, others observe a significant increase Thr-172 
phosphorylation (Moore et al., 1991; Samari et al., 2005). Due to these discrepancies 
in the literature, we decided to proceed from first principles in studies.  
 
Although the IC50 values of for PP2A, PP4 and PP5 are in the low nano-molar range, 
a higher concentration needs to be applied during cell treatment as the, intracellular 
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concentrations of compounds are often lower than the concentration applied to growth 
media. Additionally the presence of organic anion pumps (e.g. the multidrug efflux 
pump) cause a further decrease in intracellular concentration (Swingle et al., 2007). 
Therefore, we decided to treat HEK293 cells with okadaic acid concentrations of 10 
nM, 50 nM and 500 nM. The 10 and 50 nM concentrations inhibit of PP2A, PP4 and 
PP5 (but not PP1) while the 500 nM concentration should provide inhibition of most 
PPP phosphatases.  
 
To validate that okadaic acid is entering the cells and inhibiting its intended targets, 
phosphorylation of the  known PP2A substrate of Acetyl-CoA carboxylase was used 
as the positive control (Moore et al., 1991). At the higher concentrations of 50 nM and 
500 nM okadaic acid caused a significant increase in ACC Ser-79 phosphorylation 
indicating okadaic acid is indeed functional. However, at 10 nM, okadaic did not 
seem to have an significant effect on phospho-ACC levels. This result would support 
the previous statements that a higher treatment concentration than published IC50 
values are needed to inhibit intracellular phosphatases (Figure 3.4).     
 
AMPK activity was determined in lysates from okadaic acid treated HEK293 cells. 
Although no significant increases in AMPK activity was observed, there was a small 
increase in AMPK activity at 500 nM okadaic acid seen. However, this increase is 
unlikely to represent stimulation of AMPK due to phosphatase inhibition, as, due to 
the constitutively active nature of LKB1, any significant inhibition of AMPK 
phosphatase(s) would predictably lead to a much greater increase in AMPK activity. 
Secondly the small increase in AMPK activity correlated with a similarly small 
decrease in ATP:ADP ratios at the higher concentration of okadaic acid. Although 
neither of the changes were statistically significant, the decrease in ATP:ADP ratio 
levels could result in AMPK activation. Taken together, these results indicate that the 
AMPK phosphatase is okadaic acid insensitive, indicating that it is a member of the 
PPM family. 
 
It should be noted here that overall, the development of phosphatase inhibitors lags 
behind that of kinase inhibitors. Of pressing need is for the development of a potent 
and specific cell permeable PPM inhibitor, of which none currently exist.  Research 
has been conducted to find an inhibitor of PPM phosphatases, although this is still at 
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the validation stage, it could provide new tools for identifying phosphatases involved 
in AMPK regulation in the future (Aburai et al., 2010; Chuman et al., 2008; Rogers et 
al., 2006).   
 
Manipulation of PPM phosphatase expression  
Due to the lack of potent PPM inhibitors/activators, it was decided to alter the level of 
expression of specific PPM phosphatases and determine if there are any changes in 
AMPK activity as a result. This method has the advantage of assessing the function of 
each of the 17 PPM phosphatases individually.  
 
Using q-RT-PCR, the expression of 16 out of the 17 known PPM phosphatases (Lu 
and Wang, 2008) was detected in HEK293 cells. The expression levels varied, but all 
16 phosphatases were expressed in the same order of magnitude allowing the use of a 
single housekeeping gene. While this study was on-going, a study by Voss et al., 
analysed the activities of individual PPM isoforms phosphatases in HEK293 cells 
using phosphorylated casin as a substrate (Voss et al., 2011). Although the researchers 
did not measure the activities of all 17 PPM isoforms (e.g. PPM1K and PPM1M 
activities were not measured), the results from this study broadly matched the 
expression data generated in the current study. Voss et al, also reported PPM1G, 
PPM1B and PDP1 as having the highest activities again phosphorylated casein.  
 
The next step in the study was to knockdown the expression of individual PPM 
phosphatases using siRNA transfections. Conditions for knockdown were optimised 
as shown in chapter 3.2.4. Due to time and resource constraints, knockdown of 
PPM1A was used as a proxy to optimise the siRNA concentration and time of 
knockdown for the other 15 PPM phosphatases. PPM1A was chosen as its mRNA 
expression levels is in the middle range of all 16 phosphatases (Figure 3.10) This 
method has potential drawbacks as the mRNA message levels and the protein half 
lives of the PPMs could be different, meaning the optimum siRNA concentration for 
one PPM may not result in the greatest levels of knockdown for others. Nevertheless, 
significant knockdown of mRNA expression levels for all 16 PPM isoforms was 
achieved, and protein knockdown verified using a number of specific PPM antibodies.   
In this experiment, no significant changes in AMPK activity was detected in any of 
the siRNA treated samples, whether in the individual knockdown of of PPM isoforms 
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or in the multiplex knockdown of PPM1F, PPM1H and PPM1L (Figures 3.14 and 
3.15).  
 
There have been previous reports showing differential regulation of the α1 and α2 
subunits of AMPK, for example AMPK α2 show greater activation with AMP 
compared to α1 and the two isoforms tend to locate to different sub-cellular 
compartments (Salt et al., 1998). In addition, it has been reported that PP2A is 
involved in regulating the interaction between AMPK α2 and γ1 (Gimeno-Alcaniz and 
Sanz, 2003). With this in mind, AMPK was immunoprecipitated using AMPK α1 and 
α2 specific antibodies, in order to determine isoform specific activities. However, the 
kinase assays on these samples did not reveal any significant changes compared to 
overall AMPK activity (Figure 3.16).  
 
It should be noted here that although small increases in AMPK activity of 10% - 20% 
were observed in some PPM knockdown samples, they did not reach statistical 
significance (Figures 3.14, 3.15 and 3.16). Furthermore, due to the observed ability 
of pharmacological agents to activate AMPK more than 5 fold in HEK293 cells, and 
considering the constitutively active nature of LKB1, it was expected that significant 
inhibition of AMPK phosphatase(s) expression should bring about an elevation in 
AMPK activity much greater than those seen.  
 
It is possible that under conditions where AMPK activity is not stimulated, very little 
phosphatase activity is required to keep AMPK activity/phosphorylation at a basal 
level, and therefore the levels of siRNA silencing achieved in these experiments does 
not perturb the system to a sufficient extent to bring about a change in AMPK activity. 
It is also possible that during under conditions of AMPK activation, a greater quantity 
of AMPK phosphatase is recruited (perhaps due to a greater availability of its 
phosphorylated target), thereby leading to an increase in phosphatase activity under 
these circumstances., When phenformin was used to treat cells either with or without 
pre-treatment with PPM siRNAs, there was no significant differences in the level of 
activation of AMPK achieved (Figure 3.17).  
 
Although much time and resources were devoted to the experiments highlighted 
above, it was not possible to assign the identity of the AMPK phosphatase. However 
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this does not prove that PPM has no role in the regulation of AMPK activity. There 
are several features inherent to studies that utilise siRNA knockdown that makes it 
somewhat difficult to draw this conclusion. Firstly, due to resource constraints and 
lack of availability, it was only possible to procure antibodies against four of the 16 
PPM isoforms subjected to knockdown. Therefore, for the other 12 PPM isoforms, 
although good evidence mRNA silencing was obtained, it was not possible to verify 
the levels of protein knockdown.  It is possible that due to differing half-lives of the 
phosphatase proteins, there could be substantially more protein remaining for some 
phosphatass after the knockdown period than the mRNA data would suggest. 
Furthermore, although treatment with siRNA was able to reduce mRNA/protein levels 
by up to 80%, there was nevertheless some protein expression remaining. It is 
possible that the remaining phosphatase activities are able to maintain AMPK activity 
at basal levels. There is also the possibility that AMPK is in fact regulated by a 
number of protein phosphatases, which creates a level of redundancy within the 
system. Although, siRNA silencing allows for a limited degree of multiplexing of 
knockdown targets within the same cells, it is extremely difficult to decide which 
combinations of phosphatases to multiplex. It is also possible that there are as yet 
unidentified okadaic acid insensitive phosphatases which may dephosphorylate 
AMPK. Additionally, although the differential regulation of AMPK α1 and α2 
isoforms were investigated in this study, there is a possibility that different 
combinations of α, β and γ subunits are differentially regulated by different 
phosphatases. Again, the scope of this study does not allow this issue to be addressed.  
 
While the current study was in progress, a study by Voss et al. suggested PPM1E as a 
AMPK phosphatase. This study was also conducted using HEK293 cells, and used 
shRNA mediated stable knockdown to deplete phosphatase expression (Voss et al., 
2011). With PPM1E depletion, a significant elevation in AMPK phospho-Thr-172 
levels was detected, which was not present when other PPM isoforms were knocked 
down. PPM1E depletion was also able to further increase phenformin induced AMPK 
activation in HEK293 cells. These findings do not match our observations. In our 
experiments, siRNA mediated knockdown of PPM1E did not cause any significant 
changes in AMPK activity. We revisited PPM1E and conducted a new knockdown 
experiment, achieving around 64% reduction in mRNA levels. Again no significant 
change in AMPK activity was seen (included as part of the final results) (Figure 3.14).  
123 
 
 
Professor Tricia Cohen (University of Dundee) kindly supplied us with the antibodies 
targeting PPM1E and PPM1F used in the above study so that we would be able to 
investigate the level of protein knockdown. However, I was unable to optimise 
conditions for the use of these antibodies as the blots were not of sufficient quality for 
phosphatase expression levels to be interpreted.  
 
One possible reason for the discrepancy between the two studies Voss et al. used 
shRNA mediated stable knockdown of PPM isoforms which is able to maintain 
silencing of phosphatases over longer time periods. Some proteins may have relative 
long half-lives, therefore the treatment period of 72 hours in my experiments may not 
be sufficient to cause a significant reduction in the protein level of some phosphatases.   
 
Overexpression of PPM isoforms in HEK293 cells 
In other published studies which attempted to identify the AMPK phosphatase(s), 
experiments where phosphatases are over-expressed are generally not performed. One 
reason for this maybe that as PPP type phosphatases generally form multimeric 
complexes, there are simply too many possible combinations of catalytic and 
regulatory subunits for over-expression to be a feasible prospect. Over-expressing 
only the catalytic subunit for example may cause the other subunits to become rate 
limiting. In the case of PPM phosphatases, as they generally lack regulatory subunits, 
this would not be an issue, although over-expression could cause unspecific off 
targets effects.  
 
However, as these assumptions have never tested, PPM isoforms were over-expressed 
in HEK293 cells. Four PPM phosphatases were over-expressed and verified in vitro to 
be active, but this did not cause any changes to basal AMPK activity or activation by 
phenformin (Figure 3.20). This data would suggest that the four phosphatases 
investigated in this study do not dephosphorylate AMPK in HEK293 cells. Although 
no positive data emerged from this experiment, it was nevertheless possible to show 
that despite the lack of regulatory subunits and their ability to dephosphorylate AMPK 
in vitro, PPMs activity seem to be tightly regulated within the cell, and unspecific 
dephosphorylation does not occur when phosphatases are over expressed. This result 
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may give researchers more confidence to conduct PPM over-expression experiments 
in the future.  
 
Revisiting inhibitor studies 
The results from the knockdown and the over-expression of PPM isoforms in 
HEK293 cells showed that it is possible that the AMPK phosphatase belongs to the 
PPP family. Therefore, it was decided to revisit the phosphatase inhibitor studies 
while altering the experimental setup. Initially, it was decided to apply different 
concentrations of okadaic acid to HEK293 cell suspensions after cell lysis, (lacking 
the usual phosphatase inhibitors usually present in cell-lysis buffer used) to see if this 
can protect AMPK from dephosphorylation. This experimental setup was chosen as in 
cell lysates, the limited cell permeability of okadaic acid should not be a problem, 
allowing it to inhibit phosphatases at concentrations close to its IC50 values (Swingle 
et al., 2007).  
 
The results generated from this experiment seem to suggest that PP1 inhibition is 
essential for the protection of AMPK from dephosphorylation. At 5 nM, where most 
PP2A activity should be inhibited (IC50 of okadaic acid for PP2A is 0.1 – 0.3 nm), no 
protection from dephosphorylation was seen. Whereas at concentrations higher than 
40 nM, AMPK phosphorylation/activity became protected (IC50 of okadaic acid for 
PP1 is 15 – 50 nm) (Figure 3.21). Also, it would seem that inhibition of PPM type 
phosphatases are not required to protect AMPK activity, as okadaic not effective 
against this class of phosphatase. The main drawback of this experiment is its 
somewhat non-physiological nature. As in cytosolic suspensions, the normal 
regulatory mechanisms that act on phosphatases would be disrupted and the normal 
cellular compartmentalisation that may separate enzymes from unintended targets 
would be removed, thereby allowing the phosphatases enzymes to act non-specifically. 
Thus, inhibiting these enzymes may protect AMPK from dephosphorylation merely 
by virtue of inhibiting most of the phosphatase activity in cells. Nevertheless, these 
results do give additional hints as to how to proceed in future studies.  
 
The results from the above experiment coupled with published studies suggesting that 
PP1 and PP2A being involved AMPK regulation prompted us to revisit the inhibitor 
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studies and use the potent PPP inhibitor calyculin A to try to elicit a change in AMPK 
activity (Garcia-Haro et al., 2010; Magnaudeix et al., 2012; Wang et al., 2010).  
 
Calyculin A was able to cause a much greater increase in ACC pSer-79 levels 
compared to okadaic acid treatment in both HEK293 cells and primary mouse 
hepatocytes (Figures 3.22 and 3.26).  These results suggest that calyculin A inhibited 
phosphatases to a greater extent than okadiac acid. In contrast to okadaic acid 
treatment, calyculin A caused a significant increase in AMPK activity of around 50% 
in both HEK293 and mouse hepatocytes cells (Figures 3.23 and 3.27). This is likely 
to be due to the more potent inhibition of phosphatase activity by this compound. In 
addition, incubation with calyculin A was able to protect against AMPK 
dephosphorylation seen in recovering cells after H2O2 treatment (Figure 3.25).  
Together, results from this section would indicate a role for calyculin A sensitive PPP 
phosphatases in the regulation of AMPK dephosphorylation. Taking into account the 
results from okadaic acid treatments, and the differences in their potencies against 
PP1 and PP2A, it makes PP1 the more likely candidate for the AMPK phosphatase 
compared to PP2A. Additionally, it would appear that perhaps a small amount of 
phosphatases are capable of maintaining AMPK activity at basal levels, and inhibition 
of a significant proportion of the phosphatase activity (to an extent that okadaic acid 
was unable to achieve in HEK293 cells) is required to observe the consequent 
activation of AMPK.  
 
Knockdown of PPP isoforms  
Next, it was decided to carry out siRNA knockdown of PP1 and PP2A in HEK293 
cells and determine the effect on AMPK activity. Unlike the phosphatases of the PPM 
family, enzymes of PP1 and PP2A classes are holoenzymes made up of both catalytic, 
regulatory and scaffolding subunits.  As there are many more regulatory and 
scaffolding subunits compared to catalytic subunits, it was decided to direct the 
siRNA knockdown towards the catalytic subunits. Substantial knockdown of the 
catalytic subunits should limit the rate of the dephosphorylation of its targets 
regardless of the level of regulatory subunit expression in the cell.  The knockdown of 
the catalytic subunits of PPP isoforms, PP1, PP2A, PP5 and PP6 were performed. 
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siRNA silencing did not replicate the data gained from inhibitor studies (Figures 
3.31).  
 
While this study was in progress, a study implicated the PP1 catalytic subunit, along 
with its regulatory unit R6 to play important roles in the glucose induced 
dephosphorylation of AMPK in mouse pancreatic beta cells (MIN6) (Garcia-Haro et 
al., 2010). Knockdown of the α and β catalytic subunits of PP1 together or the R6 
regulatory subunit was shown to prevent the decrease in AMPK phosphorylation 
when MIN6 cells were transferred from low to high glucose media. This effect did not 
depend on the activation of the upstream kinase LKB1. Additionally, knockdown of 
PPM1A (in the same study) had no effect. Furthermore, the R6 subunit was shown to 
interact physically with the AMPK βsubunit through co-immunoprecipitation and 
yeast-two hybrid experiments. Also, PP1 was found to be the most efficient at 
dephosphorylating pre-activated, bacterially expressed AMPK. MIN6 cells were 
obtained (from James Leiper, CSC MRC) and I was able to verify the co-
immunoprecipitation of AMPK and R6 in these cells (data not shown). Additionally, 
my initial data suggested that calyculin A was able to significantly increase basal 
AMPK activity and inhibit the glucose induced decrease in AMPK activity. It should 
be noted however, that only a 25-35% drop in AMPK activity was seen after shifting 
between low to high glucose media (data not shown).  These results serve to back up 
the data shown by Garcia-Haro et al, however as the data was already in press, we did 
not continue with the validation process in MIN6 cells. However I was unable to 
replicate these results of siRNA knockdown fully in HEK293 cells. Knockdown of 
PP1 catalytic subunits were unable to prevent the decrease in AMPK activity caused 
by shifting the cells from low to high glucose media. There are several possibilities 
explanations for the discrepancy between my results that those of Garcia-Haro et, al. 
Firstly, the phosphatase that dephosphorylates AMPK may be different in HEK293 
and MIN6 cell. Also there maybe a higher reserve of phosphatase activity in HEK293 
cells, meaning the level of phosphatase knockdown achieved may not be sufficient to 
alter AMPK activity. Furthermore, MIN6 is a pancreatic beta cell-line. The AMPK 
signalling pathway in these cells maybe more sensitive to changes in glucose levels, 
as these cells are adapted in vivo to sense and respond to changes in extra-cellular 
glucose levels. This property may explain why HEK293 displayed a smaller drop in 
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AMPK activity/phosphorylation when shifted from low glucose to high glucose media. 
This sensitivity of the AMPK pathway to glucose levels may also mean that the 
system can be more easily perturbed by altering the expression of phosphatases. 
Additionally, it should be noted that the regulation of AMPK activity by PP1 maybe 
specific to the conditions of glucose deprivation, and there are other phosphatases in 
the maintenance of AMPK activity under basal conditions.  
 
In addition to PP1, during my study PP2A was also proposed as negatively regulating 
AMPK activity. Both okadaic acid treatment (at concentrations which only inhibited 
PP2A) and silencing of the PP2A catalytic subunit was shown to be able to reverse 
heat shock induced AMPK Thr-172 dephosphorylation in HepG2 cells (Wang et al., 
2010). More recently, a similar study showed both okadaic acid and PP2Ac silencing 
resulted in increased Thr-172 phosphorylation in cultured cortical neurons 
(Magnaudeix et al., 2012). It was shown that in C2C12 and primary muscle cells, 
chronic calcium exposure resulting from caffeine treatment leads to decreased AMPK 
activities, which was reversed with the application of the phosphatase inhibitor 
Calyculin A or PP2Ac siRNA (Park et al., 2013).  
 
Taken together recent publications discussed in this section seem to suggests that the 
regulation of AMPK dephosphorylation is cell–type specific, with PPM, PP1 and 
PP2A all identified as AMPK phosphatases in different cell-lines. In addition, it is 
possible that the regulation of AMPK dephosphorylation is condition specific, with 
different  phosphatase(s) responsible for maintaining basal AMPK activities (e.g. 
PPM), and other phosphatases (e.g. PP1/PP2A) becoming more important in 
conditions of cell-stress.  
 
In the case of mouse hepatocytes, knockdown experiments were attempted in these 
cells as they are more physiological compared to HEK293 cells, with alterations in 
AMPK having been shown to play important roles in vivo.  However, I was unable to 
successfully gain knockdown of any phosphatases in these cells using siRNA. Other 
members of our lab have also reported technical problems with siRNA transfection 
into hepatocytes. However, recently member of our group have been able to gain 
significant knockdown of cytosolic proteins in primary hepatocytes using 
hydrophobically-tagged siRNA oligos which do not require transfection reagents to 
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enter cells (Dr. Alicia Garcia, private communication). In future experiments, 
knockdown of phosphatases could be achieved using this method.  
 
Conclusions 
The result obtained in this study, suggest that the AMPK phosphatase in HEK293 
cells and mouse hepatocytes lie within the phospho-protein phosphatase family, and 
in this family PP1 is the more likely candidate than PP2A. 
 
While I did narrow down the enzyme class the AMPK phosphatase belongs to, we 
were unable to pinpoint the specific phosphatase(s) which mediate AMPK 
dephosphorylation. The potential reasons for this have been discussed at length in this 
section. The experimental results from this study and current literature both suggest 
that instead of a ‘master’ phosphatase, the regulation of AMPK dephosphorylation is 
mediated by multiple phosphatases. Indeed, one possibility is that the regulation of 
AMPK dephosphorylation is tissue specific, with distinct groups of phosphatases 
responsible for regulating AMPK activity in different cell-types. AMPK may also be 
dephosphorylated by distinct phosphatases under different conditions of cellular stress. 
Overall, the picture that is emerging for the regulation of AMPK by upstream 
phosphatases is rather more complicated than our current understanding of the 
upstream kinases. This study has shed light on some of the regulatory mechanisms at 
work in this important regulatory step, and is a good platform upon which future 
studies can be conducted.   
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4 Identification of AMPK interaction 
proteins 
4.1 Introduction 
After the experiments described in chapter 3 failed to pinpoint the specific AMPK 
phosphatase(s), a decision was made to change the direction towards identifying new 
AMPK interaction proteins, with a view of identifying AMPK phosphatase(s). The 
majority of previous AMPK binding proteins have been identified using co-
immunoprecipitation reactions coupled with western blotting (Garcia-Haro et al., 
2010; Kim et al., 2011b). However, this method requires the investigator to have prior 
knowledge about the identity of the AMPK interacting protein. Another method used 
by investigators to find novel AMPK interactors is the yeast two hybrid technique (Fu 
and Gao, 2009). However, this method has been shown to generate many false 
positive results (Deane et al., 2002).  In addition, proteins which normally interact in 
mammalian cells may not do so in yeast, and the fusion proteins may actually block 
potential binding sites.  
 
In this section, an approach using immunoprecipitation coupled with mass 
spectrometry was adopted for the identification of AMPK interacting proteins. This 
method does not require any prior knowledge as to the identity of the AMPK 
interacting protein and allows the simultaneous identification of multiple candidates.  
 
4.2 Results  
4.2.1 Over-expression of AMPK subunits in HEK293 and COS7 cells 
To maximise the chance of detecting interacting proteins and to capture transient  
interactions, it was initially decided to chemically cross-link overexpressed AMPK 
(α1β1γ1) in HEK293 and COS7 cells, and use mass spectrometry techniques to identify 
AMPK interacting proteins. Initially, Pilot experiments to optimise the expression of 
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the AMPK complex in these cells and verify that the protein is active as expressed 
were carried out.  
 
Mammalian expression plasmids (in pCDNA3.1) encoding for each of the α1, β1, and 
γ1 subunits of AMPK were already available in the group. These plasmids were 
transfected into either HEK293 or COS7 cells and AMPK expression determined by 
western blotting with AMPK subunit specific antibodies. The pan-β subunit antibody 
was used to immunopreciptate AMPK from cell lysates to determine the activity of 
the overexpressed AMPK complex.  
 
As can be seen in Figure 4.1, significant over-expression of AMPK α1, β1, and γ1 was 
achieved in HEK293 and COS7 cells. Quantitation of the western blots revealed that 
the level of over-expression achieved for the three subunits was very similar in both 
cell types (data not shown). AMPK activity in immune complexes showed an 
approximately 8-fold increase in HEK293 cells and a ~12 fold increase in COS7 cells 
relative to untransfected cells (Figure 4.2). 
 
4.2.2 Chemical Cross-linking of proteins in HEK293 and COS7 cells  
After confirming overexpression of AMPK in both HEK293 and COS7 cell types, 
experiments aimed at chemically cross-linking proteins in these cells were performed 
in order to provide a snapshot of protein-protein interactions.  
 
It was decided to use paraformaldehyde as the main crosslinking reagent. 
Paraformaldehyde acts primarily by crosslinking lysine residues of adjacent proteins, 
and thereby serves to preserve transient protein interactions which may otherwise be 
lost during co-immunoprecipitation. Another advantage of paraformaldehyde as a 
chemical cross-linker is its short arm length of around 2.3–2.7 Å, and thus would be 
expected to only cross-link proteins that are in close proximity (Sutherland et al., 
2008). Secondly, it also acts to inactivate most enzymes immediately upon addition to 
cells there by effectively ‘freezing’ the protein interactions in place. 
 
Proof of principle experiments were conducted to confirm the ability of 
paraformaldehyde to cross-link proteins in these cells and the optimum time period of 
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cross-linking. For this experiment, HEK293 and COS7 cells were transfected with 
AMPK α1β1γ1 with expression proceeding for 48 hours, 1% paraformaldehyde was 
added to cells to cross-link proteins for either 5 or 15 minutes. After the reaction was 
terminated using glycine solution and the cells lysed.  
 
To verify whether this method resulted in the crosslinking of AMPK, cell lysates were 
subjected to western-blot analysis and probed with the AMPK pan-β-subunit antibody. 
As seen in Figure 4.3, paraformaldehyde treatment of both cell-lines resulted in the 
appearance of higher molecular mass bands of AMPK β with a concurrent decrease in 
the intensity of the untreated band. This indicates that these subunits are being 
crosslinked to adjacent proteins, thereby giving rise to these higher molecular mass 
bands. From the above results, it was decided to use both the 5 and 15 minutes time 
points for cross-linking.  
 
4.2.3 Immunoprecipitation of AMPK and mass spectrometry analysis 
of cross-linked proteins 
In order to prepare the sample for mass spectrometric analysis, both HEK293 and 
COS7 cells over-expressing AMPK α1β1γ1 were subjected to paraformaldehyde 
treatment for 5 and 15 minutes and cells lysed. AMPK was immunoprecipitated from 
cell lysates using the pan-β subunit antibody. To verify the ability of this antibody to 
immunoprecipitate the cross-linked form of AMPK, the immune complex was 
subjected to western blot analysis probing for AMPK α1. As can be seen from Figure 
4.4, the β subunit antibody was able to co-immunoprecipitate not only native α1 
subunit but also the cross-linked α1 in HEK293 cells. Similar results were obtained for 
COS7 cells lysates, data not shown.  
 
Before the proteins in the immune complexes can be identified using mass 
spectrometry, it was necessary to reverse the cross-linking. This was achieved by 
heating the immune complexes in 2X SDS-sample buffer overnight at 60 ºC. To 
verify that this process resulted in efficient reversal of the cross-linking, the reversed 
and non-reversed samples were subjected to western blot analysis. Figure 4.5 shows 
that the cross-linking of AMPK α1 can indeed be reversed to a significant extent 
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following this treatment. After this step, the immunoprecipitated AMPK and 
associated proteins were resolved using SDS-PAGE and sent for mass spectrometric 
analysis (MS) (CSC-Proteomics unit).  
 
All over-expressed AMPK subunits were detected in the immune complexes as well 
as the endogenous AMPK α2, β2 and γ2 subunits. The detection of these endogenous 
subunits provides an internal control which indicates the cross-linking and 
immunoprecipitation steps have worked as anticipated. A further 200–400 other 
proteins were detected in the various cross-linked samples, with the 5 min cross-
linking time giving more protein hits compared to the 15 min time point. Amongst 
these proteins, PP2A regulatory subunits A- and B- were present in both HEK293 
and COS7 cells subject to 5 min cross-linking. Furthermore in the 5 minute cross-
linked COS7 sample, PP2A- catalytic subunit, PP1-γ catalytic subunit, PP5 and 
PPM1G was detected.  
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Figure 4.1 Over-expression of AMPK α1β1γ1 in HEK293 and COS7 cells 
pCDNA3.1-HIS encoding for AMPK α1β1γ1 was transfected into (A.) HEK293 or (B.) 
COS7 cells using calcium phosphate transfection reagent, cells were lysed after 48 h 
expression. Soluble cell lysates were subjected to western blot analysis probing with 
antibodies targeting AMPK α1, and β and γ1 subunits. Duplicate lanes are shown for each 
condition. Representative images were captured and processed using the Licor infared 
system associated Odyssey software.   
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Figure 4.2 Over-expression of AMPK α1β1γ1 leads to increased AMPK 
activity in HEK293 and COS7 cells 
AMPK was immunoprecipitated using the pan-β-subunit antibody (from cells transfected 
with AMPK α1β1γ1 or un-transfected control) and AMPK activity determined.  Results are 
shown as fold AMPK activity relative to untransfected control experiment. Data shown 
represent averages and standard errors (SEM) from 3 independent experiments.  
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Figure 4.3 In-vivo cross-linking of proteins in COS7 and HEK293 cells  
In-vivo cross-linking of proteins was performed in COS7 and HEK293 cells overexpressing AMPK α1β1γ1 using 1% 
paraformaldehyde with cross-linking allowed to proceed for 5 or 15 minutes before being quenched by 1.25 M glycine. Cells 
were lysed and subject to western blot. Representative western blot of (A.) COS7 and (B.) HEK293 cell crude lysate probed 
with AMPK pan-β subunit antibodies. Cross-linked AMPK-β subunit protein are highlighted by brackets.  
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Figure 4.4 Immunoprecipitation of cross-linked AMPK using pan-β subunit 
antibodies  
Immunoprecipitation reactions were performed on cell lysates from HEK293 cells (uncross-
linked and 5 min cross-linked, duplicate lanes are shown for each condition.) using the AMPK 
pan-β subunit antibody. The immuno-pellet was subjected with western blot analysis with AMPK 
α1 antibodies. Representative images were captured and processed using the Licor infared system 
associated Odyssey software.   
 
Figure 4.5 Reversal of paraformaldehyde cross-linking 
Cell lysates from COS7 and HEK293 cells which were subjected to paraformaldehyde cross-
linking (5 min) were heated in 2X SDS sample buffer over night at 60 ºC. Lysates were then 
subjected to western blot analysis and probed with AMPK α1 antibodies. Representative images 
were captured and processed using the Licor infared system associated Odyssey software.   
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4.2.4 Stable isotope labelling by amino acids in cell culture and 
quantitative proteomics in HEK293 cells    
At this point in the study, it became apparent that without a quantitative readout, it 
was very difficult to gauge which of the candidate interactors identified by MS 
analysis are bona fide physiological AMPK binding proteins and which were non-
specific interactors. In order to obtain a quantitative readout for potential AMPK 
interactors and thereby validate specificity, it was decided to use a technique called 
stable isotope labelling by amino acids in cell culture (SILAC) coupled with 
quantitative proteomics.  SILAC is a method used to achieve incorporation of labels 
into proteins for identification and quantification using mass spectrometry. The labels 
to be incorporated are either ‘heavy’ or ‘normal’ versions of amino acids (e.g. L-
Lysine and L-Arginine), with the ‘heavy’ version containing substituted stable 
isotopic nuclei, while the ‘normal’ version contains nuclei found predominantly in 
nature (e.g. 
13
C labelled L-Lysine as the ‘heavy’ amino acid and 12C L-Lysine as the 
‘normal’ version). When two identical cell populations are grown in media containing 
either ‘heavy’ or ‘normal’ forms of particular amino acids, all newly synthesised 
proteins in the two populations will contain amino acids that, while functionally 
identical will have different molecular masses. It only takes a few cell divisions to 
achieve replacement of the vast majority of the amino acids concerned with its 
isotopic analogue. These two cell populations can then be subjected to different 
conditions (e.g. one treated with a pharmacological agent and the other one untreated), 
and the cellular protein lysates extracted. The lysates can then be mixed and subjected 
to quantitative mass spectrometry, which can identify pairs of chemically identical 
peptides containing the ‘heavy’ or ‘normal’ isotopes. The changes in protein 
expression, modifications or activities caused by the differing condition(s) can then be 
identified in the ratio of peak intensities in the mass spectrum for the peptide/protein 
pairs, which is proportional to their abundance.  
 
In the experiment to quantitatively identify AMPK interactors, due to cost and 
material constraints, it was decided to use only one cell-type for the initial studies. 
HEK293 cells was chosen because their rapid division ensures rapid incorporation of 
the substitute amino acids. In addition, AMPK expression and activity have been 
characterised extensively in these cells (see Chapter 3). Clonal HEK293 cells 
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expressing endogenous AMPK were grown in media containing either ‘heavy’ or 
‘normal’ versions of the amino acids L-Lysine and L-Arginine for approximately 10 
cell division cycles, after which the cells were lysed.  
 
The cell lysates (200 µg total protein) containing ‘heavy’ isotope amino acids were 
immunoprecipitated with antibodies targeting various AMPK subunits, whereas 
lysates containing ‘normal’ isotope amino acids were immunoprecipitated with pre-
immune serum (as the control for non-specific interactions). The specific AMPK 
antibodies used along with the corresponding control sera are shown in Table 4.1. 
The AMPK and non-targeting immunoprecipitations were mixed and resolved 
together using SDS-PAGE, after which the gel was sent for MS analysis (CSC-
Proteomics unit). Quantification is shown as a ratio of enrichment of the amount of a 
particular AMPK associated protein in immunoprecipitations with AMPK antibodies 
from the ‘heavy’ isotope lysate as compared to immunoprecipitations with non-
targeting antibodies from the ‘normal’ isotope lysate. From these experiments, a list 
of interacting proteins was produced for each immunoprecipitation with an 
enrichment value for each protein. A threshold was set, whereby a potential 
interaction protein has to be enriched 2 fold or more by immunoprecipitation with 
AMPK pan-β antibodies compared to non-targeting antibodies. Proteins reaching this 
threshold were considered for further analysis.  
 
 
 
 
As can be seen from (Table 4.2), both immunoprecipitations resulted in high levels of 
enrichment of AMPK subunits, including the α1, α2, β1, β2, γ1 and γ2 subunits. The 
enrichment for these subunits ranged from 7.6 to 31.7 fold. In addition, the known 
AMPK substrate acetyl-CoA carboxylase was detected in the immunoprecipitation 
with both α and β subunit antibodies under basal conditions. Immunoprecipitation 
IP number Heavy isotope IP Light isotope IP AMPK 
activation 
1 Pan-β Subunit antibody Pre-immune serum, 
Rabbit 
basal 
2 α1+ α2 subunit antibodies Sheep IgG basal 
Table 4.1 Antibodies and controls used in SILAC MS 
Table showing the antibodies used and corresponding control immunoprecipitations for the 
SILAC MS experiments conducted in this chapter.  
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with AMPK α enriched ACC protein by 4.7 fold whereas immunoprecipitation with 
the β subunit resulted in 2.6 fold enrichment (Table 4.2). 
 
Analysis of the data revealed that all three members of an important cellular complex 
were enriched by both AMPK α and β immunoprecipitations (Table 4.2). The 
PAK1/GIT1/βPIX complex consists of P21-activated protein kinase 1 (PAK1), ARF 
GTPase-activating protein 1 (GIT-1) and Rho guanine nucleotide exchange factor 7 
(βPIX). PAK1 and its associated proteins are involved in the regulation of 
cytoskeletal arrangement and cell motility (Ong et al., 2011b).  
 
Due to the ability of PAK1 and its associated proteins GIT1 and βPIX to be  
immunoprecipitated by both AMPK α and β antibodies with large enrichment folds, 
this interaction is unlikely to be due to non-specific protein binding and may represent 
a ‘real’ interaction with physiological effects. In addition, PAK1 is an established 
controller of cell motility and growth. In recent years AMPK has also been implicated 
to regulate similar processes (Bae et al., 2011; Nakano et al., 2010; Nakano and 
Takashima, 2012). For these reasons the next part of this thesis was spent 
characterising the nature of AMPK’s interaction with the PAK1/GIT1/βPIX complex.  
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Protein Name Gene Name Enrichment ratio (AMPKβ) Enrichment ratio (AMPKα) 
NOC3-like protein AD24 135.50 27.12 
AKAP 120-like protein AKAP350 47.25 6.71 
Cytoplasmic dynein 1 heavy chain 1 DHC1 44.74 3.06 
AMPK γ-1 subunit PRKAG1 31.74 11.20 
AMPK α-2 subunit PRKAA2 28.75 15.73 
AMPK β-1 subunit PRKAB1 27.37 14.34 
AMPK α-1 subunit PRKAA1 26.47 16.63 
Adenylate cyclase-stimulating G alpha protein GNAS1 24.31 2.92 
H/ACA ribonucleoprotein complex subunit 4/Dyskerin NOLA4 22.76 6.93 
p21-activated kinase 1 PAK1 19.47 4.30 
AMPK γ-2 subunit PRKAG2 18.41 7.63 
52 kDa Ro protein RNF81 14.53 4.93 
Mitogen-activated protein kinase kinase kinase 5 MAP3K5 12.82 2.83 
Rho guanine nucleotide exchange factor (GEF) 11 ARHGEF11 12.68 2.48 
Tousled-like kinase 2 TLK2 11.77 3.62 
AMPK β-2 subunit PRKAB2 8.90 10.95 
Treacher Collins syndrome protein/Treacle protein TCOF1 7.62 3.83 
17-beta-hydroxysteroid dehydrogenase 12 HSD17B12 7.14 4.11 
Kinesin-like protein KIF11 KIF11 6.72 2.98 
14-3-3 protein gamma YWHAG 7.08 2.01 
Mitogen-activated protein kinase kinase kinase 15 MAP3K15 6.71 11.86 
ARF GTPase-activating protein GIT1 GIT1 5.81 19.84 
Rho guanine nucleotide exchange factor 7 (βPIX) ARHGEF7 5.58 14.24 
Ribophorin I RPN1 5.43 2.56 
Heat shock 70 kDa protein 9 GRP75 4.51 3.50 
Galectin-3-binding protein LGALS3BP 3.65 3.14 
Table 4.2 (page 1 of 3)  
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Protein Name Gene Name Enrichment ratio (AMPKβ) Enrichment ratio (AMPKα) 
rRNA 2'-O-methyltransferase fibrillarin FBL 3.19 7.75 
Delta-1-pyrroline-5-carboxylate synthetase ALDH18A1 3.10 6.12 
Far upstream element-binding protein 2 FUBP2 3.08 3.92 
Ribophorin I DDOST 3.00 5.24 
ATPase family AAA domain-containing protein 3B ATAD3B 2.78 4.40 
Rotatin RTTN 2.74 33.35 
Aspartate carbamoyltransferase CAD 2.67 9.75 
Acetyl-CoA carboxylase 1 ACAC 2.61 4.70 
Survival motor neuron protein SMN1 2.59 4.06 
D-3-phosphoglycerate dehydrogenase PGDH3 2.47 5.77 
Fas ligand-associated factor 1 FBP11 2.41 5.66 
Myb-binding protein 1A MYBBP1A 2.41 14.68 
Colonic and hepatic tumor over-expressed gene protein CKAP5 2.39 19.49 
Structural maintenance of chromosomes protein 1A DXS423E 2.39 5.28 
Nucleolar phosphoprotein B23 NPM1 2.38 20.61 
Ribophorin II RPN2 2.32 5.09 
Beta-coat protein COPB 2.25 5.57 
Neurofilament light polypeptide NEFL 2.20 4.38 
Importin-7 IPO7 2.20 4.52 
Nucleolin NCL 2.15 14.00 
U2-associated protein SR140 KIAA0332 2.15 6.18 
Probable ATP-dependent RNA helicase DDX20 DDX20 2.15 15.30 
Citrate transport protein SLC20A3 2.14 10.86 
UPF0197 transmembrane protein C11orf10 C11orf10 2.11 5.13 
DNA-dependent protein kinase catalytic subunit HYRC 2.11 7.29 
 
Table 4.2 (page 2 of 3)  
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Protein Name Gene Name Enrichment ratio (AMPKβ) Enrichment ratio (AMPKα) 
Adapter-related protein complex 2 beta subunit ADTB2 2.09 2.24 
Complement component 1 Q subcomponent-binding 
protein C1QBP 2.07 3.52 
General transcription factor 3C polypeptide 4 GTF3C4 2.05 6.82 
Phosphate transport proteinisoform b variant OK/SW-cl.48 2.04 10.46 
Mitochondrial 2-oxoglutarate/malate carrier protein SLC20A4 2.04 8.24 
ADP/ATP translocase 2 ANT2 2.03 10.28 
Nucleolar and coiled-body phosphoprotein 1 KIAA0035 2.02 7.69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 Potential AMPK interactors identified using SILAC/MS 
Table showing a list of protein binding proteins of AMPK identified using the SILAC/MS technique coupled with 
immunoprecipitations with AMPK Pan-β-subunit antibody or AMPK α1+α2 subunit antibodies. Proteins hits which reached 
the threshold of 2 fold enrichment after Pan-β-subunit immunoprecipitation are included. AMPK subunits identified are 
highlighted in red. Known AMPK substrates are highlighted in Green. And The PAK1/GIT1/βPIX complex are highlighted 
in bold. Abundant proteins which are common to most protein-interaction experiments (e.g. ribosomal subunits and tubulin) 
have been omitted from this list.  
(Mass spec analysis performed by the MRC CSC-Proteomics unit)  
 
Table 4.2 (page 3 of 3)  
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4.3 Discussion:  
In this Chapter, immunoprecipitation with specific AMPK antibodies coupled with 
mass spectrometry analysis was used to identify novel AMPK interacting proteins. A 
number of interesting candidates were identified including the PAK1/GIT1/βPIX 
complex (characterised in Chapter 5).  
 
Due to the wide range of upstream regulators and downstream targets of AMPK, it is 
logical to suggest that at any one time, only a very small percentage of AMPK would 
be interacting with any particular binding protein. Therefore, various techniques were 
utilised in order to maximise the chance of detecting AMPK-interacting proteins. 
AMPK was over-expressed in HEK293 and COS7 cells to increase the amount of 
protein available for binding. In-cell cross-linking using paraformaldehyde was also 
employed to capture weak or transient interactions which might be lost during the 
course of the isolation process. There are several potential drawbacks with this 
approach. Firstly, the significant increase in AMPK protein levels due to over-
expression may cause the enzyme to localise to cellular compartments which do not 
normally express endogenous AMPK and may potentially form non-physiological 
interactions. Secondly, the cross-linking procedure captures all molecules within a 
certain distance of each other (Nadeau and Carlson, 2007). Although the linker 
distance of paraformaldehyde has a very short arm length of 2.3–2.7 Å, any molecule 
close enough to AMPK will be captured, regardless of whether or not it forms a 
physiological relevant interaction. However, considering that the physiological 
relevance of all potential interactors will be validated using traditional biochemical 
techniques, any false positive results should be ruled out at this later stage.  
 
By performing AMPK over-expression coupled with in vivo cross-linking and 
immunoprecipitations with specific AMPK antibodies, a number of potential 
interaction proteins were obtained using MS techniques. In all experiments, multiple 
isoforms of the α, β, and γ subunits of AMPK were identified, which served to 
confirm that both the immunoprecipitation and the mass spectrometric processes were 
producing expected results. However several drawbacks to the experimental setup 
became apparent at this point, and will be discussed below: 
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In relation to the technique of in cell cross linking, the number of associated proteins 
detected decreased with the longer cross-linking period of 15 minutes as compared 
with the 5 minutes time point. This result is puzzling, as one would expect that with a 
longer cross-linking time, an increasing number of proteins close together would be 
linked and therefore a greater number of associated proteins would be detected.  One 
explanation for this anomaly is that the larger cross-linked complexes created by the 
longer cross-linking time point would be less able to be digested in the trypsinization 
step prior to loading onto the mass spectrometer (although effectors were made to 
reverse the cross-linking before MS analysis). As a result, these partially digested 
peptides may be less able to be detected by the mass spectrometer and therefore fewer 
associated proteins are identified. This theory would appear to suggest that although 
the cross-linking step may help to capture transient interactions which may otherwise 
to be lost, there may be difficulties involved in the detection of the cross-linked 
complexes using mass spectrometry, thus resulting in some potential interactors being 
left undetected. As a result, it was decided that in future mass spectrometric 
experiments, no chemical cross-linking would be employed. 
 
Another drawback with the above set-up was that while hundreds of proteins would 
be identified in each immune complex, without a quantitative readout as to the 
amount or ratio of each associated protein relative to AMPK it is very difficult to 
determine which interaction is “real” and which is unspecific. It would be unfeasible 
and wasteful to validate all of the potential interactors identified.  
 
Considering the points discussed above it was decided to employ a quantitative 
proteomics approach to better identify AMPK interactors. To this end, stable isotope 
labelling by amino acids in cell culture (SILAC) to achieve cellular labelling of 
proteins with “heavy” and “light” versions of the same amino acid in the HEK293 
cells was employed. This method, first reported around 10 years ago, has proven to be 
an effective technique for the identification of protein interaction networks in various 
cellular pathways (Blagoev et al., 2003; Ong and Mann, 2005).  This method coupled 
with quantitative mass spectrometry allowed me to obtain a figure for the fold 
enrichment of a particular interacting protein after immunoprecipitation with AMPK 
antibodies.  
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In these experiments, multiple AMPK subunit isoforms were greatly enriched after 
AMPK immunoprecipitation, and this result acted as an internal control validating the 
experimental approach. Furthermore, enrichment of the AMPK substrate acetyl-CoA 
carboxylase (ACC) in immune complexes with both AMPK α and β antibodies was 
seen. This is the first time our group was able to measure this interaction, and further 
serves to validate the usefulness of the method.  
 
This study has identified many potential physiological AMPK interacting proteins (of 
which reached the set threshold of two fold enrichment with the AMPK pan-β-
antibody (see Table 4.2 for full list), however due to the time and resource taken to 
characterising these interactions and elucidating its downstream effects, it was only 
possible to select a few candidates to follow up. After consideration, the next part of 
this thesis was dedicated to investigating the nature of interaction between AMPK and 
the PAK1/GIT1/βPIX complex.  
 
There were several reasons for this decision. Firstly, as stated in the results section, all 
three members of the complex were highly enriched by both AMPK α and β 
antibodies, reducing the chance of unspecific binding of the proteins to a particular 
antibody. Another reason for this choice was the important role the PAK1/GIT1/βPIX 
complex in both normal physiology and pathology. Of the three proteins in this 
complex, the most tractable for study is the serine/threonine kinase PAK1. The 
regulation and function of PAK1 and its relevance to AMPK signalling are described 
in detail in the introduction section.  
 
Although time and resource constraints limited the number of AMPK interacting 
proteins we could follow up. There were other interesting candidates that could form 
the basis of a new study. For example, the proteins mitogen-activated protein kinase 
kinase kinase 5/ASK1 (MAP3K5) and Mitogen-activated protein kinase kinase kinase 
15 (MAP3K15) were enriched following pull-downs with both AMPK α and β 
antibodies (Table 4.2). Both ASK1 and MAP3K15 are part of the mitogen-activated 
protein kinase pathway, which phosphorylates and activates Mitogen-activated 
protein kinase kinase (MAP2K) which in turn activates Mitogen-activated protein 
kinase (MAPK). Examples of MAPKs include c-Jun N-terminal kinase (JNK) and 
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p38 MAPK. This pathway is activated in response to various types of stress including 
osmotic pressure, tumour necrosis factor-α, endoplasmic reticulum stress and reactive 
oxygen species (Soga et al., 2012). MAPKs, which are the effectors of this pathway, 
plays important roles in the regulation of apoptosis, inflammation, and cell 
morphogenesis.  
 
A recent paper has proposed a potential link between AMPK and ASK1. Treatment of 
MCF-7 breast cancer cells with the plant flavonoid quercetin caused activation of both 
ASK1 and AMPK, and activation AMPK are necessary for ASK1 to mediate its 
apoptotic effects through stimulation of the downstream kinase p38 MAPK. The 
authors goes on to suggest that AMPK may be an upstream regulator of ASK1 (Lee et 
al., 2010). In comparison to ASK1, rather less is known about MAP3K15. In recent 
studies however, MAP3K15 has been shown to be increased in liver cirrhosis and 
knockdown of MAP3K15 protected Hela cells from stress-induced cell death. 
Knockout of MAP3K15 in mice have led to the appearance of a hypertensive 
phenotype. In fact the similarities between MAP3K15 and ASK1 has led researcher to 
propose ASK3 as the new name for this kinase (Kaji et al., 2010; Naguro et al., 2012).  
It can be seen that identification of two enzymes of the MAP3K family as AMPK 
interaction proteins is an interesting result and in future studies, these interaction can 
be investigated further and any physiological implications elucidated.  
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5 Investigation of AMPK regulation of PAK1 
5.1 Introduction 
Having identified that the PAK1/GIT1/βPIX complex interacts with AMPK, I went 
on to investigate the functional and physiological implications of this interaction. In 
this chapter, experiments were conducted both in cells (transformed and primary cells) 
and in cell free assays. Using these approaches, AMPK was found to both 
phosphorylate and activate PAK1. In addition experiments were also conducted to 
elucidate the physiological relevance of this activation.  
 
5.2 The PAK1/GIT1/βPIX complex interacts with 
AMPK  
Co-immunoprecipitation experiments were conducted to validate the MS data 
showing an interaction of AMPK with the PAK1/GIT1/βPIX complex. In order to 
detect endogenous levels of PAK1, GIT1 and βPIX, HEK293 cell lysates (20 μg total 
protein) were subjected to western blot analysis. All three proteins were detected in 
HEK293 cell lysates at molecular masses corresponding to their predicted masses 
(Figure 5.1). Having confirmed that available antibodies were able to detect 
endogenous levels of these proteins, the ability of the complex to co-
immunoprecipiate with AMPK was investigated. Anti-AMPK α (α1+α2) antibody was 
used to immunoprecipitate AMPK from HEK293 cell lysates (300 μg total protein). 
The immune-complexes were subjected to SDS-PAGE and western blot analysis 
using antibodies against PAK1, GIT1 or βPIX. As shown in Figure 5.2, all three 
proteins were detected in the AMPK immune complexes.  Due to cross-reaction with 
the IgG light chain, it was not possible to detect the β and γ subunits of AMPK in the 
immune-complexes by western blotting (not shown). Immunoprecipitations were also 
conducted with anti-PAK1 antibody and the immune-complexes subjected to western 
blot analysis probed with anti-AMPK antibodies. As can be seen in Figure 5.2, 
AMPK α was readily detected in anti-PAK1 immune complexes. 
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Figure 5.1 Detection of endogenous PAK1, GIT1, βPIX in HEK293 cells 
HEK293 lysates (20 µg) were subjected to western blot analysis with anti-GIT1, -PAK1 and 
-βPIX antibodies and detected using the Licor Odyssey system. The migration of molecular 
mass markers is indicated on the left and the identity of the bands is indicated on the right.  
 
 
 
 
 
 
 
Figure 5.2 Validation of AMPK interaction with PAK1, GIT1 and 
βPIX  
HEK293 cell lysates were subjected to immunoprecipitation analysis using anti-AMPK 
α antibodies (sheep IgG was used as control immunoprecipitation) and immune-
complexes analysed by western blot analysis using anti-PAK1, -GIT1 and -βPIX 
antibodies. Anti-PAK1 antibody was also used in immunoprecipitation reactions 
(Protein A Sepharose as control) and the resulting western blot probed for AMPK α. 
(Note: For the detection of GIT1 interaction with AMPK, lanes were separated as 
different parts of the same gel were used for AMPK α and control 
immunoprecipitations). (n = 2 independent experiments) 
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5.3 Investigation of the effect of AMPK on PAK1 
As PAK1, GIT1 and βPIX form a complex, it is likely that AMPK interacts with this 
complex as a whole rather than with each of these proteins individually. Due to time 
constraints, it was decided to concentrate on experiments to validate the effects of 
AMPK on PAK1, rather than focus on the nature of the AMPK/PAK1/GIT1/ βPIX 
complex interaction. This decision was made as the function of PAK1 is relatively 
well understood compared to the other two proteins, and as a kinase is the main 
effector protein when PAK1, GIT1 and βPIX are in complex. 
 
5.3.1 Phosphorylation of PAK1 by AMPK 
In order to investigate whether AMPK directly phosphorylates PAK1, commercial, 
unactivatable GST-PAK protein (from Stratech) was obtained. This PAK1 isoform 
contains a partial (77 amino acid) deletion of its kinase domain which renders it 
unactivatable. PAK1 protein was incubated with 
32
P-ATP in the presence and absence 
of active AMPK (α1β1γ1) (AMPK expressed and activated as described in chapter 2). 
The incorporation of 
32
P was visualised using autoradiography. As can be seen from 
Figure 5.3, whereas incubation of PAK1 alone with 
32
P-ATP did not result in any 
detectable radiolabelling, incubation of PAK1 with active AMPK resulted in readily 
detectable 
32
P-phosphate incorporation. This result demonstrates that AMPK 
phosphorylates PAK1 in vitro. Additional labelled bands migrating at approximately 
63 and 38 kDa correspond to AMPK α1 and β1 subunits, respectively.  
 
An estimation of the stoichiometry of phosphorylation (ATP incorporation) was 
determined from the autoradiograph this estimated by spotting serial dilutions of the 
[
32
P-γ]ATP onto filter paper and exposing this alongside the gel.  Using this method 
the stoichiometry was estimated to be around 0.4 – 0.8 mole/mole for different 
experiments.  
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Figure 5.3 AMPK phosphorylates PAK1 in vitro 
GST-PAK1 (1000 ng) was incubated with [
32
P-γ]ATP in the presence and absence of 
AMPK α1β1γ1 (200 ng) for 45 minutes at 37ºC. Samples were resolved by SDS-PAGE and 
visualised by staining with Coomassie (upper panel) and radiolabelled products detected by 
autoradiography (lower panel). The corresponding molecular markers are indicated on the 
left. Identity of the protein and radiolabelled bands is indicated on the right.   (n = 3 
independent experiments) 
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5.3.2 Identification of AMPK phosphorylation sites on PAK1 
After finding that AMPK directly phosphorylated PAK1, the next step was to  identify 
the specific residue(s) on which this phosphorylation took place. GST-PAK1 
construct (obtained via a kind gift from Katrin Rittinger (NIMR, MRC)) was used to 
generate kinase dead GST-PAK1 (GST-KD-PAK1) by introducing a mutation of 
aspartic acid residue 406 (within the ATP-binding region of the PAK1 kinase domain) 
to an alanine. GST-WT-PAK1 and GST-KD-PAK1 were purified from E.coli (as 
described in sections 2.26). A Coomassie stained gel of the purified proteins is shown 
in Figure 5.4. The full length GST-PAK1 migrates at approximately 95 kDa. 
However, as can be seen, in addition to the full-length protein, a number of 
degradation products were also present after protein purification. Densitometric 
analysis of the gel revealed that full-length PAK1 accounts for about 15% - 30% of 
the total protein in various purifications. All protein bands were confirmed as PAK1 
by probing western blots with specific PAK1 antibodies (data not shown). The band 
corresponding to full-length PAK1 was excised from the gel and subjected to mass 
spectrometry, following digestion by trypsin. All of the peptides identified 
corresponded either to PAK1 or GST.  
 
GST-KD-PAK1 was incubated with 
32
P-ATP in the presence and absence of AMPK 
and analysed by SDS-PAGE followed by autoradiography. KD-PAK1 was 
phosphorylated by AMPK (Figure 5.5). In a parallel incubation. GST-KD-PAK1 was 
incubated with AMPK and unlabelled ATP, and the band corresponding to full-length 
PAK1 excised, digested with trypsin and subjected to analysis by MS.  
 
The mass spectrometry analysis achieved sequence coverage of around 65% and is 
shown in Figure 5.6. A total of three phosphopeptides were identified with >90% 
confidence, and these are highlighted in green in the sequence coverage. In two of the 
peptides it was possible to assign the phosphorylation sites unambiguously: 
SAEDYNSSNTLNVK (Ser-156 of PAK1) and LRSIVSVGDPK (Ser-258 of PAK1). 
In the third peptide, however, it was not possible to assign the phosphorylation site 
and any one of the three residues highlighted are candidates: NTSTMIGAGSK (Thr-
20, Ser-21 and Thr-22 of PAK1). Despite this ambiguity, it was decided to investigate 
the role of phosphorylation within this peptide, since Ser-21 lies within a favorable 
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consensus sequence for AMPK phosphorylation and a previous publication has 
implicated the equivalent residue in PAK2 (Ser-20) as a potential target for 
phosphorylation by AMPK (Banko et al. 2011). Additionally a previous study has 
implicated residues in this region as being phosphorylated by protein kinases such as 
Akt (Banko et al., 2011; Fryer et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Purification of recombinant PAK1 
Glutathione S-transferase (GST) tagged WT or KD (D406A) PAK1 were expressed in E. 
coli and purified using glutathione-Sepharose chromatography. Proteins (5 µg) were 
resolved by SDS-PAGE and visualised by staining with Coomassie Blue. The migration of 
the molecular weight markers is indicated on the left (kDa), the identity of the bands are 
indicated on the right.   
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Figure 5.5 AMPK phosphorylation of Kinase dead PAK1 
GST-KD-PAK1 was incubated with [
32
P-γ]ATP in the presence and absence of AMPK for 
30 minutes at 37 ºC Samples were resolved by SDS-PAGE and visualised by staining with 
Coomassie (upper panel) and radiolabelled products detected by autoradiography (lower 
panel). The bands corresponding to full-length GST-PAK1 are shown. The corresponding 
molecular markers are indicated on the left. Identity of the protein and radiolabelled bands 
are indicated on the right.    
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Figure 5.6 Phosphopeptide mapping of PAK1 phosphorylated by AMPK  
GST-KD-PAK1 was incubated with ATP in the absence and presence of active AMPK. The proteins were resolved using SDS-PAGE and 
the band corresponding to full-length GST-PAK1 was digested with trypsin and subjected to MS analysis. The sequence coverage is 
indicated in red with phosphorylation sites which appear after addition of AMPK shown in green.   
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5.3.3 Production of mutant PAK1 protein 
In view of the results shown above, it was decided to produce mutant versions of 
PAK1 on GST-WT-PAK1 and GST-KD-PAK1 backgrounds. In the first mutant, all 
three residues, Thr-20, Ser-21 and Thr-22 were mutated into non-phosphorylatable 
alanine residues (here on referred to as the AAA-mutant). In view of the study 
showing Akt phosphorylating PAK1 on Ser-21 and the more recent study showing 
phosphorylation of PAK2 by AMPK at Ser-20 (Banko et al., 2011; Zhou et al., 2003)., 
a second mutant where only Ser-21 was mutated to alanine (S21A-PAK1) was also 
generated. In total, four mutants versions of PAK1 have been expressed and 
visualised using SDS-PAGE (shown in Figure 5.7).  
 
5.3.4 AMPK phosphorylation of mutant PAK1 proteins 
To identify the major phosphorylation site(s) of AMPK on PAK1, active AMPK was 
incubated with either GST-KD-PAK1, GST-AAA-KD-PAK1 or GST-S21A-KD-
PAK1 in the presence of 
32
P-ATP. 
32
P-Phosphate-incorporation was visualised by 
autoradiography. As shown in Figure 5.8, both the triple AAA mutation and the 
S21A mutation significantly reduced the ability of AMPK to phosphorylate PAK1. 
This data would indicate that the major AMPK phosphorylation site on PAK1 is Ser-
21.  
 
156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Production of recombinant mutant form of PAK1 protein 
The S21A single mutation and the T20A, S21A, T22A (AAA mutant) triple mutation was 
introduced into GST tagged expression constructs coding for WT and KD PAK1. Proteins 
were expressed in E.coli and purified using glutathione-Sepharose chromatography. Proteins 
(5 µg) were resolved by SDS-PAGE and visualised with Coomassie Blue staining. The 
migration of the molecular mass markers is indicated on the left (kDa), and the identity of 
the bands are indicated on the right.   
 
 
 
 
 
 
 
Figure 5.8 AMPK phosphorylation of mutant PAK1 
GST-KD-PAK1, GST-KD-T20A S21A T22A (AAA) -PAK1, and GST-KD-S21A-PAK1 
were incubated with [
32
P-γ]ATP in the presence of activated AMPK for 30 minutes at 37ºC. 
Samples were resolved by SDS-PAGE and visualised by staining with Coomassie (upper 
panel) and radiolabelled products detected by autoradiography (lower panel). The bands 
corresponding to full-length GST-PAK1 are shown.  Identity of the protein and 
radiolabelled bands are indicated on the right (GST-KD-PAK1 incubation with AMPK shown 
in duplicate).    
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5.3.5 AMPK activates PAK1 in vitro  
In order to determine the functional effect of AMPK phosphorylation on PAK1, 
phospho-antibodies against two PAK1 activation sites were obtained, namely pSer-
199 and pThr-423 (Bokoch, 2003). WT-PAK1 was incubated with ATP in the 
presence and absence of active AMPK. The samples were then subjected to western 
blot analysis using pPAK1 activation site antibodies. As shown in Figure 5.9, when 
PAK1 was incubated with ATP alone there was no detectable phosphorylation of 
either pSer-199 or pThr-423. However, following the addition of AMPK, strong 
signals were observed for both sites, suggesting that AMPK phosphorylation of PAK1 
leads to concomitant activation. 
 
To further confirm that AMPK activates PAK1, PAK1 activity was measured before 
and after phosphorylation by AMPK The commercial PAK1 substrate PAKtide was 
obtained. PAKtide was synthesised according to the preferred PAK1 phosphorylation 
consensus sequence and thus should be a specific substrate (Rennefahrt et al., 2007; 
Wu and Wang, 2003; Yoshii et al., 2001). To validate the ability of activated PAK1 to 
phosphorylate PAKtide, Cdc-42 activated PAK1 (Stratech) was taken into radioactive 
kinase assays with PAKtide. As shown in Figure 5.10A, PAK1 was able to 
phosphorylate PAKtide. Next, varying amounts of PAK1 was used to phosphorylate 
PAKtide to determine linearity of this assay. As seen in Figure 5.10B, 
32
P-phosphate 
incorporation into PAKtide was directly proportional to the amount of PAK1 used, 
thus this substrate can be used to directly assess PAK1 activity.  
 
In order to determine whether AMPK phosphorylated PAKtide, which could interfere 
with subsequent experiments, AMPK was taken into a PAKtide assay (Figure 5.11). 
AMPK is much less able to phosphorylate PAKtide compared to the SAMS substrate. 
The efficiency of phosphorylation PAKtide was 2.8% that of SAMS. These results 
indicate that AMPK binding to PAK1 should cause little interference in the PAK1 
activation assays. Nevertheless, appropriate control experiments were included in all 
subsequent experiments.  
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WT or mutant GST-PAK1 (all produced in house) was incubated with unlabelled-
ATP in the presence of active AMPK. After incubation, glutathione-Sepharose beads 
was used to precipitate GST-PAK1 from the mixture and the PAK1 activity assayed 
using PAKtide (Figure 5.12). Validation experiments conducted showed that there 
were no detectable unspecific binding of AMPK activity directly to the glutathione 
sepharose used to immunopreciptate PAK1. In addition, to determine the basal level 
of PAK1 activity, un-activated GST-WT-PAK was incubated with ATP in the 
absence of AMPK, and then precipitated using glutathione-sepharose., PAKtide 
assays performed using these precipitants showed no detectable kinase activity.  
 
As seen from Figure 5.12, co-incubation with AMPK resulted in much higher activity 
of WT-PAK1 compared to that of KD-PAK1 or S21A-WT-PAK1 (both mutants 
achieving similar specific activities of <15% compared to WT-PAK1 after incubation 
with AMPK). Together, these results suggest that AMPK phosphorylation of PAK1 
on Ser-21 leads to PAK1 activation. To note, In our study, the specific activity of 
PAK1 achieved by AMPK incubation was around 25%-30% that of Cdc42 activated 
PAK1.  
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Figure 5.9 Incubation of AMPK with PAK1 results in phosphorylation of 
PAK1 activations sites 
Purified GST-WT-PAK1 incubated with ATP in the presence or absence of activated AMPK. 
Western blot analysis was performed and the blot was probed with phosho-antibodies against 
PAK1 activation sites i.e. pT423 and pS199.  
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Figure 5.10 Validation of PAK1 kinase assay 
A. Cdc-42 activated PAK1 (100 ng) was incubated with PAKtide for 30 minutes at 30 ºC in 
the presence of [
32
P-γ]ATP. Activities have been calculated and plotted as specific activity 
(nmol/min/mg).  
B. Varying amounts of PAK1 (100 ng – 400 ng) were assayed as in (A) with PAKtide. Kinase 
activity is plotted as fold activity with the activities of 100 ng PAK1 taken to be 1 fold.   
 
 
 
 
 
 
 
A.  
 
 
 
 
 
 
 
B.  
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Figure 5.11 AMPK does not phosphorylate PAKtide efficiently  
AMPK (α1β1γ1) (100 ng) were incubated with PAKtide or SAMS peptide (as a positive 
control) for 30 minutes at 37ºC in the presence of [
32
P-γ]ATP. AMPK activity is plotted as 
percentage 
32
P incorporation relative to that of SAMS assay for 100 ng AMPK (taken as 
100%).  Data shown represent averages and standard errors (SEM) from 3 independent 
experiments.  
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Figure 5.12 AMPK activates PAK1 in vitro 
GST tagged WT-PAK1, KD-PAK1, S21A-WT-PAK1 was incubated with ATP in the presence 
of active AMPK (200 ng). PAK1 was then isolated by binding to glutathione-Sepharose. The 
glutathione-Sepharose beads were washed with PBS, and PAK1 activity present on the beads 
measured using PAKtide as substrate. Activities have been calculated and plotted as specific 
activity (nmol/min/mg). Data shown represent averages and standard errors (SEM) from 3 
independent experiments.  
* Indicates a significant difference in activity with when WT-PAK1 activities are compared to 
both KD-PAK1 and S21-WT-PAK1 activities as judged by an one way ANOVA (P<0.05).  
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5.3.6 Activation of AMPK in HEK293 cells leads to increased PAK1 
activity 
Having demonstrated the ability of AMPK to activate PAK1 in vitro, experiments to 
determine whether this might occur in intact cells were carried out. HEK293 cells 
were treated with several compounds known to activate AMPK (see Figure 3.4). 
After treatment, the activity of endogenous PAK1 and AMPK were measured 
following immunoprecipitation from cell lysates.  
 
All three treatments led to a significant activation of AMPK and a concurrent increase 
in PAK1 activity (Figure 5.13). In the case of PAK1, H2O2, phenformin and 
ionomycin caused increases in kinase activities of approximately 3.8 fold, 2.7 fold 
and 2.5 fold respectively. The result from this experiment suggests that AMPK is 
capable of activating PAK1 in cells, as well as in cell-free assays.  
 
5.3.7 AMPK regulation of PAK1 activity in cortical neurons  
After obtaining promising results in HEK293 cells, it was decided to conduct further 
experiments in a more physiological cell-type. Primary cortical neurons was used as 
the cell-type of choice due to its abundant expression of PAK1, and the established 
roles of the enzyme in regulating neuronal growth and axonal branching (Kreis and 
Barnier, 2009).  
 
Primary mouse cortical neurons were isolated from embryonic day 14 C57 black-6 
mice and cultured as described in Chapter 2. On day in vitro (DIV14) cells were lysed 
and immunoprecipitated with either AMPK or PAK1 antibodies. As shown in Figure 
5.14, AMPK and PAK1 co-immunoprecipitated from the neuronal lysates.  
 
Next, DIV14 cortical neurons were treated with three AMPK activators, Ionomycin, 
H2O2 and M991, a new novel AMPK activator (Giordanetto and Karis, 2012) (M991 
corresponds to compound 9 in Figure 4 of this reference). As in HEK293 cells, both 
PAK1 activity and phosphorylation increased in line with AMPK phosphorylation 
(Figure 5.15A). H2O2 caused a 3.24 fold increase in AMPK phosphorylation and a 2.8 
fold increase in PAK1 phosphorylation, while for ionomycin the increased 
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phosphorylation was 2.71 fold and 2.47 fold for AMPK and PAK1 respectively, the 
M991 compound was the weakest AMPK activators tested, causing increase in pT172 
levels of 2.15 fold and pPAK1 of 1.79 fold.  In addition, as can be seen in (Figure 
5.15B), the activity of both enzymes correlate with the data obtained from western 
blot experiments. To note, the pPAK1 (pThr-423) antibody is also able to detect pThr-
402 of PAK2. In our experiments with neuronal lysates, we picked up two bands, the 
top band corresponding to pPAK1 (MW 70 kDa) and a lower less pronounced band 
corresponding to pPAK2 (MW 62 kDa) (Figure 5.15) All quantitation was done with 
the top band.    
 
In order to confirm the elevation of PAK1 activity caused by compounds shown 
above is indeed mediated through AMPK activation, neurons were treated with M991 
in the presence and absence of the AMPK inhibitor Compound C. As can be seen 
from Figure 5.16, pre-treatment with compound C was able to largely abolish M991 
mediated increases in PAK1 phosphorylation.  
 
5.3.8 PAK1 phosphorylation and activity are reduced in AMPK α1 
knockout cortical neurons 
To further validate the results obtained above, a genetic model for AMPK depletion 
was sought, the AMPK α1 knockout mice was available in our lab, which have been 
previously verified (Jørgensen et al., 2004). AMPK α1 and α2 catalytic subunits are 
expressed throughout the brain, with higher expression for both subunits at embryonic 
stages compared to adult brains (Culmsee et al., 2001). Moreover, data from a  recent 
study indicates that the expression of α1 in mouse cortical neurons is higher than that 
α2 expression  (Williams et al., 2011).  
 
Initially, we conducted experiments to measure AMPK α1 and α2 activities in wild 
type and α1 knockout neurons using subunit specific antibodies. As shown in Figure 
5.17, AMPK α1 activity was largely abolished in the neurons of the knockout mice, 
being around 2-5% of the wild type neurons. On the other hand, AMPK α2 activity in 
the knockout neurons were found to be ~16% higher than wild type. However this 
difference was not statistically significant. Next, overall AMPK 
activity/phosphorylation (of both α1 and α2 subunits) was measured in the α1 knockout 
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and wild type neurons. As seen in Figure 5.18, in the α1 knockout neurons both 
AMPK activities (of 53%) and the phosphorylation of Thr-172 (of 43%) was much 
reduced compared to wild type.  
 
Having confirmed that AMPK activity and phosphorylation is reduced in the α1 
knockout neurons, experiments were conducted to see if this had any impact on PAK1 
activity. Neuronal cell lysates from both wild type and α1 knockout mice were probed 
with the PAK1 pThr-423 antibody and also subjected to PAK1 kinase assays. PAK1 
activity/phosphorylation in the α1 knockout neurons were significantly reduced 
compared to that of wild type (Figure 5.19). The levels of kinase activity and 
phosphorylation for AMPK and PAK1 were reduced to around 40% - 50% of the 
levels seen in wild type cells.   
 
Next, to see if PAK1 activity can be stimulated by AMPK activators in the absence of 
AMPK α1, M991 was used to treat α1 knockout neurons, and the lysates then 
subjected to western blot analysis and kinase assays (Figure 5.20). M991 induced 
significant increases in the activities and phosphorylation of both AMPK and PAK1, 
despite the lack of AMPK α1 subunits. Increases in activities and phosphorylation of 
between ~0.8 fold and 1.2 fold was seen for both enzymes. These results suggest that 
both AMPK α1 and α2 complexes are able activate PAK1. 
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Figure 5.13 AMPK activation leads to elevated PAK1 activity in HEK293 cells 
HEK293 cells were treated with H2O2 (0.5 mM 30 min), phenformin (5 mM, 30 min), or 
ionomycin (2.5 μm 5 min) and PAK1/AMPK were immunoprecipitated using either anti-PAK1 
or anti-AMPK-pan-β antibodies respectively and their activity determined. Results are shown as 
fold activity of PAK1/AMPK relative to Mock treated (control) cells. Data shown represent 
averages and standard errors (SEM) from 3 independent experiments.  The increases in 
AMPK/PAK1 activities as a results of all treatments shown above are statistically significant 
(P<0.05).  
 
 
 
 
 
 
 
Figure 5.14 Co-immunoprecipitation of AMPK and PAK1 in mouse primary 
cortical neurons 
Mouse cortical neurons were subjected to immunoprecipitation using antibodies against (A) 
AMPK α subunit  (sheep IgG as the control) or (B) PAK1 (protein A sephrose as the control). 
Immune-complexes were subjected to western blot analysis using antibodies against either 
PAK1 (in A) or AMPKα (in B). Images obtained using the Licor infrared imaging system.  
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Figure 5.15 Stimulation of AMPK leads to PAK1 activation in mouse cortical neurons  
(A) Cultured mouse cortical neurons (DIV14) were incubated with or without the AMPK activators H2O2 (0.5 mM 30 min), ionomycin (2.5 µM 5 
min) and M991 (100 µM 60 min). After treatment, cells lysates were subjected to western blot analysis with anti-PAK1-pT423, AMPK pT172 
and actin antibodies. The relative level of signals were quantified using the Licor Odyssey software using actin as a protein control.  
(B)  PAK1 and AMPK activity in immune complexes isolated by immunoprecipitation  using anti-PAK1 or anti-AMPK-β antibodies was determined. 
Results are shown as fold PAK1/AMPK activity relative to untreated cells. Data shown represent averages and standard errors (SEM) from 3 
independent experiments.  
(The increases in AMPK/PAK1 phosphorylation/activities as a results of all treatments shown above are statistically significant, P<0.05) 
 
 
 
 
 
 
 
A. 
B. 
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Figure 5.16 Pre-treatment with the AMPK inhibitor Compound C prevents 
M991 induced PAK1 activation 
Cultured mouse cortical neurons (DIV14) was incubated with or without M991 (100 µM 60 
min), in the presence or absence of compound C (CC) (15 µM). After treatment, cells lysates 
were resolved using SDS-PAGE and subjected to western blot analysis with either PAK1 
pT423, AMPK pT172 or actin antibodies. The relative levels of signal were quantified using 
the Licor Odyssey software using actin as a loading control. Data shown represent averages 
and standard errors (SEM) from 2 independent experiments 
* Indicates a significant difference in activity/phosphorylation between M991 treated neurons 
and M991+CC treated neurons as judged by student’s t-test (P<0.05).  
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Figure 5.17 Activity of AMPK α1 and α2 complexes in WT and AMPK α1 
knockout cortical neurons 
Antibodies targeting either AMPK α1 and α2 subunits were used to immunopreciptate AMPK 
complexes from cell lysates (40 µg total protein) of cultured cortical neurons from either wild-
type or AMPK α1 knockout neurons (DIV14). The SAMS peptide assay was used to determine 
AMPK activity. Activities are plotted as specific activity (pmol/min/mg). Data shown 
represent averages and standard errors (SEM) from 3 independent experiments.  
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A. 
B. 
Figure 5.18 Overall AMPK activity/phosphorylation in AMPK WT and α1 
knockout cortical neurons 
(A) Representative Western blot of total cell lysates (50 μg) from either wild-type or 
AMPK α1 knockout neurons (DIV14) probed with pThr-172 and actin antibodies. The 
relative levels of signal were quantified using the Licor Odyssey software using actin as 
loading control.  
(B) The pan-β subunit AMPK antibody was used to immunopreciptate AMPK complexes 
from cell lysates of cultured cortical neurons from either wild-type or AMPK α1 
knockout mice (DIV14) and AMPK activity determined. Data shown represent 
averages and standard errors (SEM) from 3 independent experiments.  
* Indicates a significant difference in activity/phosphorylation between the WT and α1 KO 
neurons as judged by a student’s t-test (P<0.05).  
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Figure 5.19 PAK1 phosphorylation/activity is reduced in AMPK α1 
knockout neurons 
(A) Representative western blot of total cell lysates (50 μg) from either WT or AMPK α1 
knockout cortical neurons (DIV14) (2 mice) probed with AMPK-pT172, PAK1-pT423, 
and actin antibodies. Relative levels were quantified using the Licor Odyssey software.  
(B)  PAK1 and AMPK was immunoprecipitated using anti-PAK1 or anti-AMPK-β 
antibodies respectively from either WT or AMPK α1 knockout neurons, and PAK1 and 
AMPK activities assayed. Results are shown as percentage AMPK/PAK1 activity 
relative to the WT neurons. Data shown represent averages and standard errors (SEM) 
from 3 independent experiments.  
* Indicates a significant difference in activity/phosphorylation between the WT and α1 KO 
neurons as judged by a student’s t-test (P<0.05).  
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Figure 5.20 M991 treatment enhances PAK1 phosphorylation/activity in AMPK 
α1 knockout cortical neurons  
AMPK α1 knockout cortical neurons (DIV14) (2 mice) were either mock treated (Control) or 
treated with the M991 (100 μM, 60 min) and cells lysed.  
(A) Representative Western blot of total cell lysates (50 μg) were probed with AMPK-pT-172, 
PAK1-pT423, and actin antibodies. The relative level of signal were quantitated using the 
Licor Odyssey software against Actin from 3 independent experiments.  
(B) PAK1 and AMPK was immunoprecipitated using anti-PAK1 or anti-AMPK-β antibodies 
and activities assayed. Results are shown as percentage AMPK/PAK1 activity relative to 
mock treated neurons. Data shown represent averages and standard errors (SEM) from 3 
independent experiments.  
* Indicates a significant difference in activity/phosphorylation with between the treated and non-
treated neurons as judged by a student’s t-test (P<0.05).  
 
 
 
 
 
 
 
 
A. 
B. 
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5.3.9 Physiological implications of AMPK regulation of PAK1  
PAK1 is known to be involved in axon branching and neurite formation (Zhang et al., 
2005). Additionally, it has been reported that CaMKKβ facilitates neuronal spine 
outgrowth via positive regulation of the PAK1/GIT1/βPIX complex (Saneyoshi et al., 
2008). 
 
In view of these publications, the potential role of AMPK in regulating PAK1 
mediated axonogenesis was investigated. Neurons from Wild-type or AMPK α1 
knockout mice were isolated from E14 day embryos. On day in vitro 7, the neurons 
were either mock treated or treated for 5 days with agents which directly modulate 
AMPK activity, i.e. M991 and the AMPK inhibitor, Compound C. The CaMKKβ 
inhibitor STO-609, which has been shown to inhibit the formation of dendritic 
protrusions was used as a positive control (Saneyoshi et al., 2008). After treatment, 
neurons were fixed, permeabilized and stained with Alexa488-Phalloidin, which binds 
F-actin. When visualised using confocal microscopy, a good signal was obtained, with 
the actin filaments clearly visible (Figure 5.23).  From general inspection of images, 
the density of axons/dendrites in each field appeared to increase with the application 
of AMPK activators and decrease following with treatment with either compound C 
or STO-609. Additionally, WT neurons seem to have a greater density of 
axons/dendrites compared to α1 knockout cells. Unfortunately, while axons and cell 
bodies were clearly visible, the fields were simply too dense to be able to identify 
individual dendrites or spines. Axons and dendrites of different cells were overlapping 
and it was not possible to follow the course of single dendrites with certainty. As a 
result, quantification of protrusions/spines from each dendrite was not possible, and 
thus it was not possible to obtain a figure for the effects of the various treatments or of 
knockout of AMPK α1 expression.  
 
In an attempt to overcome these problems, in subsequent experiments neurons were 
plated at lower densities (from 25% - 50% of original density). However, at these 
lower densities, the survival of neurons in culture was greatly impaired.  
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Phalloidin was also applied at lower concentrations in an effort to lower the signal 
intensity.  However this had little effect and the field was still saturated with signal 
making the spines unidentifiable (data not shown).  
 
In view of the experimental difficulties encountered, it was decided to try to obtain a 
more specific readout of axon/dendrite formation in place of actin-binding. To do this, 
quantification of postsynaptic density protein 95 (PSD95) was chosen. PSD95 
specifically localises to the post-synaptic densities of dendritic spines (PSD) and has 
been shown to co-localise with PAK1 (Hayashi et al., 2007; Sheng and Sala, 2001). 
 
In this experiment, wild type and AMPK α1 knockout neurons were isolated and 
treated with M991, compound C or STO-609 as above. Cells were fixed and 
permeabilized after 4 days of treatment (DIV12). Two different PSD95 antibodies 
were obtained from Pierce antibodies (USA) and used to stain the treated and 
untreated neurons. However, after trying a variety of antibody concentrations, and 
other optimisation protocols, no signal could be obtained, despite being able to detect 
PSD95 protein by conventional western blotting (data not shown). This work is on-
going, and antibodies from Cell Signalling (Boston, USA) will be tested. 
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Figure 5.21 Effect of pharmacological treatment on dendritic branching of 
primary cortical neurons 
Primary mouse cortical neurons (DIV7) were treated for 5 days with M991 (50 μM), 
Compound C (7.5 μM), STO-609 (20 μM). Cells were stained with Alexa488-Phalloidin and 
visualised under the Leica-SP5 confocal microscope. Representative images were taken with 
40x objective lens and shown above.  
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5.3.10 AMPK enhances cancer cell invasion through PAK1 signalling 
As introduced in Chapter 1, previous publications have reported that both AMPK and 
PAK1 may be involved in regulating the migration and invasion of a number of 
cancer cells types (Nagalingam et al., 2012). Recently, PAK1 has been suggested as a 
therapeutic target for BRAF wild-type melanoma (Ong et al., 2013). Through our 
collaboration with Professor Richard Marais’s group (Institute of Cancer Research, 
UK), we obtained two melanoma cancer cell-lines, WM1361 and WM1366, to test if 
AMPK could modulate the invasion of these cells via activation of PAK1. Both 
WM1361 and WM1366 cell-lines contain the NRAS (Q61K) mutation. Expression 
studies performed by our collaborators have shown that PAK1 is expressed in both 
cell-lines.  
 
To my knowledge, AMPK activity and activation has not been previously 
characterised in the cell-lines described above, and so this was established prior to 
further studies involving the migration/invasion assays. As can be seen, both cell 
types express active AMPK, with specific activities of 95 pmol/min/mg (lysate) for 
WM1361 cells and 58 pmol/min/mg for WM1366 (Figure 5.22). Next, the activation 
profile of AMPK for these cells was assayed in order to determine the most potent 
AMPK activator to be used in the invasion assay. Both cell-lines were treated for 16 
hours with increasing concentrations of phenformin, AICAR and A769662. For both 
cell lines, the most pronounced AMPK activation was seen with A769662 treatment 
(200 μM).  In WM1366 cells, A769662 (200 μM) was able to activate AMPK >5-fold. 
In WM1361 cells the level of activation achieved from all treatments was weaker with 
A769662 giving a maximal activation of ~3-fold (Figure 5.23). In view of the above 
results, A769662 was chosen for activating AMPK in the invasion assays.  
 
Using the data generated above, our collaborators conducted assays to determine if 
AMPK activation affected the rate of invasion of melanoma cell-lines. Cells were 
placed at the bottom of the invasion chamber and separated from the chemo-attractant 
(DMEM with 10% FBS) by a layer of collagen. The cells are then given time to 
invade through the collagen towards the chemo-attractant, and following this the 
number of invading cells is quantified by confocal microscopy. 
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From the results, it can be seen that treatment with A769662 at 200 μM significantly 
(P<0.05) increased the invasiveness of WM1361 and WM1366 cells by 1.96 fold and 
1.65 fold respectively (Figure 5.24). At this point in the study, Professor Richard 
Marais’s group relocated to a different institute and were unable to continue to offer 
assistance in the running of the invasion assays. As a consequence, the remaining 
experiments were transferred in house. Due to time and resource constraints, it was 
decided to use only WM1361 cells in future experiments, as it showed the greatest 
increase in cell invasion after activation of AMPK.  
 
Before conducting our own invasion assays, the effect of AMPK activation in 
WM1361 cells on PAK1 activity was determined. In addition, the effect of IPA3, an 
inhibitor of PAK1 (Deacon et al., 2008) was utilised in some experiments. Cells were 
treated for 16 hours with A769662 in the presence or absence of IPA3. After 
treatment, cells were lysed and AMPK/PAK1 activities determined. As shown in 
Figure 5.25, A769662 was able activate both AMPK and PAK1. IPA-3 had no effect 
on AMPK activation by A769662, while being able to largely abolish PAK1 
activation by A769662. Having validated the activation of PAK1 through AMPK 
stimulation, and confirmed the effectiveness of IPA-3 as a specific PAK1 inhibitor, it 
was possible to investigate the effect of AMPK/PAK1 on invasion.  
 
Due to the lack of a high-throughput confocal microscope for quantitation of invading 
cells in the Institute such as the INCELL 3000 as used by our collaborator, it was 
decided to alter the protocols and use a slightly different invasion assay in future 
experiments. The transwell invasion assay is based on the original Boyden chamber 
migration assay, in which cells migrate towards a chemo-attractant across a cell 
permeable membrane. To create an invasion assay, the porous membrane is blocked 
with an additional layer of extra-cellular matrix gel, through which the cells invades.  
 
Transwell invasion assay kits were obtained from Millipore (Massachusetts, USA). In 
this experiment, WM1361 melaonma cells were subjected to four different conditions. 
1. Cells were pre-treated for 4 hours with A769662. Next, the pre-treated cells were 
washed into serum free DMEM containing A769662, and pipetted into the inserts. 2. 
Cells were pre-treated with both A769662 and the PAK1 inhibitor IPA-3 and washed 
into serum free media containing both compounds and pipetted into inserts. 3. Cells 
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were left untreated and washed into serum free DMEM and placed into inserts in 4. 
Cells were left untreated and placed into inserts in media containing 20% FBS to act 
as a no chemo-attractant control. The wells underneath all inserts conditional 1-4) 
were filled with media containing 20% FBS as chemo-attractant.  The cells were then 
allowed to invade for 48 hours. After this, the ECM layer was removed along with 
non-invading cells. Cells which have invaded through the membrane were then 
stained using crystal violet dye. The number of stained cells were visualised under the 
microscope, with images of representative fields taken, The cells in each field are then 
counted and averaged (Figure 5.26).    
 
As can be seen from Figure 5.26, treatment with A769662 causes the average number 
of invading cells per field to increase by 2.32 fold,, from 31 cell/field to 71 cells/field 
(P<0.05), therefore corroborating the data from our collaborators that AMPK 
activation increased invasion of melanoma cells. However, with dual treatment of 
A769662 and IPA3, there was no significant increase in the number of invading cells 
beyond control.  
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Figure 5.22 Activity of AMPK in melanoma cell-lines 
AMPK pan-β subunit antibodies was used to immunopreciptate AMPK complexes from 
WM1361 and WM1366 cells (50 µg total protein) and AMPK activity determined. Activity 
has been calculated and plotted as specific activity (pmol/min/mg). Data shown represent 
averages and standard errors (SEM) from 3 independent experiments. 
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A. 
B. 
Figure 5.23 Activation of AMPK in melanoma cells 
(A) WM1361 and (B) WM1366 cells were incubated for 16 hours in the presence or absence of 
either phenformin (1 mM and 2 mM), AICAR (200 μM and 400 μM), or A769662 (100 μM 
and 200 μM). After treatment AMPK activity was determined. Results are shown as fold 
AMPK activity relative to mock treated (control) cells. Data shown represent averages and 
standard errors (SEM) from 3 independent experiments.  
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Figure 5.25 Treatment of WM1361 cells with A769662 and IPA3 
WM1361 cells were incubated for 16 hours with or without either A769662 (200 μM), IPA3 
(10 μM) or both A769662 and IPA3. After treatment, PAK1 and AMPK were 
immunoprecipitated using either anti-PAK1 or anti-AMPK-β antibodies respectively and 
activities determined. Results are shown as fold AMPK/PAK1 activity relative to the untreated 
control cells. Data shown represent averages and standard errors (SEM) from 3 independent 
experiments.  
 
 
 
 
 
 
 
Figure 5.24 AMPK activation stimulates invasion of melanoma cell-lines 
WM1361 and WM1366 cells were incubated for 16 hours in the presence or absence of 
A769662 (200 μM) then taken into the 3D collagen invasion assay for 24 hours. Invasion index 
is calculated as the number of invading cells at 50 μm divided by number of cells at 3 μm. 
Values are expressed as invasion fold relative to mock treated (control) cells. Data shown 
represent averages and SEM from 3 independent experiments. * Indicates a significant increase 
in invasion between the treated and control cells as judged by a student’s t-test (P<0.05).  
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Figure 5.26 (A) A769662 increases invasion of WM1361 melaonma cells via PAK1 signalling 
(A) Representative images of transwell invasion assays for WM1361 cells are shown (40x objective lens). Cells were placed into transwell invasion assay 
inserts in the presence and absence of either A769662 (200 μM), IPA3 (10 μM) or both compounds together. Cells were incubated for 48 hours at 37ºC 
(to facilitate invasion), after which the non-invading cell were removed and invaded cells stained with crystal violet dye. The stained cells were visualised 
under a standard light microscope (bright field image 10X objective). With images random fields taken for each insert. (B) Graphical representation of 
the average number of cells per field for treated and non-treated cells (shown on the next page)  
 
 
 
 
 
 
A. 
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B. 
Figure 5.27 (B) A769662 induced AMPK activation increases invasion of 
WM1361 melaonma cells via PAK1 
From images taken of treated and non-treated cells shown in Figure 5.27(A), cells in each field 
are counted and averaged, and the average number of cells per field for each treatment is 
shown on the graph above. Data shown represent averages and standard errors (SEM) from 3 
independent experiments.  
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5.3 Discussion 
In this section, the nature of the interaction between AMPK and PAK1 was 
investigated, extending from the initial results obtained in Chapter 4.  
 
Validation of direct interaction between AMPK and the PAK1 complex 
From the result shown in Chapter 5, immunoprecipitation with antibodies targeting 
either the AMPK α or β antibodies was shown to enrich for the PAK1/βPIX/GIT1 
signalling complex.   
 
Initially, experiments aimed at confirming that the PAK1/GIT1/βPIX complex 
interacts with AMPK in HEK293 cells were carried out. This was achieved using co-
immunoprecipitation using AMPK and PAK1 antibodies, coupled with western blot 
analysis using reciprocal antibodies (and both AMPK and PAK1 antibodies) (Figure 
5.2). The validation of AMPK/PAK1 binding using two different methods (MS 
analysis and western blotting) adds weight to the conclusion that this interaction does 
indeed occur in cells. It is well documented, that PAK1, GIT1 and βPIX are able to 
form a complex in vivo (Manabe et al., 2002; Manser et al., 1998), thus it is very 
likely that the PAK1/GIT1/βPIX signalling complex interacted with AMPK as an 
entire complex rather than as individual components. Unfortunately, while βPIX and 
GIT1 expression was readily detectable using the commercial antibodies available 
(Cell Signalling, USA) (and βPIX and GIT1 were detected in anti-AMPK-α immune-
complexes), these antibodies did not prove successful in immunoprecipitation 
reactions.  
 
Due to time and resource constraints, I was unable to fully characterise the nature of 
AMPK’s interaction with all three members of the PAK1/GIT1/βPIX complex. In 
most studies, PAK1 has been assumed to be the main effector protein in the complex. 
GIT1 and βPIX may be involved in the cellular localisation of the complex, in the 
regulation of PAK1 activation or providing protein scaffolds on which PAK1 
phosphorylation of substrates can take place (Manabe et al., 2002; Saneyoshi et al., 
2008; Turner et al., 1999). Therefore, I chose to concentrate my efforts on 
investigating the role of the interaction between AMPK and PAK1.  
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Phosphorylation of and activation PAK1 by AMPK in vitro 
This study is the first to show direct phosphorylation of PAK1 by AMPK. In previous 
publications where AMPK has been suggested to activate PAK1, no direct 
phosphorylation was reported and it was assumed that activation occurred through 
Rac1 stimulation (an upstream regulator of PAK1) (Bae et al., 2011; Lee et al., 2008).  
 
While it is accepted that the main mechanism of PAK1 activation is via binding of 
active Cdc42 or Rac1, studies have shown that phosphorylation of PAK1 is able to 
activate the enzyme. The first report of a potential upstream kinase of PAK1 came in 
2000, when a study by King et al. showed phosphorylation of the critical activation 
site, Thr-423 in PAK1 only occurred via an intermolecular mechanism, and not 
through auto-phosphorylation as previously thought. Furthermore, 3-
phosphoinositide-dependent kinase-1 (PDK1) was shown to directly phosphorylate 
and activate PAK1 at Thr-423 in-vitro and expression of PDK1 in COS-7 cells led to 
increased PAK1 activation (Bokoch, 2003; King et al., 2000). Two separate studies 
have shown that both Akt and cGMP-dependent protein kinase (PKG) were able to 
activate PAK1 through phosphorylation of Ser-21 . Furthermore, phosphorylation by 
Akt reduced the ability of PAK1 to bind the adapter protein Nck (Zhou et al., 2003). 
Additionally, in neuronal cells undergoing mitosis, cyclin-depenent kinase 5 (CDK-5) 
was found to phosphorylate PAK1 on Thr-212 leading to changes in the regulation of 
microtubule dynamics and remodelling of the axonal growth cone (Banerjee et al., 
2002; Rashid et al., 2001). From these reports, it appears that PAK1 is regulated by 
direct phosphorylation as well as GTPase binding. While this study was in progress, a 
study was published which showed that AMPK was able to directly phosphorylate 
PAK2, another member of the Group 1 PAK1 family (Banko et al., 2011).  
 
In light of the above publications, it was decided to investigate the possibility of 
AMPK acting as a PAK1 kinase. First, in-vitro phosphorylation experiments were 
performed where AMPK was used to phosphorylate PAK1.  
 
Incubation of both commercial unactivatable PAK1 and KD-PAK1 (in house) with 
active AMPK led to PAK1 phosphorylation (Figures 5.3 and 5.5), showing that 
PAK1 is an AMPK substrate in vitro.  
186 
 
The specific residues on PAK1 phosphorylated by AMPK were identified. To 
eliminate auto-phosphorylation, catalytically inactive (kinase-dead) PAK1 was use in 
these phosphorylation experiments. Although, full length GST-PAK1 fusion protein 
was made, it was not possible to fully eliminate degradation of the protein. Of note, 
while other labs have produced less degraded PAK1 protein, expression was normally 
achieved in baculovirus and not E. Coli (Fryer et al., 2006; Zhou et al., 2003).  
 
As with commercial PAK1, AMPK was also able to phosphorylate PAK1 protein 
produced in-house (Figure 5.5). Mass spectrometric analysis identified three AMPK 
phosphorylation sites. One of these sites resides in the NTSTMIGAGSK (Thr-20, 
Ser-21, Thr-22) peptide. While a single phosphate peak was detected, the candidate 
phosphorylation site could be any one of the residues highlighted in green.  
 
Analysis with the ScanSite software showed that residues with in this peptide were 
potential AMPK phosphorylation sites, and Ser-21 is an already established Akt and 
PKG phosphorylation site (Fryer et al., 2006; Zhou et al., 2003). Furthermore, AMPK 
α2 has been reported to directly phosphorylate a member of the PAK family, PAK2 on 
Ser-20, which corresponds to the Ser-21 residue on PAK1. Using site-directed 
mutagenesis, Ser-21 was found to be the major AMPK phosphorylation site within 
PAK1 (Figure 5.8).  
 
Having identified the major AMPK phosphorylation site in PAK1, the next logical 
step was to characterise its functional implications. The study by Zhou et al, has 
shown that phosphorylation of the Ser-21 residue by Akt was able to cause PAK1 
activation and increased cell migration (Zhou et al., 2003), therefore my initial 
investigation focused on the effects of AMPK phosphorylation on PAK1 activity and 
cell migration/cancer cell invasion.  
 
Phosphorylation by AMPK was able to significantly increase the activity of wild type 
PAK1, but not that of S21A-PAK1 or KD-AMPK (Figure 5.12). This result is in line 
with the publications described previously, where kinases such as Akt, PDK1, and 
CDK5 are able to phosphorylate and activate PAK1 independently of Cdc42 or Rac1. 
However, in previous studies as well as the present study, the level of activation by 
upstream kinases was less than by either Rac1 or Cdc42 (Figure 5.12). This indicates 
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GTPase binding may still be the most potent mechanism of PAK1 activation. PAK1 
contains an auto-inhibitory domain (amino acids 70 – 149), which is released from the 
catalytic domain after GTPase binding (Lei et al., 2000). Ser-21 is not in the auto-
inhibitory domain, so it is not surprising, perhaps, that phosphorylation of this site 
does not lead to full activation of PAK1 as the binding of Cdc42/Rac can achieve. It is 
possible that direct phosphorylation by AMPK acts to further modify the activation of 
PAK1 by Cdc42/Rac leading to altered/more potent effects for the PAK1 signalling 
pathway in vivo. In future, the interplay between AMPK and Cdc42/Rac in the 
regulating PAK1 activation could be investigated. It would be interesting to elucidate 
the effects of AMPK on the activity of PAK1 which has been pre-activated by 
upstream GTPases.  
 
Cellular models of PAK1 activation by AMPK 
In order to move the study from an in vitro basis to a more physiological environment, 
additional experiments in HEK293 cells were conducted. Treatment of HEK293 cells 
with the AMPK activators H2O2, phenformin and A769662 caused concurrent 
increases in both AMPK and PAK1 (Figure 5.13).  
 
To substantiate these findings, further studies using a more physiologically relevant 
cell-type of primary embryonic mouse cortical neurons were carried out. This 
decision was made for several reasons. Firstly, PAK1 is well expressed in the brain, 
where it is involved in the regulation of processes such as axon generation and neurite 
branching (Kreis and Barnier, 2009). Secondly, neurons also exhibit substantial 
AMPK activity and express both AMPK α1 and α2 catalytic subunits (Bright et al, 
unpublished data).  Additionally, the AMPK upstream kinase CaMKKβ has recently 
been implicated to promote neuronal spine outgrowth via activation of the 
PAK1/GIT1/βPIX complex (Saneyoshi et al., 2008).  
 
As in HEK293 cells, known activators of AMPK were able to stimulate PAK1 in 
embryonic neurons and the trend of PAK1 activation tracked that of AMPK activation 
for all three activators used (Figure 5.15). Compound C was able to largely abolish 
the increase in both AMPK and PAK1 activities caused by M991, indicating that the 
M991 induced PAK1 activation was indeed acting through AMPK (Figure 5.16). In 
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addition to experiments using WT neurons, neurons from knockout mice, in which the 
AMPK activity was markedly reduced, were used (Figures 5.17 – 5.19). The 
reduction of PAK1 phosphorylation in α1 knockout neurons further reinforces the 
above results showing AMPK activation of PAK1 in cells. The ability of M991 to 
stimulate PAK1 activity in α1 knockout neurons suggests that stimulation of either α1 
or α2 AMPK catalytic subunits is capable of activating PAK1. 
 
The above results from HEK293 cells and primary neurons indicate that AMPK could 
activate PAK1 in cells as well as in vitro. Other groups have proposed links between 
AMPK and PAK isoforms in the past. Notably in the study by Lee et al, AMPK 
activation by retinoic acid and AICAR was shown to increase PAK phosphorylation 
(Lee et al., 2008). Another paper recently implicated AMPK activation to increase the 
phagocytotic ability of macrophages through stimulation of PAK1/2 activity (Bae et 
al., 2011). However, both these papers propose an indirect link whereby AMPK 
causes PAK activation via stimulation of Rac1. In the current study, evidence points 
to PAK1 activation via direct phosphorylation by AMPK. Additionally, the earlier 
reports do not specify which PAK isoforms is activated by AMPK, and the study by 
Lee et al did not specify the phosphorylation site their antibodies targeted.  
 
The phospho-PAK1 antibodies used in my study cross react with PAK2 protein 
phosphorylated on Thr-402. Activation of AMPK in cortical neurons led to increased 
phosphorylation of PAK2. This result corroborates data from the recent study by 
Banko et al which shows AMPK-mediated phosphorylation and activation of PAK2 
both in vitro and in cells, and suggests a more general role for AMPK in the 
regulation of the group 1 PAKs (Banko et al., 2011).  
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Physiological implications of PAK activation by AMPK 
Having shown the ability of AMPK to regulate PAK1 activity through experiments 
conducted in vitro, in transformed cell-lines and primary cells, it was important to 
elucidate the functional significance of this regulation.  
 
Many papers have previously implicated a role for PAK1 in the regulation of neuron 
morphology, polarity and the correct formation of axons and dendrites (Jacobs et al., 
2007; Nikolic, 2008). Expression of constitutively active PAK1 has been shown to 
increase the number of dendrites and to encourage neurite outgrowth (Hayashi et al., 
2007; Hayashi et al., 2002; Li et al., 2013). ShRNA mediated knockdown of PAK1 
caused an almost global inhibition of neurite growth (Jacobs et al., 2007). 
Furthermore, expression of a mutant form of PAK1 resulted in formation of abnormal 
dendritic spines (Hayashi et al., 2007). In 2005, Rac was suggested to form a 
signalling module with the GIT1/βPIX/PAK complex which acts to phosphorylate 
MLRC, leading to increased dendritic spine formation (Zhang et al., 2005). Correct 
formation of dendritic spines is very important for cognitive development, and several 
genetic and non-genetic forms of mental retardation exhibit decreased spine densities 
(Kaufmann and Moser, 2000; van Galen and Ramakers, 2005). Inhibition of group 1 
PAK isoforms resulted in impaired performance of memory tasks in a mouse model. 
Following on from the results showing memory impairment, activities and 
expressions of group 1 PAKs is reduced in neurodegenerative Alzheimer disease 
leading to the downstream loss of spine actin-regulatory protein drebrin. Additionally 
PAK inhibition in adult mice led to drebrin loss and memory impairment, strongly 
suggesting a role for PAKs in the development of the disease (Nguyen et al., 2008; 
Zhao et al., 2006). Also, PAK1 expression was seen to be up-regulated in brain 
cancers, its activities are associated with a poorer prognosis  (Kumar et al., 2006).  
 
In 2008 a study by Saneyoshi et al showed that CaMKKβ was involved in the 
regulation of the PAK1/GIT1/βPIX complex via activation of CAMKI. This led to 
PAK1 activation which results in increased formation of dendritic protrusions and 
increased frequency of mini-excitatory-postsynaptic-potentials (mEPSC). Specifically, 
CaMKKβ inhibition did not affect the development of initial projections called 
filapodia, which are long and thin in shape, while it did reduce the number of mature 
mushroom-shaped dendritic spines which form from the filapodia (Saneyoshi et al., 
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2008).  As CaMKKβ is one of two major upstream kinases of AMPK, it is possible 
AMPK activation of PAK1 in these cells could lead to similar effects as that of 
CaMKKβ. In view of this, I modified the experiments performed by Saneyoshi et al, 
to determine if there were any differences in the formation of dendritic spines 
between wild type and AMPK α1 knockout neurons. In the 2008 study, neurons were 
transfected with RFP-tagged β-actin, which allowed the visualisation of the dendrites 
and associated protrusions under confocal microscopy. To avoid the technical 
difficulty of transfecting primary neurons, Alexa-488-phalloidin was used to stain for 
F-actin to visualise dendritic protrusions. Wild type or α1 knockout neurons were 
either left un-treated or treated with AMPK activators/inhibitors then stained with 
Alexa-488-phalloidin.  
 
While good staining of actin filaments was achieved, there did seem to be a decrease 
in the density of dendritic protrusions on general inspection, although the field of cells 
was too dense to allow accurate quantitation of spines or filapodia. It is possible that 
the use of phalloidin to stain for actin filaments instead of expressing RFP-tagged β-
actin caused this drawback. Whereas β-actin preferentially co-localised to the 
expanding edge of cells, phalloidin stains all F-actin structures, leading to bright 
staining of the neuronal cell body, axons and all dendrites which could interfere with 
the visualisation of small structures such as neuronal spines (Lodish et al., 2007). 
Plating primary neurons at lower densities resulted in significant impairment of 
dendrite branching and greatly increased death of cells. The reason for this occurrence 
is not clear, but one possibility could be that neurons in culture require a sufficient 
level of local paracrine secretion, the reduction in the concentration of these factors 
due to lower cell density may have impaired cell survival and dendritic branching. In 
future experiments, it would be prudent to optimise plasmid transfection into primary 
neurons so that the experiments conducted by Saneyoshi et al can be repeated in wild 
type versus AMPK α1 knockout neurons.  
 
In view of the experimental difficulties encountered, a different readout of 
axon/dendrite protrusions than actin staining was attempted. PSD95, which 
specifically localises to the postsynaptic densities of dendritic spines and forms a 
lattice immediately under the postsynaptic membrane, emerged as an interesting 
candidate. This protein is involved in the anchoring of synaptic proteins such as 
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potassium channels, NMDA and AMPA receptors (Sheng and Sala, 2001). Due to its 
localisation at the tips of dendritic spines, the formation of which PAK1 has been 
shown to positively regulate, PSD95 was chosen as the readout for altered PAK1 
function downstream of AMPK (Deo et al., 2013; Hayashi et al., 2007; Zhang et al., 
2005). In addition, PAK1 has been shown previously to co-localise with PSD95 in 
dendritic spines, thereby regulating spine formation and maintenance (Hayashi et al., 
2007). This work is on-going, and preliminary data have indicated a decrease in 
PSD95 protein level in AMPK α1 knockout neurons (data not shown).  
 
The role of AMPK regulation of PAK1 in cancer invasion 
In parallel with the study of AMPK regulation of PAK1 in neurons, another line of 
investigation was initiated to look at possible links between the two enzymes in 
controlling the migration of normal cells as well as invasion of cancer cells. As a 
regulator of cytoskeletal dynamics and cellular motility, PAK1 has a recognised role 
in promoting migration of cells (Eswaran et al., 2012a; Whale et al., 2011).  In recent 
years, AMPK has also been implicated in as a controller of these processes . Chapter 
1 gives a detailed introduction of this topic.  
 
This research was conducted with the help of our collaborators from Richard Marais’s 
group at the Institute of Cancer Research, who specialise in research into melanoma 
cancers. After discussion, we obtained two melanoma cell-lines which express both 
AMPK and PAK1. Several studies have previously shown that both PAK1 and 
AMPK play a role in the growth and migration of melanoma cells (Martin et al., 2012; 
Ong et al., 2011a; Ong et al., 2013). The cell-lines, WM1361 and WM1366 carry 
mutations in the small GTPase NRAS, which was shown to be important in neoplastic 
development (Colombino et al., 2012; Kelleher and McArthur, 2012).  
 
As part of our collaboration, Professor Marais’s group members performed invasion 
assays using melanoma cells. This invasion assay was originally developed by 
Professor Chris Marshall’s group (ICR, UK) (Ahn et al., 2012; Sanz-Moreno et al., 
2008). Results from this experiment showed that pre-treating WM1361 and WM1366 
cells with A769662 significantly increased the ability of these cells to invade through 
collagen. Unfortunately, at this point Professor Marais’s lab relocated from London to 
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Manchester and his group were unable to assist further, so the study was transferred to 
our group. The time constraints of my PhD meant I concentrated my experiments 
using the WM1361 cell-line which showed the strongest increase in invasion after 
AMPK activation.  Additionally, the lack of a fully automated confocal microscope 
prevented me from fully replicating the collagen invasion assays. After some time, it 
was decided to use a different setup in the form of the transwell invasion assay to 
conduct further experiments.  
 
This assay shares similarities with the collagen invasion assay.  Both involve the cell 
invading through an extra-cellular matrix-like substance towards a set chemo-
attractant. The transwell invasion assay has been described in detail in a 2011 review 
by Marshall (Marshall, 2011), however a brief description will be included here. As 
stated before, this assay is a modification of the Boyden chamber migration assay, the 
difference being that a layer of matrix gel is placed over the porous membrane of the 
Boyden chamber to simulate the extra-cellular matrix for cells to invade through 
(Chen, 2005). Pre-made invasion chambers are available commercially (Millipore, 
USA), and these invasion chambers act as inserts which fit into multi-well plates. 
Cells are placed into the inserts without chemo-attractant, while the media containing 
chemo-attractant is placed into the multi-well plate (which sits under and surrounds 
the inserts). The cells are then left to invade and the outcome can be visualised under 
microscope by counting the number of cells which has invaded through the ECM 
layer and migrated through the membrane. Like the collagen invasion assays, 
A769662 was able to significantly promote invasion of WM1361 cells in the transwell 
assay, and this effect was abolished by treatment with the specific PAK1 inhibitor 
IPA3 (Figure 5.26).  
 
As stated before, AMPK has been shown to promote the migration of normal cells 
and to increase the invasion of cancer cells (Frigo et al., 2011; Kanellis et al., 2006; 
Kim et al., 2011a; Nagata et al., 2003). Although no papers yet directly link AMPK 
and PAK1 in cell migration or invasion, there have been hints that the Rac1/PAK 
pathways may have some role to play in this process. A recent paper implicated 
AMPK activation in macrophages as partially mediating increased migration and 
phagocytosis via activation of Rac1 and PAK1/2 (Bae et al., 2011). In a 2011 study 
Kim et al, found AMPK activation mediated by LPA induced migration of ovarian 
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cancer cells. In addition to AMPK, LPA treatment also resulted in the activation of 
the GTPases RhoA and Rac1. However, siRNA mediated knockdown of AMPK α1 
only attenuated LPA induced RhoA activation and not that of Rac1 (Kim et al., 
2011a). As can be seen from the limited evidence presented above, the effectors 
downstream of AMPK in the control of cell migration and invasion are not well 
understood. The results in this section helps to fill the gaps in our knowledge by 
indicating that activation of AMPK has the ability to enhance invasion of melanoma 
cells and that this effect is mediated through direct phosphorylation of PAK1.  
 
In 2003, Akt was found to phosphorylate PAK1 on Ser-21 leading to activation of 
PAK1 and a reduction in its association with the adaptor protein Nck (Zhou et al., 
2003). The same study also found that Akt phosphorylation caused release of PAK1 
from focal adhesions. These effects led to stimulation of this pathway and caused an 
increased transwell migration (the transwell invasion assay was not used) of Rat1 
cells (Zhou et al., 2003). Since AMPK also phosphorylates PAK1 on Ser-21, it is 
likely that PAK1/Nck binding is also affected, which could led to relocation of PAK1 
and thereby to the increased invasion of cancer cells observed.  
 
It is clear that further study is needed to gain the full picture of all the players 
involved in this pathway. It would be very useful to find the sites of interaction on 
AMPK and PAK1 respectively and whether AMPK binding to PAK1 affects its auto-
inhibition at all. The contribution of GIT1 and βPIX would in this pathway also needs 
to be investigated, as they tend to form a signalling complex with PAK1 (Mayhew et 
al., 2006).  
 
Conclusions 
In conclusion, several novel results are presented in this section, firstly, that AMPK is 
able to directly phosphorylate PAK1 thereby leading to activation of the enzyme. It is 
possible that this process acts to augment/supplement PAK1 activation mediated by 
Cdc42/Rac binding. Next the role of AMPK in the regulation of PAK1 signalling was 
investigated in both cortical neurons and melanoma cells and AMPK was shown to 
positively regulate both neuronal PAK1 activity and melanoma cell invasion through 
PAK1 signalling. Further work is going to unravel the finer details of this regulation.  
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6 Investigating PAK1 regulation of AMPK 
6.1 Introduction 
Having established in Chapter 5 that AMPK phosphorylation of PAK1 resulted in its 
activation, I went on to investigate if PAK1 is able to regulate AMPK activity. Like 
AMPK, PAK1 is also a serine/threonine protein kinase, thus whether PAK1 is able to 
phosphorylate AMPK was examined.  
 
There have been no previous publications which implicates any member of the 
Rac/PAK signalling pathway in the regulation of AMPK. In this study, the ability of 
PAK1 to phosphorylate and regulate the activity of AMPK was investigated.  
 
6.2 Results 
6.2.1 PAK1 phosphorylates AMPK in vitro 
PAK1 pre-activated by co-expression with Cdc42 in baculovirus was obtained from 
Stratech (also used in chapter 5), and the kinase dead (KD) (D157A mutant) forms of 
AMPK α1β1γ1 and α2β1γ1  complexes (KD-AMPK) were expressed in E. Coli using 
the protocol set out in chapter 2. To confirm that PAK1 is indeed active as described, 
it was incubated with myelin basic protein (MBP), a known PAK substrate in the 
presence of 
32
P-ATP wand the radiolabelled proteins subjected to analysis using SDS-
PAGE and autoradiography. As seen on Figure 6.1, the autoradiograph gave two 
radiolabelled bands corresponding to both PAK1 and MBP. This indicates that PAK1 
is active and was capable of both auto-phosphorylation and phosphorylation of MBP.  
 
Having established that the PAK1 was active, it was then incubated with and without 
KD-AMPK (α1β1γ1 and α2β1γ1) for increasing time periods in the presence of 
32
P-ATP. 
The incorporation of 
32
P-PO4 into proteins was visualised using auto-radiography. As 
can be seen from Figure 6.2, whereas incubation of KD-AMPK alone with 
32
P-ATP 
did not result in any detectable signal, phosphorylation of KD-AMPK with active 
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PAK1 caused the appearance of two radiolabelled protein bands, corresponding to 
PAK1 and the AMPK α1 and α2 subunits respectively. There was a marked, time 
dependent increase in labelling, showing PAK1 phosphorylates AMPK in a time 
dependent manner (Figure 6.2). In this experiment no radioactive signal was detected 
for AMPK β1 or γ1, indicating AMPK α1/α2 to be Pak1’s preferred substrate. An 
estimation of the stoichiometry of phosphorylation was determined from the 
autoradiograph. The radioactivity of the ATP was estimated by spotting serial 
dilutions of the [
32
P-γ]ATP onto filter paper and exposing this alongside the gel.  
Using this method the stoichiometry was estimated to be around 1.5 – 2.0 mole/mole.  
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Figure 6.1 Validation of PAK1 activity 
Cdc42 activated PAK1 was incubated with myelin basic protein (MBP) in the 
presence of [
32
P-γ]ATP. Proteins were resolved by SDS-PAGE and visualised by 
staining by Coomassie (left panel) and radiolabelled products detected by 
autoradiography (right panel). The corresponding molecular markers are indicated 
on the left. Identity of the protein and radiolabelled bands are indicated on the right.    
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Figure 6.2 PAK1 phosphorylates kinase dead AMPK α1 and α2 in vitro  
Activated PAK1 was incubated with [
32
P-γ]ATP in the presence and absence of kinase dead (KD) AMPK α1β1γ1 (left panel) or 
α2β1γ1, (right panel) at 30 ºC for the indicated times. Samples were resolved by SDS-PAGE and visualised by staining by 
Coomassie (upper panel) and radiolabelled products detected by autoradiography (lower panel). The corresponding molecular 
markers are indicated on the left. Identity of the protein and radiolabelled bands are indicated on the right.    
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6.2.2 The effect of PAK1 on activity of AMPK  
Having established that the α subunit of AMPK is a PAK1 substrate in vitro, the next 
step was to see if this phosphorylation had any effect on AMPK activity. To this end, 
an experiment was designed where active PAK1 was used to phosphorylate either 
wild type AMPK α1β1γ1 or α2β1γ1 complexes in the presence of ATP, which was then 
taken into an AMPK kinase assay.  
 
In order to validate whether PAK1 directly phosphorylated the SAMS peptide, which 
is used to assay AMPK’s activity, active PAK1 was taken into SAMS assays. It can 
be seen from Figure 6.3, while active PAK1 was able to phosphorylate PAKtide, the 
phosphorylation of SAMS was virtually undetectable. The PAKtide assays gave an 
average specific activity of 106 nmol/min/mg, while for the SAMS assay a specific 
activity of 0.42 nmol/min/mg was achieved (very low CPM counts were observed, 
close to background levels). This makes the PAK1’s ability to phosphorylate SAMS 
around less than 0.5% as efficient as its ability to phosphorylate PAKtide. Thus for 
the purposes of on-going experiments it can be assumed that PAK1 has no capacity to 
phosphorylate the SAMS peptide.  
 
Next, increasing amounts of active PAK1 (100ng - 200ng) were incubated with 
unactivated wild-type AMPK α1β1γ1 or α2β1γ1 complexes in the presence of ATP 
(non-radioactive) for 30 minutes. An aliquot of these mixtures were then taken into 
SAMS peptide assays to measure the activity of AMPK. As a positive control, 
CaMKKβ was co-incubated with AMPK in the presence of ATP. The results for this 
experiment are shown in Figure 6.4, as can be seen, incubation with CaMKKβ caused 
a dramatic activation of AMPK, to 420 nmol/min/mg for the α1β1γ1 complex and to 
555 nmol/min/mg for the α2β1γ1 complex. In contrast incubation with PAK1 caused 
very little elevation of AMPK activity from basal/unactivated levels.  
 
6.2.3 The effect of PAK1 on activity of pre-phosphorylated AMPK  
Having established that PAK1 incubation had no significant effect on AMPK activity 
at basal levels, it was decided to determine it can affect the activity of active AMPK. 
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To this end, both AMPK α1β1γ1 and α2β1γ1 isoforms produced in E. coli were 
activated by co-incubation with CaMKKβ overnight.  
To confirm that AMPK has been activated, the activities of both α1β1γ1 and α2β1γ1 
complexes (100ng) which have or have not been incubated with CaMKKβ were 
compared. For α1β1γ1 complex, overnight CaMKKβ activation resulted in an increase 
in kinase activity of around 409 fold from 2.91 nmol/min/mg to 1193 nmol/min/mg. 
For the α2β1γ1 complex the increase was around 393 fold from 2.12 to 833 
nmol/min/mg (Figure 6.5). Next, to determine the optimum amount of AMPK to use 
in the PAK1 phosphorylation assay, titrations of both AMPK complexes (12.5ng to 
800ng of AMPK) were assayed with the SAMS peptide. From the results Figure 6.6 
it was decided to assay the activities of 50 ng both α1 and α2 after phosphorylation by 
PAK1, as this was in the linear range of activation for both isoforms of AMPK.  
 
In a similar protocol to the previous experiment, 1000 ng of active AMPK (α1β1γ1 and 
α2β1γ1) was incubated for 30 minutes in the absence and presence of 200 ng of active 
PAK1. After this, 5% of these incubation mixtures (equivalent to 50ng of AMPK 
protein) was assayed for AMPK activity using the SAMS peptide. As shown in 
Figure 6.7, incubation of AMPK with active PAK1 caused a significant increase in 
the activity of AMPK. For the α1β1γ1 complex, PAK1 caused a 4.3 fold increase in 
AMPK activity, while for AMPK α2β1γ1 a 4.1 fold increase was seen.  Two negative 
control experiments were also conducted. Firstly, co-incubation of kinase dead PAK1 
with activated AMPK did not cause any further increase in AMPK activity. Secondly, 
co-incubation of active PAK1 with CaMKKβ phosphorylated kinase dead AMPK did 
not give significant activity when assayed with SAMS peptide (data not shown).  
 
Taken together, these results presented above show that while PAK1 was unable to 
alter the activity of non-activated AMPK, it is able to significantly increase the 
activity of AMPK which has been pre-phosphorylated by CaMKK.  
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Figure 6.3 Active PAK1 does not phosphorylate the SAMS peptide 
Activated PAK1 (100 ng) was incubated with [
32
P-γ]ATP in the presence of either 
PAKtide or SAMS peptide for 30 minutes at 30 ºC, and activities determined. Activities 
have been calculated and plotted as specific activity (nmol/min/mg). Data shown represent 
averages and standard errors (SEM) from 3 independent experiments.  
 
 
 
 
 
 
 
Figure 6.4 PAK1 does not activate non-activated AMPK in vitro 
Activated PAK1 (100 ng or 200 ng) or CAMKKβ was incubated in the presence of either 
AMPK α1β1γ1 or α2β1γ1 (1000 ng) at 30 ºC for 30 minutes with ATP. After 
phosphorylation an aliquot of the reaction was taken and AMPK activity determined. 
Activities have been calculated and plotted as specific activity (nmol/min/mg). Data 
shown represent averages and standard errors (SEM) from 3 independent experiments.  
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Figure 6.5 CaMKKβ activation of AMPK α1β1γ1 or α2β1γ1 complexes 
CaMKKβ was incubated in the presence of [32P-γ]ATP with α1β1γ1 or α2β1γ1 over night at room 
temperature. An aliquot (50 ng) of these reactions was used in a SAMS assays. Activities are 
plotted as specific activity (nmol/min/mg).  
 
 
 
 
 
 
 
Figure 6.6 Titration of AMPK in the SAMS peptide assay 
Increasing amounts of CAMKKβ activated AMPK α1β1γ1or α2β1γ1 (12.5 ng – 800 ng) were 
assayed using the SAMS peptide. Activities are plotted as (background corrected) counts per 
minute against nanograms of AMPK used.  
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Figure 6.7 PAK1 causes further activation of CaMKKβ phosphorylated 
AMPK  
CaMKKβ phosphorylated AMPK α1β1γ1 or α2β1γ1 (1000 ng) was incubated in the presence and 
absence of activated PAK1 (200 ng) at 30 ºC for 30 minutes with ATP. After phosphorylation a 
aliquot was taken into a AMPK activity assay (50 ng AMPK). Data shown represent averages 
and standard errors (SEM) from 3 independent experiments. * Indicates a significant increase in 
AMPK activation between the assays performed in the presence and absence of PAK1 as 
judged by student’s t-tests (P<0.05).   
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6.2.4 PAK1 phosphorylation sites on AMPK α  
Having determined that PAK1 further activated CaMKKβ phosphorylated AMPK, the 
next step was to determine the mechanism that underlies this activation. As seen from 
Figure 6.2, AMPK is phosphorylated by PAK1 on the α subunits. It is logical to 
suggest that this phosphorylation of AMPK is linked to its activation.    
 
The effect of PAK1 on complexes containing either AMPK α1 or α2 subunits were 
similar, thus it was decided to focus future experiments on complexes containing the 
α1β1γ1 subunits only.  In order to identify the specific sites on AMPK phosphorylated 
by PAK1, KD-AMPK α1β1γ1 complex was incubated in the presence and absence of 
active PAK1 with ATP. After phosphorylation of AMPK, the mixture was resolved 
SDS-PAGE and Coomassie stained to visualise the proteins. The band corresponding 
to AMPK α1 was excised from the gel and subjected to tandem mass spectrometry 
analysis to identify phosphorylated peptides.  
 
The mass spectrometric analyses achieved sequence coverages of 77% and 81% for 
AMPK α1, two phospho-peptides were identified which only appeared following 
phosphorylation by PAK1. The first peptide identified is SQSRPNDIMAEVCR. The 
PAK1 phosphorylation site is either the serine residue at position 1 or position 3 in 
this peptide (highlighted in red) which corresponds to Ser-403 or Ser-405 in rat 
AMPK α1 used. Unfortunately, the mass spec analysis did not provide enough 
information to resolve the exact location of the phospho-residue. The second 
phosphorylated residue corresponds to Thr-377 on AMPK α1. Thr-377 was previously 
identified as an AMPK auto-phosphorylation site (Xiao et al., 2011). Of note, Thr-377 
was only phosphorylated after PAK1 incubation of 30 minutes, whereas the Ser-
403/Ser-405 site was phosphorylated after a 15 minute co-incubation.  The sequence 
coverages with the phospho-sites highlighted are shown in Figure 6.8.  
 
As KD-AMPK was used in this experiment, the phosphorylation sites identified 
should not be as a result of AMPK auto-phosphorylation.   
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Figure 6.8 Phospho-peptide mass spectrometry analysis of PAK1 phosphorylated AMPK 
Kinase dead (D157A) AMPK α1β1γ1 was incubated in the absence and presence of active PAK1 at 30 ºC for 15/30 minutes with 
ATP. The proteins were resolved using SDS-PAGE and detected using Coomassie staining. The band corresponding to AMPK α1 
was subjected to Tandem mass spectrometry analysis (CSC proteomics unit). The sequence coverage is indicated in red with 
identified phosphopeptide shown in green.   
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6.2.5 Mutation of PAK1 phosphorylation sites in AMPK 
In order to confirm that the sites identified on AMPK α1 are indeed PAK1 
phosphorylation sites, and to see if this phosphorylation mediates PAK1’s effect on 
AMPK activity. These residues are replaced by the non-phosphorylatable alanine 
amino acids. Since the specific site which PAK1 phosphorylates in the 
SQSRPNDIMAEVCR peptide is ambiguous, a double amino acid mutation was 
generated where both serine(s) at positions 1 and 3 (highlighted in red) are converted 
into non-phosphorylatable alanines (i.e. SQS-AQA).  
 
To produce the mutant AMPK α1 described above, the corresponding S403A/S405A 
double mutant (to be called the AQA mutant), and T377A mutant were introduced 
into the tricistronic vectors containing either WT or KD version of the AMPK α1β1γ1 
complex using specific primers (see Appendix 2). All mutations were generated using 
site-directed mutagenesis methods and confirmed by DNA sequencing. After 
expressing, these proteins are analysed using SDS-PAGE and shown in Figure 6.9. 
 
6.2.6 Phosphorylation of AMPK mutants by PAK1  
To determine the ability of PAK1 to phosphorylate AMPK α1 at the sites identified 
above, active PAK1 was incubated in the presence of 
32
P-ATP with various mutants 
of AMPK (α1β1γ1 complex), i.e. KD-AMPK, KD-AQA-AMPK and KD-377A-
AMPK. The incorporation of 
32
P into proteins were visualised using autoradiography. 
As can be seen in Figure 6.10, PAK1 was able to phosphorylate KD-AMPK to a 
much greater extent compared to KD-AQA-AMPK and KD-377A-AMPK. It appears 
the ability of PAK1 to phosphorylate the AQA and T377A mutants was reduced to a 
similar extent, although quantitative analysis of the radio-labelled bands for AMPK α1 
shows that 
32
P-PO4 incorporation into the AQA mutant is slightly less (around 20% 
less) than that into the T377A mutant (data not shown).  
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6.2.7 The effect of PAK1 phosphorylation on the activity of mutant 
AMPK  
To test if these mutants have any effect on the ability of PAK1 to further activate pre-
phosphorylated AMPK. CaMKKβ phosphorylated AMPK complexes were used 
(α1β1γ1). Figure 6.11 shows results of the activity of the different AMPK complexes. 
All three forms of AMPK are able to be activated by CaMKKβ, with WT-AMPK 
activity of 880 nmol/min/mg, AQA-AMPK activity of 530 nmol/min/mg and T377A-
AMPK activity of 1090 nmol/min/mg.  
 
The experiment to determine the effect of PAK1 phosphorylation of activity of these 
AMPK mutants was conducted in the same way as in section 6.2.3, active PAK1 was 
incubated with  of the WT and mutant forms of AMPK in the presence of ATP, with a 
fraction (5%) of the mixture then taken into the SAMS peptide assay.  
 
The results from this experiment are shown in Figure 6.12. Of note, the degree of 
activation of WT-AMPK in this experiment is much greater than recorded in the 
previous experiment (Figure 6.7), this is perhaps due the fact that a new batch of 
active PAK1 was used with a much greater specific activity compared to that used  
previous experiments (Data not shown). Phosphorylation by PAK1 induced a 10.3 
fold activation of AMPK, while for the S403A/S405A and T377A mutants the 
activation was much more modest 1.5 fold and 2.9 fold respectively.  
 
The data shown above would suggest that it is the phosphorylation of AMPK by 
PAK1 on the residues in the α subunit that lead to its activation.  
 
6.2.8 Expression of the AMPK AAA triple mutant and its effects on 
PAK1 induced phosphorylation  
Although both the AQA and the T377A mutants were much less able to be 
phosphorylated and activated by PAK1, the activation/phosphorylation was not 
entirely abolished. In order to see if the phosphorylation of AMPK can be completely 
abolished, a T377A/S403A/S405A triple mutant (from here on referred to as the AAA 
Triple mutant) was created (by inserting the T377A mutation into the vectors 
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containing the AQA mutation). All three mutations were verified as present using 
DNA sequencing (Data not shown).  
 
The triple mutant in the KD background was incubated with and without of PAK1 
(Figure 6.13). In this experiment the AQA and T377A mutants were also included for 
comparison. KD-AMPK is a much better substrate for PAK1 compared all three 
mutants. PAK1 phosphorylation of AMPK was almost completely abolished in the 
KD-triple mutant (Figure 6.13), thereby indicating that the Ser-403/405 and Thr-377 
are the predominant PAK1 phosphorylation sites in AMPK.  
 
In can be seen that in these experiments, PAK1 seems to phosphorylate the T377A 
mutant to a greater extent compared to the AQA mutant, although 
32
P-ATP 
incorporation into both mutants is still much less than that of KD-AMPK. This result 
is somewhat different to that shown in Figure 6.10, where the ability of PAK1 
phosphorylation of the T377A mutant was only slightly greater than the AQA mutant. 
In addition, with PAK1 incubation, there is also a small amount of phosphorylation of 
AMPK β/γ subunits.  Due to the proximity of the β1 and γ1 bands, we were unable to 
distinguish which subunit this phosphorylation corresponds to. 
 
After determining that the T377A/S403A/S405A triple mutant essentially abolished 
the ability PAK1’s ability to phosphorylate AMPK, experiments were planned to see 
what its effects are on PAK1 induced activation. These experiments are currently in 
progress.  
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Figure 6.9 Expression of mutant AMPK complexes 
Wild type (WT) or kinase dead (KD) AMPK α1β1γ1 complexes with or without α subunit point 
mutations were expressed in E. Coli and purified by nickel-sephrose chromatography and gel 
filtration. Proteins were resolved using SDS-PAGE and Coomassie staining. The migration of 
the molecular weight markers are indicated on the left and the identity of the proteins are 
indicated on the right.  
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Figure 6.10 PAK1 phosphorylation of KD AMPK mutants  
KD-AMPK α1β1γ1complexes harbouring the AQA and T377A was incubated with [
32
P-γ]ATP 
in the presence and absence PAK1 (200 ng), at 30 ºC for 30 minutes. Samples were resolved by 
SDS-PAGE and visualised by Coomassie staining (upper panel) and radiolabelled products 
detected by autoradiography (lower panel). The corresponding molecular markers are indicated 
on the left. Identity of the protein and radiolabelled bands are indicated on the right.    
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Figure 6.11 CaMKKβ activation of AMPK complexes 
WT AMPK α1β1γ1 complex or complexes harbouring the AQA and T377A mutations was 
incubated with CaMKKβ overnight at room temperature in the presence of ATP. An aliquot (50 
ng) of these reactions was used in a SAMS assays. Activities are plotted as specific activity 
(nmol/min/mg). Data shown represent averages and standard errors (SEM) from 4 independent 
experiments.  
 
 
 
 
 
 
 
 
 
 
Figure 6.12 PAK1 activation of pre-phosphorylated WT and mutant AMPK  
CaMKKβ phosphorylated WT or mutant (AQA and T377A) AMPK α1β1γ1 complexes were 
incubated in the absence and presence of PAK1 (200 ng) at 30 ºC for 30 minutes with ATP. 
After phosphorylation an aliquot of this reaction was taken into an AMPK activity assay. Data 
shown represent averages and standard errors (SEM) from 3 independent experiments.  
* Indicates a significant change in activity from WT (P<0.05) as judges by one way ANOVA. 
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Figure 6.13 PAK1 phosphorylation of KD AMPK mutants  
KD-AMPK α1β1γ1 complex or complexes harbouring the AQA (S403A+S405A), T377A, and 
AAA (T377A+ S403A+S405A) mutations were incubated with [
32
P-γ]ATP in the presence and 
absence of  in the presence and absence of PAK1 for 30 min at 30 ºC. Samples were resolved 
by SDS-PAGE and visualised by staining by Coomassie (upper panel) and radiolabelled 
products detected by autoradiography (lower panel). The corresponding molecular markers are 
indicated on the left. Identity of the protein and radiolabelled bands are indicated on the right. 
Representative image from 2 independent experiments.  
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6.3 Discussion:  
In chapter 5, the effects of AMPK phosphorylation of PAK1 were investigated, and it 
was concluded that AMPK activates PAK1 and mediates its downstream effects. In 
the current chapter, the goal was to investigate any potential effects PAK1 might have 
on AMPK.  Like AMPK, PAK1 is also a protein kinase and exerts its effects through 
phosphorylation of downstream targets. Consequently, it is possible for PAK1 to 
regulate AMPK through direct phosphorylation.  
 
Currently there is no evidence to suggest any of the PAK family members regulates 
any component of the AMPK signalling pathway or any AMPK related kinase. The 
work presented in this chapter shows for the first time that PAK1 is able to 
phosphorylate AMPK at two sites and causes further activation of CaMKKβ 
phosphorylated AMPK.  
 
PAK1 phosphorylation of AMPK  
Like many other protein kinases, AMPK has an obligate requirement for 
phosphorylation on a Threonine residue in the activation loop in the kinase domain for 
its activation (Hawley et al., 1996). Three upstream kinases have been suggested to 
phosphorylate AMPK at this residue. The two established AMPK upstream kinases 
are LKB1 and CaMKKβ, both of which were identified as AMPK regulators around 
10 years ago (Hawley et al., 2003; Shaw et al., 2004; Woods et al., 2005; Woods et al., 
2003a). Since then the only new AMPK kinase that has been suggested was the TAK1. 
Indeed the role of this enzyme in AMPK regulation is still unclear (Steinberg and 
Kemp, 2009). In the current study, PAK1 is shown to phosphorylate the α subunit of 
AMPK on sites other than the Thr-172 residue and enhancing its activity as a result.  
 
In addition to determining the ability of PAK1 to phosphorylate AMPK, it was critical 
to determine how this effects AMPK function. Phosphorylation of AMPK with active 
PAK1 had no significant effect on AMPK activity (Figure 6.4). This is logical, as 
from the phosphorylation data, it can be seen that PAK1 does not phosphorylate 
AMPK in the Thr-172 residue, which is absolutely required for activity of the AMPK 
molecule (Hawley et al., 1996). Therefore, AMPK will have to be pre-phosphorylated 
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by its upstream kinases before any stimulatory effects of PAK1 phosphorylation on it 
can be seen. 
 
Additional phosphorylation sites have been shown to be able to further modulate 
AMPK activity secondary to Thr-172 phosphorylation (Steinberg and Kemp, 2009). 
Mitchelhill et al, were the first to identify α1 Ser-485 as being phosphorylated in rat 
livers, and this was confirmed by experiments conducted with bacterially expressed 
AMPK (Mitchelhill et al., 1997; Woods et al., 2003b). More recently, the α1 Ser-485 
site has been suggested to be involved in cAMP mediated AMPK inhibition and 
Ser485 phosphorylation of α1 was necessary for forskolin to inhibit AMPK activity 
(Hurley et al., 2006). In another study, Akt has been shown to directly phosphorylate 
α1 Ser-485 as part of the insulin signalling cascade which leads to reduced Thr-172 
phosphorylation by LKB1 (Horman et al., 2006). Recently, p70S6 kinase has been 
shown to phosphorylate hypothalamic AMPK α2 on Ser-491 (which corresponds to α1 
Ser-485) and thereby inhibiting its activity, leading to reduced food intake (Dagon et 
al., 2012).  Although the effects of Ser-485 phosphorylation have been the subject of 
numerous studies, how the signal is transmitted from the C-terminus (where the Ser-
485 sites lies) of α1 to the catalytic domain is unknown. In addition to Ser-485, studies 
have shown that PKA mediated phosphorylation at Ser-173 reduces the ability of 
LKB1 to phosphorylate Thr-172, thereby leading to reduced AMPK activity (Djouder 
et al., 2010). Additionally, Thr259, Thr-373, Thr-379, Thr-481, Ser-499, Ser-514, Ser-
515 and  Thr-517 have also been identified as AMPK α1 phosphorylation sites, the 
physiological roles of most of the sites identified remains unexplored (Horman et al., 
2006; Hurley et al., 2006; Steinberg and Kemp, 2009; Villen et al., 2007; Woods et al., 
2003b). It is significant that many of the additional phosphorylation sites identified in 
AMPK α subunit are close to the C terminus, which is involved in binding to other 
AMPK subunits.   
 
Thus, in the next stage of this study, the ability of PAK1 to modulate the activity of 
activated AMPK was investigated. While PAK1 was unable to directly activate 
AMPK in the basal/un-activated state, it was able to cause further activation by >4-5 
fold of both AMPK α1β1γ1 and α2β1γ1 which were pre-phosphorylated by CaMKKβ. 
This suggests that the PAK1 phosphorylation sites on AMPK are secondary 
regulatory sites which are able to further modulate AMPK activity. Of the three 
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residues identified as potential PAK1 phosphorylation sites, T377 is not present in the 
AMPK α2 isoform. Serine residues equivalent to S403 and S405 (in α1) are present in 
α2. However, inspection of the crystal structures of truncated AMPK a1β2γ1 and full-
length α2β1γ1 do not reveal any obvious mechanistic insight into how these sites might 
affect AMPK activity. (Xiao et al., 2011).  
 
The underlying mechanism of AMPK activation by PAK1 
The most likely method by which PAK1 activates AMPK is through direct 
phosphorylation. To identify the specific residues within the AMPK α subunit which 
PAK1 phosphorylated, tandem mass spectrometry analysis was performed on AMPK 
α1 subunit protein after PAK1 phosphorylation. The time and resource pressures of 
this project prohibited the analysis of PAK1 phosphorylation sites on AMPK  α2. As 
there was little difference between the ability of PAK1 to phosphorylate and further 
activate AMPK α1 or α2, perhaps there is little difference in the regulation of the two 
subunits by PAK1. 
 
Mass spectrometry analysis showed PAK1 phosphorylated AMPK α1 on two sites. 
From the data, it was seen that the Ser-403/Ser-405 site (mass spec analysis could not 
resolve the specific site of phosphorylation) was phosphorylated after 15 minutes 
incubation with PAK1 while the Thr-377 site did not become phosphorylated until 
after 30 minutes. This result would suggest that the Ser-403/Ser-405 site is the 
preferential site for PAK1 compared to Thr-377 and may a more significant role in 
regulating the activity of AMPK.  
 
According to current knowledge, the phosphorylation of Ser-403/Ser-405 identified in 
this study has not been shown as a phosphorylation site of AMPK in previous studies.  
AMPK Thr-377 (α1) on the other hand, have been shown to be phosphorylated in vivo, 
in both insect cells and mouse liver (Steinberg and Kemp, 2009; Villen et al., 2007). 
Although it was suggested to be an auto-phosphorylation site of AMPK, the 
researchers did not explore the function or physiological implication of 
phosphorylation at this site.  
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As can be seen in Figure 6.10, compared to PAK1’s phosphorylation of KD-AMPK 
α1, phosphorylation of both the AQA and the T377A mutants was much reduced. This 
data suggests that both Ser-403/Ser-405 and the Thr-377 identified by mass 
spectrometry analysis are indeed phosphorylated by PAK1. Additionally, from the 
data it appears that PAK1 showed some preference towards Ser-403/Ser-405 site 
compared to the Thr-377 site. This inference was born out in later experiment where 
PAK1 phosphorylation of above two AMPK mutants and the triple mutant was 
compared to KD-AMPK phosphorylation (Figure 6.13). In this experiment, which 
was performed with a new batch of commercial PAK1 protein which was more active 
than the batch used for previous experiments, showed that although the 
phosphorylation of both AQA and T377A mutants were reduced compared to KD-
AMPK, there is clearly more substantial T377A phosphorylation compared to AQA. 
Importantly, PAK1 phosphorylation of AMPK was almost completely abolished in 
triple mutant, this result showed that these sites corresponds to the major PAK1 
phosphorylation sites in AMPK.  
 
The data generated from SAMS assays showed that both AQA and T377A mutations 
were able to greatly attenuate the ability of PAK1 to enhance the activity of pre-
phosphorylated AMPK (Figure 6.12). Taken together, PAK1’s ability to 
phosphorylate and activate AMPK suggests that this enzyme may be a novel upstream 
kinase for AMPK. In addition, this study is the first to show the activity of Thr-172 
phosphorylated AMPK can be further enhanced by phosphorylation at additional sites. 
This hints at an additional layer of AMPK regulation previously unknown and opens 
the possibility that activation of AMPK is not all or nothing but in fact consists of 
several states of increasing activation modulated by different upstream kinases.  
 
Further experiments are needed to validate these observations in a more physiological 
in vivo system, this work is currently on going. Experiments are currently being 
conducted to determine if PAK1 activation of AMPK can be completely abolished in 
the AAA mutant.  
 
Potential relevance of PAK activation of AMPK in physiology and pathology 
This is the first study which establishes direct phosphorylation of AMPK by PAK1 
and the enhancement in AMPK activation that results from this. With further research, 
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the finer details of this activation and its physiological roles should become clear. At 
this stage, we are nevertheless able to make some logical inferences about the 
functional relevance of this activation, and points in normal physiology and pathology 
where the paths of these two enzymes could converge.  
 
Both AMPK and PAK1 are protein kinases, with AMPK mainly involved in the 
control of cellular energy state and PAK1 involved in the regulation of actin 
organisation, cell polarity and cell migration. In recent years, new evidence has 
emerged which may help us link the function of these two enzymes.  
 
Some of the most important roles that PAK1 plays is the regulation of cytoskeletal 
dynamics, cell polarity and motility (Bokoch, 2003; Kreis and Barnier, 2009). In 
recent years, AMPK has also been shown to be involved in these processes. AMPK 
activity has been found to be important for maintaining normal cell polarity especially 
under conditions of energy stress (Brenman, 2007). In a drosophila model system 
where AMPK activity was abolished, severe abnormalities in cell polarity was seen, 
and in epithelial cells were seen to lose their normal cell polarity upon the expression 
either LKB1 or AMPK mutants (Lee et al., 2007; Mirouse et al., 2007). In canine 
kidney cells, treated with the AMPK activator A769662 caused shortening of actin 
stress fibres which led to cytoskeletal reorganisation (Miranda et al., 2010).  
 
PAK1 has also been implicated as an important regulator of the function of myosin 
regulatory light chain (MLC), a component of both myosin II (Park et al., 2011). 
Expression of constitutively active PAK1 in NIH-3T3 cells caused increased MLC 
phosphorylation (Sells et al., 1999). PAK1 has also been suggested to exert an 
inhibitory effect on myosin phosphatase targeting protein 1 (MYPT1) which leads to 
increased MLC phosphorylation (Takizawa et al., 2002). Indeed, PAK1 has been 
shown to directly phosphorylate MLC in in-vitro preparations (Chew et al., 1998).  
The field is controversial however, with other studies implicating PAK1 as having an 
inhibitory effect on MLC phosphorylation through an inhibitory phosphorylation of 
MLCK (Sanders et al., 1999; Wirth et al., 2003).  A recently publication has put 
forward an explanation for this apparent discrepancy, by suggesting that while PAK1 
enhances MLC phosphorylation under physiological conditions, it acts to inhibit its 
actions under pathological situations (Chu et al., 2013). Interestingly, AMPK has also 
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been shown to regulate MLC. Activation of AMPK increased the phosphorylation of 
cofillin and myosin light chain. Additionally, AMPK has also been shown to directly 
phosphorylate MLC on the key regulation site at Ser-19 (Lee et al., 2007; Miranda et 
al., 2010). Taken together the regulation of MLC phosphorylation could present 
another point of convergence of PAK1 and AMPK. It is possible post PAK1 
activation, AMPK acts as the effector protein to regulate in MLC phosphorylation. 
This could be achieved either through direct phosphorylation or indirectly by either 
activation of MLCK or the inhibition of MYPT (Bultot et al., 2009). 
 
As discussed in Chapter1, activation of PAK1 has been shown to promote tumour cell 
survival through multiple signalling pathways (Eswaran et al., 2012b). It is logical to 
suggest that in these tumour cells, especially within large solid tumours, have 
relatively low energy stores which will make preserving adequate cellular ATP levels 
a priority; it is then rational to assume that activation of AMPK will be helpful in 
circumstances in maintaining survival of cells. Traditionally, activation of AMPK was 
seen to restrain cancer cell growth through the inhibition of protein and fatty acid 
synthesis. However, more recently, AMPK has been suggested to have a pro-
tumourgenic role through the promotion of cell survival under states of energy stress. 
For example, in prostate cancer cells, inhibition of AMPK activity/expression of 
AMPK led to decreased cancer cell proliferation and increased cell death (Park et al., 
2009). In another study, expression of the AMPK β1 subunit was found to be essential 
for tumour cell survival (Ros et al., 2012). Furthermore, in brain tumour models, 
AMPK has been found to be highly activated during the early stages of tumourgenesis, 
and AMPK α1α2 double knockout MEFs have a severely impaired ability to form 
tumours in vivo (Jang et al., 2011; Laderoute et al., 2006).  From the above evidence, 
it can be seen that a potential link between PAK1 and AMPK exists in cancer, 
whereby the ability of PAK1 to further activate AMPK in energy deprived cancer 
cells could help it mediate effects in the enhancement of cancer cell survival.  
 
Another major role PAK1 plays in cancer formation is its ability to promote the 
migration and invasion of cancer cells (Vadlamudi et al., 2000). Likewise, in recent 
years, AMPK activation has been shown to enhance the migration and invasion and 
cancer cells (Frigo et al., 2011; Kim et al., 2011a). This could provide another 
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potential linking point for these two enzymes, where part of the effect of PAK1 on 
cell migration and cancer cell invasion is mediated through AMPK.  
 
Conclusions 
The results presented here have are novel and suggest a novel role for PAK1 in the 
regulation of AMPK activity. Further studies are needed to clarify the mechanistic 
details of this activation and its physiological implications. We are currently in the 
process of planning/conducting experiments in model cell-lines to see if activation of 
PAK1 results to stimulation of AMPK activities.  
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7 Conclusions and Future perspectives   
As a central regulator of the cellular energy state, AMPK plays both positive and 
negative roles in a wide range of disease states. AMPK has emerged as a potential 
drug target for conditions such as type 2 diabetes, cardiovascular diseases and cancer 
(Steinberg and Kemp, 2009). Gaining a fuller understanding of both the regulation of 
AMPK activity and its downstream effects will aid the design of new treatments 
which modulate this important enzyme.  
 
In Chapter 3, experiments were conducted with the aim of investigating the regulation 
of AMPK activity by protein phosphatase and to identify the specific phosphatase(s) 
which act to dephosphorylate AMPK on the critical Thr-172 residue. HEK293 cells 
identified as the cell-line of choice due to its relative high level of AMPK expression 
and the ability of endogenous AMPK activity to be dynamically modulated by 
pharmacological activators and manipulation of expression (e.g. of upstream kinases). 
Primary mouse hepatocytes were also used for selected experiments to provide a more 
physiological counterpart to HEK293 cells. 
 
Both pharmacological inhibition of phosphatase and siRNA mediated knockdown 
were used to identify candidate AMPK phosphatases. Knockdown of individual PPM 
phosphatases was able to significantly decrease the expression of these proteins in 
HEK293 cells. However this did not lead to significant elevation of AMPK activity 
either at basal levels or pre-activated by phenformin. Treatment of both HEK293 cells 
and primary hepatocytes with the phosphatase inhibitor Calyculin A caused 
significant elevations in AMPK activity. These results suggest that the AMPK 
phosphatase lies within the PPP family, and judging by the concentrations of inhibitor 
used, the candidate is more likely to be PP1 than PP2A. Knockdown of individual or 
combinations of PPP enzymes, PP1, PP2A, PP5 and PP6 did not produce positive 
results. Several inferences can be drawn from the results shown in this chapter. The 
discrepancy between the results from inhibitor studies and those obtained from siRNA 
knockdown suggest two things, either a very low level of phosphatase 
activity/expression is required to maintain AMPK activity under basal and activated 
conditions, or that AMPK is regulated by a number of phosphatase simultaneously, 
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and inhibition of all or most of these are required to generate a significant disturbance 
in AMPK activity. Either way, there does seem to be a substantial level of 
reserve/redundancy built into the system. This is not overly surprising, due to the wide 
ranging effects of AMPK, its activity needs to be tightly controlled when cells are not 
undergoing stressful conditions. Having a large pool of AMPK phosphatases in 
reserve to prevent aberrant activation of AMPK at basal levels may be helpful.  
 
While knockdown of PPM phosphatases did not produce any positive results, it does 
not mean that these phosphatase are not involved in AMPK regulation. Future studies 
are likely to greatly benefit from new pharmacological inhibitors of these 
phosphatases, the use of which will hopefully give us a definitive answer as to their 
involvement in AMPK dephosphorylation.  
 
Results from recent studies have suggested that different phosphatases maybe 
involved the dephosphorylation of AMPK under different conditions. For example, 
the PP1-R6 complex have been suggested to inactivate AMPK in response to increase 
glucose levels in the MIN6 pancreatic β cells. On the other hand siRNA knockdown 
of PP2A catalytic subunit was shown to be able to reverse heat shock induced AMPK 
Thr-172 dephosphorylation in HepG2 cells (Garcia-Haro et al., 2010; Wang et al., 
2010). With this in mind, coupled with the indications drawn from the results of this 
study, it is perhaps wise for future studies to focus on specific conditions of cellular 
stress in relevant cell-types, instead of trying to identify a ‘master’ AMPK 
phosphatase.  
 
Results from this and other studies have indicated PPP family members to be involved 
in AMPK dephosphorylation. As described in chapter 1, PPP family phosphatases 
such as PP1 and PP2A are mostly multimeric enzymes, where a limited number of 
catalytic subunits isoforms combine with a much larger number of regulatory subunit 
isoforms to confer substrate and conditional specificity. It is therefore possible that a 
particular PPP phosphatase could combine with different regulatory subunits to exert 
control on AMPK activity under different conditions. For example, the regulatory 
subunit that helps regulate AMPK activity under basal conditions could be replaced 
with another when cells undergo stressful conditions, which would help fine-tune 
AMPK activity under those conditions. Future experiments could perhaps help shed 
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more light on this process by identifying the full range of  regulatory subunits which 
assists in AMPK dephosphorylation under different conditions and in different tissue-
types. 
 
In Chapter 4, SILAC coupled with quantitative mass spectrometry was utilised to 
identify novel AMPK interacting proteins. To my knowledge, this is the first time that 
such a technique has been used for AMPK. Over 60 potential AMPK interacting 
proteins were identified, which fitted with our selection protocols, of which the 
PAK1/GIT1/βPIX complex was chosen for further investigation. However, the list of 
interactors generated contains other interesting candidates, such as ASK1 and 
MAP3K15, and future work can be carried out to investigate the physiological 
significance of these interactions.  
 
Following the successful application this SILAC/mass spectrometry in HEK293 cells, 
other members of our group have begun utilising this technique to screen for AMPK 
interacting proteins in more physiological cell types such as primary cortical neurons. 
In future experiments perhaps more cell-types can be included in these studies. In 
addition to identifying novel interaction proteins, any variations in the AMPK 
interacome in different cells would also be revealed by this method.  
 
In Chapter 5, the functional relevance of AMPK’s interaction with PAK1 was 
investigated. AMPK was found to directly phosphorylate PAK1 on the Ser-21 which 
activated the enzyme independent of GTPase binding. Furthermore, it was shown that 
activation of AMPK in number of cell-lines (including HEK293 cells, primary 
cortical neurons and melanoma cells) led to increased PAK1 phosphorylation/activity. 
Importantly, PAK1 phosphorylation and activity was found to be reduced in AMPK 
α1 knockout neurons which serves to back up the results obtained using 
pharmacological agents. As PAK1 has been shown to be involved in neuronal 
branching and dendrite formation, it is likely that such as sustained reduction in PAK1 
activity will have implications on these structures in the developing brains of AMPK 
α1 knockout mice. Although, due to technical difficulties, my experiments were not 
able to pinpoint the nature of these structural disturbances. Future experiments could 
follow on this work to identify if there are any differences in the post-synaptic 
structures of wild-type and AMPK α1 knockout mice.  
222 
 
 
Interestingly the Ser-21 site has also previously been identified as an Akt 
phosphorylation site, which has also been demonstrated to activate PAK1 (Zhou et al., 
2003). Phosphorylation of this site was reported to reduce binding of PAK1 to Nck 
which led to increases in cell migration. In the current study, AMPK activation of 
PAK1 in melanoma cell-lines led to increases in the invasion of these cells. These 
data suggest that both AMPK and Akt are able to increase cell motility by the similar 
mechanisms. In the current study, time constraints meant that the effects of AMPK 
activation on PAK1 interaction with Nck and other PAK1 binding proteins were not 
investigated, and this could form a part of a future study.  
 
Recently, AMPK has been implicated in the regulation of cell migration and invasion. 
The results of this study shows that activation of AMPK leads to increased invasion of 
melanoma cancer cells through PAK1 signalling. Our group is currently in the process 
of validating the results shown in chapter 5 by repeating invasion experiments with 
M991 (as opposed to A769662), a new and more potent specific activator of AMPK. 
Additional studies aimed at verifying these results with an additional PAK1 inhibitor, 
such as the PF-3758309 compound used by Ong et al to investigate melanoma tumour 
signalling (Ong et al., 2013) are currently being planned. RNAi mediated knockdown 
of AMPK and PAK1 can also be used to validate the proposed pathway. Although at 
this point the involvement of Rac1 in stimulating cancer cell invasion after AMPK 
activation cannot be excluded, we plan to conduct experiments using specific Rac1 
inhibitors (e.g. the NSC23766 compound) to reveal these effects. 
 
In the future, the downstream effects of this novel signalling pathway on cell 
migration/invasion could be tested in other cancer cells as well as normal non-
neoplastic cell-lines. This signalling cascade could contain attractive drug targets, the 
modulation of which can be used to reduce the invasive and metastatic ability of 
cancer cells.  We await future experiments to shed more light on this possibility. 
 
As PAK1 is also a serine/threonine kinase, the possibility that it may be capable of 
phosphorylating AMPK was investigated in Chapter 6. PAK1 was able to directly 
phosphorylate the AMPK α subunit on the Thr-377 and Ser-403/405 residues. This 
phosphorylation did not result in activation of non-activated AMPK. This is not 
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surprising as PAK1 did not phosphorylate the critical Thr-172 residue, which is 
absolutely required for AMPK activity. However, PAK1 was able to significantly 
increase the activity of CaMKKβ phosphorylated AMPK by over four fold. Mutation 
of the PAK1 phosphorylation sites on AMPK α1 to alanine abolished this activation.  
 
To our knowledge, this study presents the first report that phosphorylation of 
additional sites on AMPK is able to further increase the activity of Thr-172 
phosphorylated AMPK. This opens up the possibility that there may be different 
grades of AMPK activation and in some states active AMPK requires further 
stimulation by PAK1 before exerting its downstream effects. There may be other 
members of this ‘second layer’ upstream kinase family which are able to regulate the 
activity of Thr-172 phosphorylated AMPK.   
 
We are currently in the process of planning/conducting experiments to further validate 
the PAK1’s effects on AMPK. The next step would be to use cellular models in order 
to reveal the physiological implications of this regulation. RNAi techniques coupled 
with pharmacological agents will be used to manipulate PAK1 activity/expression 
with the resulting effects on AMPK analysed. By phosphorylating AMPK, it is 
possible that PAK1 has previously unknown effects on cellular metabolism. In future 
experiments, this possibility could be investigated by the using model cell-lines and  
perhaps tissue specific knock-out models where PAK1 expression is selectively 
silenced.  
 
Additionally, due to time constraints, the interaction between the PAK1 associated 
proteins GIT1 and PIX was not fully investigated during this study. Future work could 
focus on these two proteins to reveal the physiological relevance of these interactions.  
 
In conclusion, the work presented in this thesis goes someway in furthering our 
understanding of the regulation of AMPK and its downstream effects. Much work still 
needs to be conducted in order to fully reveal the implications of AMPK’s interaction 
with PAK1 and its associated proteins. Further experiments are currently on going.
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Appendices  
Appendix 1 
Table showing the siRNA sequences used for knockdown of protein phosphatases in 
Chapter 3. (In some instances the siRNA sequences were not supplied).  
 
(Page 1 of 2) 
Target Direction Sequence (siRNA 1) Sequence (siRNA 2) 
PPM1A Sense GGAUGUUAUGGGAAAUGAAtt GACUUGAAGUCACUGAUGAtt 
Antisense UUCAUUUCCCAUAACAUCCca UCAUCAGUGACUUCAAGUCtg 
PPM1B Sense ACAUGAGUAUUGUACUAGUtt AGAUAACAUGAGUAUUGUAtt 
Antisense ACUAGUACAAUACUCAUGUta UACAAUACUCAUGUUAUCUcg 
PPM1D Sense GGGUCUUCCUAGCACAUCAtt GGACAUUAGAAGAGUCCAAtt 
Antisense UGAUGUGCUAGGAAGACCCgt UUGGACUCUUCUAAUGUCCtt 
PPM1E Sense GAGGCAAAAUAGUUGGAAAtt GAGUAGAUGCUGCUAUUUAtt 
Antisense UUUCCAACUAUUUUGCCUCca UAAAUAGCAGCAUCUACUCcc 
PPM1F Sense UGUGAACCGCGCCUACUUUtt GGAUGAGAAGGCGCGCAUUtt 
Antisense AAAGUAGGCGCGGUUCACAgg AAUGCGCGCCUUCUCAUCCtg 
PPM1G Sense CCAUGACUAUUGAAGAGCUtt CUCUGACAGUGGUACAACAtt 
Antisense AGCUCUUCAAUAGUCAUGGta UGUUGUACCACUGUCAGAGcc 
PPM1H Sense GCGGAUAUCUAAUGACCGAtt GAGACGACAUUUCUGUAUAtt 
Antisense UCGGUCAUUAGAUAUCCGCca UAUACAGAAAUGUCGUCUCct 
PPM1J Sense CCAAUGUCCCGGGAGUUUAtt UGCUAGUCCUGGGAACAGAtt 
Antisense UAAACUCCCGGGACAUUGGaa UCUGUUCCCAGGACUAGCAca 
PPM1K Sense GCCCUAUUGCGAGAUGGUAtt GAAUUAACUUCAUGGUGAAtt 
Antisense UACCAUCUCGCAAUAGGGCta UUCACCAUGAAGUUAAUUCca 
PPM1L Sense GGACUACGAGAAAGACAAAtt GAGCAUAGUUUUACAGUCAtt 
Antisense UUUGUCUUUCUCGUAGUCCtg UGACUGUAAAACUAUGCUCtt 
PPM1M Sense GGGAUGUACUGUCCAACGAtt AGAAGGUUUUGUUCAGGGAtt 
Antisense UCGUUGGACAGUACAUCCCag UCCCUGAACAAAACCUUCUgt 
ILKAP Sense GCAUCAAAACUUAAUCAGAtt CAUGCAGCCUUAAGCCUCAtt 
Antisense UCUGAUUAAGUUUUGAUGCaa UGAGGCUUAAGGCUGCAUGtt 
PHLPP1 Sense GAUCUAAGGUUGAACGUAAtt GUCUUAACCUUUCCAAUAAtt 
Antisense UUACGUUCAACCUUAGAUCca UUAUUGGAAAGGUUAAGACtc 
PHLPP2 Sense GAUUCUACAGUUACGUAAAtt CUGUCAAUGCUGUACGUCAtt 
Antisense UUGACGUAACUGUAGAAUCtg UGACGUACAGCAUUGACAGct 
PDP1 Sense Sequence not supplied Sequence not supplied 
Antisense Sequence not supplied Sequence not supplied 
PDP2 Sense Sequence not supplied Sequence not supplied 
Antisense Sequence not supplied Sequence not supplied 
PPP1CA Sense CGAGAGCAACUACCUCUUUtt CGACCUUCUGCGACUAUUUtt 
Antisense AAAGAGGUAGUUGCUCUCGgg AAAUAGUCGCAGAAGGUCGta 
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Appendix 2 
The following oligonucleotides were used in this study to introduce mutations into 
various proteins. 
 
 
 
 
 
Target Direction Sequence (siRNA 1) Sequence (siRNA 2) 
PPP1CB 
Sense GAUCUUCUGUUGUCAUGGAtt GCUAUGGUCUGAUCCAGAUtt 
Antisense UCCAUGACAACAGAAGAUCtt AUCUGGAUCAGACCAUAGCaa 
PPP1CC 
Sense CAGCUUCAGGAGAAUGAAAtt CACAGACUGUUUUAACUGUtt 
Antisense UUUCAUUCUCCUGAAGCUGga ACAGUUAAAACAGUCUGUGaa 
PPP2CA 
Sense CCAAACUAUUGUUAUCGUUtt GCUUGUAGCUCUUAAGGUUtt 
Antisense AACGAUAACAAUAGUUUGGag AACCUUAAGAGCUACAAGCag 
PPP2CB 
Sense CAAUUACUGUUAUCGUUGUtt GGAUAUUAUUCAGUGGAGtt 
Antisense ACAACGAUAACAGUAAUUGgg UCUCCACUGAAUAAUAUCCtc 
PPP5C 
Sense Sequence not supplied Sequence not supplied 
Antisense Sequence not supplied Sequence not supplied 
PPP6C 
Sense GCCUGAUCGUAUUACACUUtt CCAUCGAACGGAAUCAGGAtt 
Antisense AAGUGUAAUACGAUCAGGCca UCCUGAUUCCGUUCGAUGGtt 
Protein Mutation Driection Sequence 
PAK1 D406A 
Forward  GCTCTGTCAAGTTAACTGCCTTTGGATTCTGTGCACA 
Reverse TGTGCACAGAATCCAAAGGCAGTTAACTTGACAGAGC 
PAK1 S21A 
Forward  CTCCGATGAGAAACACCGCCACTATGATTGGAGCCG 
Reverse GAGGCTACTCTTTGTGGCGGTGATACTAACCTCGGC 
PAK1 
T20A,S21A,T22A 
(AAA) 
Forward  CCCCTCCGATGAGAAACGCCGCCGCTATGATTGGAGCCGGC 
Reverse GGGGAGGCTACTCTTTGCGGCGGCGATACTAACCTCGGCCG 
AMPK 
S403A,S405A 
(AQA) 
Forward  GGCAAAGTGGCATTTGGGGATTCGAGCTCAAGCCCGACCCAATGACATC 
Reverse GATGTCATTGGGTCGGGCTTGAGCTCGAATCCCCAAATGCCACTTTGCC 
AMPK T377A 
Forward  AGGGCCCGACACGCCCTAGATGAATTA 
Reverse TAATTCATATAGGGCGTGTCGGGCCCT 
 252 
Appendix 3 
Antibodies.  
A table of the non-commercial antibodies and the antigen that they were raised against.  
 
Antibody Animal raised in Peptide antigen 
α1 Sheep TSPPDSFLDDHHLTR 
α2 Sheep MDDSAMHIPPGLKPH 
Pan-β (SIP2) Rabbit β1-GST fusion protein 
(W/o  first 68 amino acids) 
 
 
 
